POLINUCLEOTÍDEOS QUE CODIFICAM ANTÍGENOS VP1 DO NOROVÍRUS E USOS DO MESMO

MRNA polynucleotides encoding norovirus VP1 polypeptides, modified with N1-methylpseudouridine, offer a promising solution for preventing and treating norovirus infections by inducing effective immune responses.

BR112025024174A2Pending Publication Date: 2026-11-10MERCK SHARP & DOHME LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112025024174
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-08
Filing Date
2024-05-06
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

There is currently no specific prophylactic or therapeutic treatment for norovirus infections, which are highly contagious and cause significant gastroenteritis worldwide, affecting millions annually, particularly in children under five years of age.

Method used

Development of mRNA polynucleotides encoding norovirus VP1 polypeptides, modified with N1-methylpseudouridine to enhance stability, and formulated into vaccine compositions for administration in mammals, potentially preventing and treating norovirus infections.

Benefits of technology

The mRNA-based vaccine compositions induce immune responses effective in preventing and treating norovirus infections by generating antigenic polypeptides, providing prophylactic and therapeutic benefits.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention is directed to nucleic acids and related immunogenic polypeptides for the prevention or treatment of infectious diseases. In particular, the nucleic acids and immunogenic polypeptides provide utility for the prophylactic prevention of norovirus infections in a mammal. The invention is further directed to nucleic acid-based vaccine compositions and a kit of parts comprising the vaccine compositions, as well as methods of treatment and medical uses relating to the nucleic acids, vaccine compositions, and kit of parts.
Need to check novelty before this filing date? Find Prior Art

Description

1 / 109 Polynucleotides encoding norovirus VP1 antigens and their uses. CROSS-REFERENCE TO RELATED REQUESTS

[001] This patent application claims the benefit of U.S. Provisional Patent Application Serial No. 63 / 500,749, filed May 8, 2023, the full content of which is incorporated by reference in the present invention. REFERENCE TO THE LIST OF SEQUENCES SUBMITTED ELECTRONICALLY

[002] The contents of the electronic sequence listing (25691-WOPCT_SL.xml; Size: 6 kilobytes; and Creation Date: August 24, 2023) are incorporated in the present invention by reference in their entirety. TECHNICAL FIELD

[003] This disclosure relates generally to messenger ribonucleic acid (mRNA) compositions and vaccines, as well as methods of using compositions and vaccines for the treatment of infectious diseases such as norovirus. BACKGROUND

[004] Norovirus, also referred to as "Norwalk virus," was named after an outbreak of acute gastroenteritis at an elementary school in Norwalk, Ohio. Symptoms of norovirus infection appear within 12 to 48 hours of exposure and are characterized by nausea, vomiting, persistent diarrhea, lethargy, myasthenia gravis, myalgia, headache, cough, and / or fever. Although severe illness is uncommon and norovirus infections are usually self-limiting, norovirus remains one of the most common causes of acute gastroenteritis in people of all ages. There are approximately 700 million reported norovirus infections annually worldwide, with children under five years of age representing the largest number. Petition 870250101498, dated 05 / 11 / 2025, pp. 391 / 546 2 / 109 approximately 28.5% of all annual infections.

[005] Taxonomically, noroviruses are a diverse group of single-stranded, positive-sense, non-enveloped RNA viruses belonging to the family Caliciviridae. Noroviruses contain a linear, non-segmented, positive-sense RNA genome of approximately 7.5 kilobases, which encodes a large polyprotein that is cleaved into six smaller non-structural proteins (NS1 / 2 to NS7) by the viral 3C-like protease (NS6), a major structural protein (VP1) of about 58 to 60 kDa, and a secondary capsid protein (VP2). Noroviruses can be genetically classified into at least seven different genogroups (GI, GII, GIII, GIV, GV, GVI, and GVII), which can be further divided into different genetic clusters or genotypes. Most noroviruses that infect humans belong to genogroups GI and GII. Noroviruses of genogroup II, genotype 4 (abbreviated as GII).4) They are responsible for the majority of gastroenteritis outbreaks in adults and frequently spread globally.

[006] Norovirus is highly contagious and transmissible, with just five virions being sufficient to cause an infection. It is typically transmitted through contaminated water or food via the fecal-oral route. However, airborne transmission via aerosolized viruses has been documented. Therefore, preventive measures such as frequent handwashing, disinfecting surfaces, and avoiding contact with infected individuals can help reduce the risk of infection.

[007] Currently, there is no specific prophylactic or therapeutic treatment for norovirus infections. Therapy is limited to palliative care for acute infections. Therefore, there is a strong need for additional therapeutic measures against norovirus infections. The objective of the present invention is to provide pharmaceutical compositions for the prophylactic and therapeutic treatment of norovirus infections. Petition 870250101498, dated 05 / 11 / 2025, pp. 392 / 546 3 / 109 therapeutic treatment of norovirus infections. In particular, some aspects of the present invention provide norovirus vaccines that can be administered to a mammal for the prevention and / or treatment of a norovirus infection. SUMMARY

[008] The present disclosure provides mRNA polynucleotides, vaccine pharmaceutical compositions, and kits comprising them. The mRNA polynucleotides, vaccine compositions, and kits are useful for the prophylactic and therapeutic treatment of norovirus infections. The present disclosure further provides vectors and host cells comprising the mRNA polynucleotides, methods for producing the vaccine pharmaceutical compositions, and methods for using the vaccine pharmaceutical compositions for the treatment of norovirus infections.

[009] In one aspect, the present disclosure provides an mRNA polynucleotide encoding a norovirus VP1 polypeptide, wherein the mRNA polynucleotide is derived from a norovirus selected from the group consisting of: a norovirus GII.4, GI.1, GII.2, GII.3 and GII.6, and wherein at least one uridine residue in the mRNA polynucleotide is replaced with N1-methylpseudouridine.

[010] In one aspect, the present disclosure provides an mRNA polynucleotide encoding a norovirus VP1 polypeptide, wherein the mRNA polynucleotide is selected from the group consisting of SEQ ID NOs: 1 to 5 and sequences having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity therewith, and wherein at least one uridine residue in the mRNA polynucleotide is substituted with N1-methylpseudouridine. In certain embodiments, the norovirus VP1 polypeptide is an antigenic polypeptide. Petition 870250101498, dated 05 / 11 / 2025, pp. 393 / 546 4 / 109

[011] In one aspect, the present disclosure provides an mRNA polynucleotide encoding a norovirus VP1 polypeptide, wherein the mRNA polynucleotide is selected from the group consisting of SEQ ID NOs: 1 to 5, and wherein at least one uridine residue in the mRNA polynucleotide is replaced with N1-methylpseudouridine.

[012] In some embodiments, the mRNA polynucleotide is derived from a norovirus selected from the group consisting of noroviruses GII.4, GII.1, GII.2, GII.3 and GII.6.

[013] In some embodiments, the mRNA polynucleotide additionally comprises a heterologous 5' untranslated region (UTR) and a heterologous 3' UTR region.

[014] In some embodiments, the 5' UTR comprises the polynucleotide sequence of SEQ ID NO: 6. In some embodiments, the 5' UTR additionally comprises the structure Cap 5' N7-Methyl-G(3'Ome)ppp.

[015] In some embodiments, the UTR 3' comprises a poly(A) sequence and / or a poly(C) sequence. In some embodiments, the poly(A) sequence comprises 10 to 200 adenosine nucleotides (SEQ ID NO: 19) and / or the poly(C) sequence comprises 10 to 200 cytosine nucleotides (SEQ ID NO: 20).

[016] In some embodiments, the poly(A) sequence comprises 10 to 100 adenosine nucleotides (SEQ ID NO: 21). In some embodiments, the poly(A) sequence comprises 10 to 80 adenosine nucleotides (SEQ ID NO: 22). In some embodiments, the poly(A) sequence comprises 50 to 70 adenosine nucleotides (SEQ ID NO: 23). In certain embodiments, the poly(A) sequence comprises 80 adenine nucleotides (SEQ ID NO: 24).

[017] In some embodiments, the poly(C) sequence comprises 10 to 100 cytosine nucleotides (SEQ ID NO: 25). In some embodiments, the Petition 870250101498, dated 05 / 11 / 2025, pp. 394 / 546 5 / 109 poly(C) sequence comprises 20 to 70 cytosine nucleotides (SEQ ID NO: 26). In some embodiments, the poly(C) sequence comprises 20 to 60 cytosine nucleotides (SEQ ID NO: 27). In some embodiments, the poly(C) sequence comprises 10 to 40 cytosine nucleotides (SEQ ID NO: 28).

[018] In some embodiments, the 3' UTR comprises the polynucleotide sequence of SEQ ID NO: 7 or SEQ ID NO: 8. In certain embodiments, the 3' UTR comprises the polynucleotide sequence of SEQ ID NO: 7. In certain embodiments, the 3' UTR comprises the polynucleotide sequence of SEQ ID NO: 8.

[019] In certain embodiments, the mRNA polynucleotide comprises, from the 5' to the 3' direction: a 5' UTR comprising the polynucleotide sequence of SEQ ID NO: 6; a polynucleotide encoding a norovirus VP1 polypeptide, wherein the polynucleotide is selected from the group consisting of SEQ ID NOs: 1 to 5 and sequences having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity therewith; and a 3' UTR comprising the polynucleotide sequence of SEQ ID NO: 7; and wherein the 5' UTR additionally comprises the 5' Cap N7-Methyl-G(3'OMe)ppp structure, and all uridine residues in the polynucleotide encoding the norovirus VP1 polypeptide are substituted with N1-methylpseudouridine. In certain embodiments, the norovirus VP1 polypeptide is an antigenic polypeptide.

[020] In certain embodiments, the mRNA polynucleotide comprises, from the 5' to the 3' direction: a 5' UTR comprising the polynucleotide sequence of SEQ ID NO: 6; a polynucleotide encoding a norovirus VP1 polypeptide, wherein the polynucleotide is selected from the group consisting of SEQ ID NOs: 1 to 5; and a 3' UTR comprising the polynucleotide sequence of SEQ ID NO: 7; and wherein the 5' UTR comprises Petition 870250101498, dated 05 / 11 / 2025, pages 395 / 546 6 / 109 additionally the Cap 5' N7-Methyl-G(3'Ome)ppp structure, and all uridine residues in the polynucleotide encoding the norovirus VP1 polypeptide are replaced with N1-methylpseudouridine.

[021] In certain embodiments, the mRNA polynucleotide comprises, from the 5' to the 3' direction: a 5' UTR comprising the polynucleotide sequence of SEQ ID NO: 6; a polynucleotide encoding a norovirus VP1 polypeptide, wherein the polynucleotide is selected from the group consisting of SEQ ID NOs: 1 to 5 and sequences having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity therewith; and a 3' UTR comprising the polynucleotide sequence of SEQ ID NO: 8; and wherein the 5' UTR additionally comprises the 5' Cap N7-Methyl-G(3'OMe)ppp structure, and all uridine residues in the polynucleotide encoding the norovirus VP1 polypeptide are substituted with N1-methylpseudouridine. In certain embodiments, the norovirus VP1 polypeptide is an antigenic polypeptide.

[022] In certain embodiments, the mRNA polynucleotide comprises, from the 5' to the 3' direction: a 5' UTR comprising the polynucleotide sequence of SEQ ID NO: 6; a polynucleotide encoding a norovirus VP1 polypeptide, wherein the polynucleotide is selected from the group consisting of SEQ ID NOs: 1 to 5; and a 3' UTR comprising the polynucleotide sequence of SEQ ID NO: 8; and wherein the 5' UTR further comprises the 5' Cap N7-Methyl-G(3'OMe)ppp structure, and all uridine residues in the polynucleotide encoding the norovirus VP1 polypeptide are substituted with N1-methylpseudouridine.

[023] In some embodiments, the mRNA polynucleotide comprises at least one histone stem loop structure. In some embodiments, at least 50% of the uridine residues in the polynucleotide of Petition 870250101498, dated 05 / 11 / 2025, pp. 396 / 546 7 / 109 mRNA are replaced with N1-methylpseudouridine. In some embodiments, at least 75% of the uridine residues in the mRNA polynucleotide are replaced with N1-methylpseudouridine. In some embodiments, at least 85% of the uridine residues in the mRNA polynucleotide are replaced with N1-methylpseudouridine. In some embodiments, at least 90% of the uridine residues in the mRNA polynucleotide are replaced with N1-methylpseudouridine. In some embodiments, at least 95% of the uridine residues in the mRNA polynucleotide are replaced with N1-methylpseudouridine. In some embodiments, at least 96% of the uridine residues in the mRNA polynucleotide are replaced with N1-methylpseudouridine. In some embodiments, at least 97% of the uridine residues in the mRNA polynucleotide are replaced with N1-methylpseudouridine. In some embodiments, at least 98% of the uridine residues in the mRNA polynucleotide are replaced with N1-methylpseudouridine.In some embodiments, at least 99% of the uridine residues in the mRNA polynucleotide are replaced with N1-methylpseudouridine. In certain embodiments, 100% of the uridine residues in the mRNA polynucleotide are replaced with N1-methylpseudouridine.

[024] In another aspect, the present disclosure provides a combination of one or more mRNA polynucleotides, as described in the present invention. In specific embodiments, the one or more mRNA polynucleotides are 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 to 2 mRNA polynucleotides, as described in the present invention. In specific embodiments, the one or more mRNA polynucleotides are at least one, at least two, at least three, at least four, at least five, or five mRNA polynucleotides, as described in this invention.

[025] In another aspect, the present disclosure provides a composition Petition 870250101498, dated 05 / 11 / 2025, pp. 397 / 546 8 / 109 comprising at least one mRNA polynucleotide encoding a norovirus VP1 polypeptide, as described in the present invention, and a pharmaceutically acceptable carrier.

[026] In another aspect, the present disclosure provides a composition comprising at least two mRNA polynucleotides encoding norovirus VP1 polypeptides, as described in the present invention, and a pharmaceutically acceptable carrier.

[027] In another aspect, the present disclosure provides a composition comprising at least three mRNA polynucleotides encoding norovirus VP1 polypeptides, as described in the present invention, and a pharmaceutically acceptable carrier.

[028] In another aspect, the present disclosure provides a composition comprising at least four mRNA polynucleotides encoding norovirus VP1 polypeptides, as described in the present invention, and a pharmaceutically acceptable carrier.

[029] In another aspect, the present disclosure provides a composition comprising at least five mRNA polynucleotides encoding norovirus VP1 polypeptides, as described in the present invention, and a pharmaceutically acceptable carrier. In some embodiments, the at least five mRNA polynucleotides are derived from noroviruses GII.4, GI.1, GII.2, GII.3 and GII.6. In some embodiments, the composition comprises five mRNA polynucleotides, each derived from one of the noroviruses GII.4, GI.1, GII.2, GII.3 and GII.6, and a pharmaceutically acceptable carrier.

[030] In another aspect, the present disclosure provides a composition comprising five mRNA polynucleotides encoding norovirus VP1 polypeptides and a pharmaceutically acceptable carrier, wherein each of the five mRNA polynucleotides comprises, from the 5' to the 3' direction: a Petition 870250101498, dated 05 / 11 / 2025, pp. 398 / 546 9 / 109 UTR 5' comprising the polynucleotide sequence of SEQ ID NO: 6; a polynucleotide encoding a norovirus VP1 polypeptide, wherein the polynucleotide is selected from the group consisting of SEQ ID NOs: 1 to 5 and sequences having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with them; and a UTR 3' comprising the polynucleotide sequence of SEQ ID NO: 7; and wherein the 5' UTR additionally comprises the structure Cap 5' N7-Methyl-G(3'OMe)ppp, and wherein the composition comprises each of the SEQ ID NOs: 1 to 5, or sequences having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with it, wherein in each of the SEQ ID NOs: 1 to 5, or sequences having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with it, all uridine residues in the five polynucleotides mRNA molecules are replaced with N1-methylpseudouridine.In certain forms, the VP1 polypeptide of norovirus is an antigenic polypeptide.

[031] In another aspect, the present disclosure provides a composition comprising five mRNA polynucleotides encoding norovirus VP1 polypeptides and a pharmaceutically acceptable carrier, wherein each of the five mRNA polynucleotides comprises, from the 5' to the 3' direction: a 5' UTR comprising the polynucleotide sequence of SEQ ID NO: 6; a polynucleotide encoding a norovirus VP1 polypeptide, wherein the polynucleotide is selected from the group consisting of SEQ ID NOs: 1 to 5; and a 3' UTR comprising the polynucleotide sequence of SEQ ID NO: 7; and wherein the 5' UTR additionally comprises the 5' Cap N7Methyl-G(3'OMe)ppp structure, and wherein the composition comprises each of SEQ ID NOs: 1 to 5, wherein in each of the SEQ ID NOs: 1 to 5 all uridine residues in the five mRNA polynucleotides are substituted with N1 Petition 870250101498, dated 05 / 11 / 2025, pp. 399 / 546 10 / 109 methylpseudouridine.

[032] In another aspect, the present disclosure provides a composition comprising five mRNA polynucleotides encoding norovirus VP1 polypeptides and a pharmaceutically acceptable carrier, wherein each of the five mRNA polynucleotides comprises, from the 5' to the 3' direction: a 5' UTR comprising the polynucleotide sequence of SEQ ID NO: 6; a polynucleotide encoding a norovirus VP1 polypeptide, wherein the polynucleotide is selected from the group consisting of SEQ ID NOs: 1 to 5 and sequences having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity therewith; and a 3' UTR comprising the polynucleotide sequence of SEQ ID NO: 8;and wherein the 5' UTR additionally comprises the 5' Cap N7-Methyl-G(3'OMe)ppp structure, and wherein the composition comprises each of the SEQ ID NOs: 1 to 5, and sequences having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with them, wherein in each of the SEQ ID NOs: 1 to 5, or sequences having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with them, all uridine residues in the five polynucleotides of mRNAs are replaced with N1-methylpseudouridine. In certain embodiments, the VP1 polypeptide of norovirus is an antigenic polypeptide.

[033] In another aspect, the present disclosure provides a composition comprising five mRNA polynucleotides encoding norovirus VP1 polypeptides and a pharmaceutically acceptable carrier, wherein each of the five mRNA polynucleotides comprises, from the 5' to the 3' direction: a 5' UTR comprising the polynucleotide sequence of SEQ ID NO: 6; a polynucleotide encoding a norovirus VP1 polypeptide, wherein the polynucleotide is selected from the group consisting of SEQ IDs NO: 1 Petition 870250101498, dated 05 / 11 / 2025, pages 400 / 546 11 / 109 to 5; and a 3' UTR comprising the polynucleotide sequence of SEQ ID NO: 8; and wherein the 5' UTR further comprises the 5' cap structure N7Methyl-G(3'OMe)ppp, and wherein the composition comprises each of the SEQ ID NOs: 1 to 5, wherein in each of the SEQ ID NOs: 1 to 5 all uridine residues in the five mRNA polynucleotides are substituted with N1-methylpseudouridine.

[034] In some embodiments, the composition further comprises one or more additional mRNA polynucleotides derived from a norovirus selected from the group consisting of a norovirus of genogroup I, a norovirus of genogroup II, a norovirus of genogroup III, a norovirus of genogroup IV, and a norovirus of genogroup V. In some embodiments, the VP1 polypeptide of the norovirus in the composition is derived from a norovirus of genogroup I or a norovirus of genogroup II. In some embodiments, the VP1 polypeptide of the norovirus in the composition is derived from a genogroup selected from the group consisting of: a norovirus GII.4, GI.1, GII.2, GII.3, and GII.6. In some embodiments, the VP1 polypeptide of the norovirus in the composition is selected from the group consisting of SEQ ID NOs: 14 to 18 and sequences with at least 70% identity therewith.

[035] In another aspect, the present disclosure provides a composition comprising at least one mRNA polynucleotide encoding a norovirus VP1 polypeptide and a pharmaceutically acceptable carrier. In some embodiments, the composition further comprises at least one, at least two, at least three, at least four, or at least five mRNA polynucleotides encoding a norovirus VP1 polypeptide.

[036] In some embodiments, each mRNA polynucleotide is encapsulated separately in a lipid nanoparticle (LNP) comprising one or more cationic or polycationic compounds. Petition 870250101498, dated 05 / 11 / 2025, pp. 401 / 546 12 / 109

[037] In some embodiments, each mRNA polynucleotide is encapsulated together in an LNP comprising one or more cationic or polycationic compounds.

[038] In some embodiments, each mRNA polynucleotide encapsulated in the LNP is present in an equal quantity.

[039] In some embodiments, each mRNA polynucleotide encapsulated in the LNP is not present in equal quantity.

[040] In some embodiments, LNP comprises one or more of the following components: a cationic lipid, a sterol, a phospholipid, and a polyethylene glycol lipid. In other embodiments, LNP comprises a cationic lipid, a sterol, a phospholipid, and a polyethylene glycol lipid.

[041] In some embodiments, LNP comprises 34 to 59 mol % of a cationic lipid, 30 to 48 mol % of a sterol, 10 to 24 mol % of a phospholipid and 1 to 2 mol % of a polyethylene glycol lipid.

[042] In some embodiments, the cationic lipid is selected from Petition 870250101498, dated 05 / 11 / 2025, pp. 402 / 546 13 / 109

[043] In some forms, the sterol is: (V).

[044] In some embodiments, in which the phospholipid is selected to

[045] In some embodiments, the polyethylene glycol lipid is selected Petition 870250101498, dated 05 / 11 / 2025, pp. 403 / 546 14 / 109

[046] In some embodiments, the cationic lipid is (13Z, 16Z)-N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine.

[047] In some forms, the sterol is cholesterol.

[048] In some embodiments, the phospholipid is distearolphosphatidylcholine (DSPC).

[049] In some embodiments, the polyethylene glycol lipid is dimyristoyl glycerol-polyethylene glycol (DMG-PEG).

[050] In some embodiments, the LNP comprises 49 to 59 mol% of (13Z, 16Z)-N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine. In other embodiments, the LNP comprises about 58 mol% of (13Z, 16Z)-N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine. In certain embodiments, the LNP comprises about 49 mol% of (13Z, 16Z)-N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine. Petition 870250101498, dated 05 / 11 / 2025, pp. 404 / 546 15 / 109

[051] In another aspect, the present disclosure provides a vaccine comprising an mRNA polynucleotide, a combination or a composition, as described in the present invention.

[052] In some embodiments, the vaccine additionally comprises a pharmaceutically acceptable carrier. In some embodiments, the vaccine additionally comprises an adjuvant.

[053] In some forms, the vaccine is monovalent, bivalent, trivalent, quadrivalent or pentavalent.

[054] In some embodiments, the mRNA polynucleotide, combination, composition and / or vaccine, as described in the present invention, are immunogenic in a mammalian species.

[055] In another aspect, the present disclosure provides a kit or kit of parts comprising an mRNA polynucleotide, a combination, a composition or a vaccine, as described in the present invention, wherein the kit or kit of parts optionally further comprises a liquid vehicle for solubilization and / or technical instructions providing information on administration and dosage of the components.

[056] In another aspect, the present disclosure provides an mRNA polynucleotide, a combination, a composition, a vaccine or a kit or kit of parts, as described in the present invention, for use as a medicament.

[057] In another aspect, the present disclosure provides an mRNA polynucleotide, a combination, a composition, a vaccine or a kit or kit of parts, as described in the present invention, for use in the manufacture of a medicament for the treatment or prophylaxis of a norovirus infection or a disorder related to a norovirus infection.

[058] In another aspect, the present disclosure provides an mRNA polynucleotide, a combination, a composition, a vaccine or a kit or kit of Petition 870250101498, dated 05 / 11 / 2025, pages 405 / 546 16 / 109 parts, as described in the present invention, for use in the treatment or prophylaxis of a norovirus infection or a disorder related to a norovirus infection.

[059] In another aspect, the present disclosure provides an mRNA polynucleotide, a combination, a composition, a vaccine or a kit or kit of parts, as described in the present invention, wherein an effective amount of the polynucleotide, combination, composition, vaccine or active component of the kit or kit of parts is administered by injection.

[060] In another aspect, the present disclosure provides a method for treating or preventing a disorder, wherein the method comprises administering to a needy individual an effective amount of an mRNA polynucleotide, a combination, a composition, a vaccine, or an active ingredient of the kit or kit of parts, as described in the present invention. In some embodiments, the disorder is a norovirus infection or a disorder related to a norovirus infection.

[061] In another aspect, the present disclosure provides a vector comprising one or more nucleic acids encoding an mRNA polynucleotide, as described in the present invention.

[062] In another aspect, the present disclosure provides a host cell comprising an mRNA polynucleotide, a combination or a vector, as described in the present invention.

[063] In another aspect, the present disclosure provides a polypeptide encoded by an mRNA polynucleotide, as described in the present invention.

[064] In another aspect, the present disclosure provides a method for producing a virus-like particle (VLP) comprising one or more norovirus VP1 polypeptides, wherein the method comprises transcribing a Petition 870250101498, dated 05 / 11 / 2025, pages 406 / 546 17 / 109 mRNA polynucleotide, a combination or a vector, as described in the present invention, in a recombinant nucleic acid expression system under conditions suitable for the assembly of one or more norovirus VP1 polypeptides expressed in a VLP.

[065] In another aspect, the present disclosure provides a VLP comprising one or more norovirus VP1 polypeptides produced according to the method described in the present invention.

[066] The summary of the technology described above is not exhaustive and other attributes and advantages of the technology will be apparent from the following detailed description and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS

[067] FIGURE 1 shows a 2% agarose E-gel of purified mRNA for the five coded norovirus VP1 sequences.

[068] FIGURES 2A to 2E show a graph depicting the interpolated endpoint titers detected in sera from mice vaccinated with the test vaccines. FIGURE 2A shows the titer for GI.1; FIGURE 2B shows the titer for GII.2; FIGURE 2C shows the titer for GII.3; FIGURE 2D shows the titer for GII.4; and FIGURE 2E shows the titer for GII.6.

[069] FIGURES 3A to 3E show a graph depicting the blocking titers of histocompatibility blood group antigen (HBGA) detected in sera from mice vaccinated with the test vaccines. FIGURE 3A shows the titer for GI.1; FIGURE 3B shows the titer for GII.2; FIGURE 3C shows the titer for GII.3; FIGURE 3D shows the titer for GII.4; and FIGURE 3E shows the titer for GII.6.

[070] FIGURES 4A to 4E show a graph depicting the interpolated endpoint titers detected in sera from NHPs vaccinated with the test vaccines. FIGURE 4A shows the titer for GI.1; FIGURE 4B shows the titer for Petition 870250101498, dated 05 / 11 / 2025, pp. 407 / 546 18 / 109 GII.2; FIGURE 4C shows the title for GII.3; FIGURE 4D shows the title for GII.4; and FIGURE 4E shows the title for GII.6.

[071] FIGURES 5A to 5E show a graph depicting the HBGA blocking titers detected in sera from NHPs vaccinated with the test vaccines. FIGURE 5A shows the titer for GI.1; FIGURE 5B shows the titer for GII.2; FIGURE 5C shows the titer for GII.3; FIGURE 5D shows the titer for GII.4; and FIGURE 5E shows the titer for GII.6. DETAILED DESCRIPTION

[072] The present disclosure provides mRNA polynucleotides, vaccine pharmaceutical compositions and kits comprising the same. The mRNA polynucleotides, vaccine compositions and kits are useful for the prophylactic and therapeutic treatment of norovirus infections. The present disclosure also provides vectors and host cells comprising the mRNA polynucleotides, methods for producing the vaccine pharmaceutical compositions and methods for using the vaccine pharmaceutical compositions for the treatment of norovirus infections. Definitions

[073] The definitions of various terms used in the present invention are listed in the present invention. These definitions apply to the terms as they are used throughout this specification and claims, unless otherwise limited in specific cases, individually or as part of a larger group.

[074] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning commonly understood by someone with common knowledge of the art. Generally, the nomenclature used in the present invention and the laboratory procedures in cell culture, molecular genetics, organic chemistry and chemistry of Petition 870250101498, dated 05 / 11 / 2025, pp. 408 / 546 19 / 109 peptides are those that are well-known and commonly used in the technique.

[075] As used in the present invention, the articles “a” and “an” refer to one or more of (i.e., at least one) grammatical object of the article. By way of example, an element means one or more of an element. Furthermore, the use of the term including, as well as other forms such as include, includes and included, is not limiting.

[076] As used in the present invention, the term about in quantitative terms refers to plus or minus 10% of the value it modifies (rounded to the nearest whole number if the value is not subdivisible, such as a number of molecules or nucleotides).

[077] All ranges disclosed in the present invention include the aforementioned endpoint and are independently combinable (for example, the range from 50 mg to 500 mg includes the endpoints, 50 mg and 500 mg, and all intermediate values). The endpoints of the ranges and any values ​​disclosed in the present invention are not limited to the precise range or value; they are sufficiently imprecise to include values ​​that approximate those ranges and / or values.

[078] As used in the present invention, the term comprising may include embodiments consisting of and essentially consisting of. The terms comprising, including, having, has, may, contains and variants thereof, as used in this invention, are intended to be open transition phrases, terms or words that require the presence of the named ingredients / steps and permit the presence of other ingredients / steps. However, such a description should be interpreted as also describing compositions or processes such as consisting of and essentially consisting of the enumerated components, which permit the presence of only the components or compounds. Petition 870250101498, dated 05 / 11 / 2025, pp. 409 / 546 20 / 109 named, together with any acceptable carriers or fluids, and excludes other components or compounds. Nucleic acids / polynucleotides

[079] Norovirus vaccines, as provided in the present invention, comprise at least one (one or more) ribonucleic acid (RNA) polynucleotide having an open reading frame encoding at least one antigenic norovirus polypeptide. The term “nucleic acid”, in its broadest sense, includes any compound and / or substance comprising a polymer of nucleotides. These polymers are referred to as “polynucleotides”.Nucleic acids (also called polynucleotides) can be, or may include, for example, ribonucleic acids (RNAs), deoxyribonucleic acids (DNAs), threose nucleic acids (TNAs), glycolic nucleic acids (GNAs), peptide nucleic acids (PNAs), blocked nucleic acids (LNAs, including LNA having a β-D-ribo configuration, α-LNA having an α-L-ribo configuration (a diastereomer of LNA), 2'-amino-LNA having a 2'-amino functionalization and 2'-amino-α-LNA having a 2'-amino functionalization), ethylene nucleic acids (ENA), cyclohexenyl nucleic acids (CeNA), or chimeras or combinations thereof.

[080] In some embodiments, the polynucleotides of the present disclosure function as messenger RNA (mRNA). “Messenger RNA” (mRNA) refers to any polynucleotide that encodes one (at least one) polypeptide (a polymer of naturally occurring, unnaturally occurring, or modified amino acids) and can be translated to produce the encoded polypeptide in vitro, in vivo, in situ, or ex vivo. Those skilled in the art will understand that, except where otherwise indicated, the polynucleotide sequences presented in the present patent application will feature “T”s in a representative DNA sequence, but where the sequence represents RNA, the Petition 870250101498, dated 05 / 11 / 2025, pages 410 / 546 21 / 109 Ts would be replaced with Us.

[081] The basic components of an mRNA molecule typically include at least one coding region, a 5' untranslated region (UTR), a 3' UTR, a 5' cap, and a poly(A) tail. The polynucleotides of the present disclosure can function as mRNA, but can be distinguished from wild-type mRNA in their functional and / or structural design attributes, which serve to overcome existing problems of effective polypeptide expression using nucleic acid-based therapies.

[082] In some embodiments, an RNA polynucleotide of a norovirus vaccine codes 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2, 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, 2 to 4, 2 to 3, 3 to 10, 3 to 9, 3 to 8,3 to 7, 3 to 6, 3 to 5, 3 to 4, 4 to 10, 4 to 9, 4 to 8, 4 to 7, 4 to 6, 4 to 5, 5 to 10, 5 to 9, 5 to 8.5 7, 5 to 6, 6 to 10, 6 to 9, 6 to 8, 6 to 7, 7 to 10, 7 to 9, 7 to 8, 8 to 10, 8 to 9, or 9 to 10 antigenic polypeptides. In some embodiments, one RNA polynucleotide of a norovirus vaccine encodes an antigenic polypeptide derived from a single norovirus genotype, i.e., the vaccine is monovalent. In some embodiments, the RNA polynucleotides of a norovirus vaccine encode antigenic polypeptides derived from two distinct norovirus genotypes, i.e., the vaccine is bivalent. In some embodiments, the RNA polynucleotides of a norovirus vaccine encode antigenic polypeptides derived from three distinct norovirus genotypes, i.e., the vaccine is trivalent. In some forms, the RNA polynucleotide of a norovirus vaccine encodes antigenic polypeptides derived from four distinct norovirus genotypes, meaning the vaccine is quadrivalent.In certain forms, the RNA polynucleotides in the norovirus vaccine encode antigenic polypeptides derived from five distinct norovirus genotypes, meaning the vaccine is pentavalent. Petition 870250101498, dated 05 / 11 / 2025, pp. 411 / 546 22 / 109

[083] In some embodiments, the polynucleotides of the present disclosure are codon-optimized. Codon optimization methods are known in the art and can be used as provided in the present invention.Codon optimization, in some modalities, can be used to match codon frequencies in target and host organisms to ensure proper folding; bias GC content to increase mRNA stability or reduce secondary structures; minimize tandem repeat codons or base runs that may impair gene construction or expression; customize transcriptional and translational control regions; insert or remove protein trafficking sequences; remove / add post-translational modification sites in the encoded protein (e.g., glycosylation sites); add, remove, or shuffle protein domains; insert or restrict sites; modify ribosome binding sites and mRNA degradation sites; adjust translation rates to allow the various protein domains to fold properly; or reduce or eliminate problematic secondary structures within the polynucleotide.Tools, algorithms, and services for codon optimization are known in the art; non-limiting examples include services from GeneArt (Life Technologies), DNA2.0 (Menlo Park, CA), and / or proprietary methods. In some embodiments, the open read-frame (ORF) sequence is optimized using optimization algorithms.

[084] In some embodiments, a codon-optimized sequence shares less than 95% sequence identity, less than 90% sequence identity, less than 85% sequence identity, less than 80% sequence identity, or less than 75% sequence identity with a natural or wild-type sequence. In certain embodiments of the present invention, the codon-optimized polynucleotide sequence is Petition 870250101498, dated 05 / 11 / 2025, pp. 412 / 546 23 / 109 any of the SEQ ID NOs: 1 to 5 or 9 to 13, or a sequence having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity therewith. In certain embodiments of the present invention, the codon-optimized polynucleotide sequence is any of the SEQ ID NOs: 1 to 5 or 9 to 13.

[085] In addition to a coding region, a mature mRNA comprises a 5' untranslated region (UTR) and a 3' UTR, which play important roles in the regulation of gene expression. A “5' UTR” refers to a region of an mRNA that is directly upstream (i.e., 5') of the start codon (i.e., the first codon of an mRNA transcript translated by a ribosome) that does not code for a polypeptide. A “3' UTR” refers to a region of an mRNA that is directly downstream (i.e., 3') of the stop codon (i.e., the codon of an mRNA transcript that signals the termination of translation) that does not code for a polypeptide. In some embodiments of the present invention, the 5' UTR is SEQ ID NO: 6. In some embodiments, the 3' UTR is SEQ ID NO: 7 or SEQ ID NO: 8.

[086] The 5' UTR may additionally comprise a 5' cap sequence. 5' polynucleotide capping can be completed concomitantly during an in vitro transcription reaction using the following RNA cap chemical analogs to generate the 5' guanosine cap structure, according to the manufacturer's protocols: 3'-O-Me-m7G(5')ppp(5')G [the ARCA cap];G(5')ppp(5')A;G(5')ppp(5')G;m7G(5')ppp(5')A;m7G(5')ppp(5')G (New New England BioLabs, Ipswich, MA). The 5' capping of the modified RNA can be completed post-transcriptionally using a Vaccinia Virus Capping Enzyme to generate the “Cap 0” structure: m7G(5')ppp(5')G (New England BioLabs, Ipswich, MA). The Cap 1 structure can be generated using either the Vaccinia Virus Capping Enzyme or a 2'-O methyltransferase to generate: Petition 870250101498, dated 05 / 11 / 2025, pp. 413 / 546 24 / 109 m7G(5')ppp(5')G-2'-O-methyl. The Cap 2 structure can be generated from the Cap 1 structure followed by 2'-O-methylation of the 5'-antepenultimate nucleotide using a 2'-O-methyltransferase. The Cap 3 structure can be generated from the Cap 2 structure followed by 2'-O-methylation of the 5'-pre-antepenultimate nucleotide using a 2'-O-methyltransferase. The enzymes are preferably derived from a recombinant source. In certain embodiments of the present invention, the 5' cap structure is N7-Methyl-G(3'OMe)ppp.

[087] The 3' UTR may additionally comprise a poly(A) sequence or a poly(C) sequence, which are typically located at the 3' end of an mRNA. A poly(A) sequence, also called a poly(A) tail or poly(A) 3' tail, is typically understood to be a sequence of adenosine nucleotides, for example, up to about 400 adenosine nucleotides (SEQ ID NO: 29), for example, from about 10 to about 400, preferably from about 10 to about 200, more preferably from about 20 to about 80, even more preferably from about 40 to about 80, most preferably from about 60 to about 80 adenosine nucleotides. In certain embodiments of the present invention, the poly(A) sequence comprises 80 adenine nucleotides (SEQ ID NO: 24).A poly(C) sequence, also called a poly(C) tail or poly(C) 3' tail, is typically understood to be a sequence of cytidine nucleotides, for example, up to about 400 cytidine nucleotides (SEQ ID NO: 31), for example, from about 10 to about 400, preferably from about 10 to about 200, more preferably from about 20 to about 80, even more preferably from about 40 to about 80, most preferably from about 60 to about 80 cytidine nucleotides. In certain embodiments of the present invention, the poly(C) sequence comprises 80 cytidine nucleotides (SEQ ID NO: 30).

[088] In the context of the present invention, a poly(A) sequence can Petition 870250101498, dated 05 / 11 / 2025, pp. 414 / 546 25 / 109 be located within an mRNA or any other nucleic acid molecule, such as, for example, in a vector, for example, in a vector that serves as a template for the generation of an RNA, preferably an mRNA, for example, by transcription of the vector. Furthermore, poly(A) sequences, or poly(A) tails, can be generated in vitro by enzymatic polyadenylation of RNA, for example, using Poly(A)polymerases (PAP) derived from E. coli or yeast. Additionally, RNA polyadenylation can be achieved using immobilized PAP enzymes, for example, in a polyadenylation reactor. See International Patent Application Publication WO 2016 / 174271. Chemical Modifications

[089] The RNA vaccines of the present disclosure comprise at least one ribonucleic acid (RNA) polynucleotide having an open reading frame encoding at least one antigenic norovirus polypeptide comprising at least one chemical modification.

[090] The terms “chemical modification” and “chemically modified” refer to modification with respect to adenosine (A), guanosine (G), uridine (U), thymidine (T), or cytidine (C) ribonucleosides or deoxyribonucleosides in at least one of their positions, patterns, percentage, or population. Generally, these terms do not refer to modifications of ribonucleotides present in naturally occurring 5'-terminal cap mRNA moieties. With respect to a polypeptide, the term “modification” refers to a modification with respect to the canonical set of 20 amino acids. Polypeptides, as provided in the present invention, are also considered “modified” if they contain amino acid substitutions, insertions, or a combination of substitutions and insertions.

[091] Polynucleotides (for example, RNA polynucleotides, such as mRNA polynucleotides), in some embodiments, comprise several Petition 870250101498, dated 05 / 11 / 2025, pages 415 / 546 26 / 109 (more than one) different modifications. In some embodiments, a specific region of a polynucleotide contains one, two, or more nucleoside or nucleotide modifications (optionally different). In some embodiments, a modified RNA polynucleotide (e.g., a modified mRNA polynucleotide), introduced into a cell or organism, exhibits reduced degradation in the cell or organism, respectively, compared to an unmodified polynucleotide. In some embodiments, a modified RNA polynucleotide (e.g., a modified mRNA polynucleotide), introduced into a cell or organism, may exhibit reduced immunogenicity in the cell or organism, respectively (e.g., a reduced innate response).

[092] Polynucleotide modifications include, without limitation, those described in the present invention. Polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) may comprise naturally occurring modifications, non-naturally occurring modifications, or the polynucleotide may comprise a combination of naturally occurring and non-naturally occurring modifications. Polynucleotides may include any useful modification, for example, of a sugar, a nucleobase, or an internucleosidic linkage (e.g., to a phosphate linkage, a phosphodiester bond, or the phosphodiester backbone).

[093] Polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides), in some embodiments, comprise unnatural modified nucleotides that are introduced during the synthesis or post-synthesis of the polynucleotides to achieve desired functions or properties. The modifications may be present in internucleotide linkages, purine or pyrimidine bases, or sugars. The modification may be introduced by chemical synthesis or by a polymerase enzyme in Petition 870250101498, dated 05 / 11 / 2025, pages 416 / 546 27 / 109 terminal of a chain or anywhere else in the chain. Any of the regions of a polynucleotide can be chemically modified.

[094] The present disclosure provides nucleosides and modified nucleotides of a polynucleotide (e.g., RNA polynucleotides, such as mRNA polynucleotides). A nucleoside refers to a compound containing a sugar molecule (e.g., a pentose or ribose) or a derivative thereof in combination with an organic base (e.g., a purine or pyrimidine) or a derivative thereof (also referred to in the present invention as a nucleobase). A nucleotide refers to a nucleoside including a phosphate group. The modified nucleotides may be synthesized by any useful method, such as, for example, chemically, enzymatically, or recombinantly, to include one or more modified or non-natural nucleosides. The polynucleotides may comprise one or more linked nucleoside regions. Such regions may have variable backbone linkages.The linkages can be standard phosphodiester bonds, in which case the polynucleotides would comprise nucleotide regions.

[095] Modified nucleotide base pairing encompasses not only the standard adenosine-thymine, adenosine-uracil, or guanosine-cytosine base pairs, but also base pairs formed between nucleotides and / or modified nucleotides comprising non-standard or modified bases, wherein the arrangement of hydrogen bond donors and acceptors allows hydrogen bonding between a non-standard base and a standard base or between two complementary non-standard base structures. An example of such non-standard base pairing is the base pairing between the modified nucleotide inosine and adenine, cytosine, or uracil. Any base / sugar or linker combination may be incorporated into the polynucleotides of the present disclosure. Petition 870250101498, dated 05 / 11 / 2025, pp. 417 / 546 28 / 109

[096] Modifications of polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) that are useful in the vaccines of the present disclosure include, but are not limited to, the following: 2-methylthio-N6(cis-hydroxyisopentenyl)adenosine; 2-methylthio-N6-methyladenosine; 2-methylthio-N6threonyl carbamoyladenosine; N6-glycinylcarbamoyladenosine; N6-isopentenyladenosine; N6-methyladenosine; N6-threonylcarbamoyladenosine; 1,2'O-dimethyladenosine; 1-methyladenosine; 2'-O-methyladenosine; 2'-Oribosyladenosine (phosphate); 2-methyladenosine; 2-methylthio-N6 is 2-methylthio-N6hydroxynorvalyl carbamoyladenosine; 2'-O-methyladenosine; 2'-O-ribosyladenosine (phosphate); Isopentenyladenosine; N6-(cis-hydroxyisopentenyl)adenosine; N6,2'-Odimethyladenosine; N6,2'-O-dimethyladenosine; N6,N6,2'-O-trimethyladenosine; N6,N6-dimethyladenosine; N6-acetyladenosine; N6hydroxynorvalylcarbamoyladenosine; N6-methyl-N6-threonylcarbamoyladenosine; 2methyladenosine; 2-methylthio-N6-isopentenyladenosine; 7-deaza-adenosine;N1-methyladenosine; N6, N6 (dimethyl)adenine; N6-cis-hydroxy-isopentenyl-adenosine; α-thio-adenosine; 2-(amino)adenine; 2-(aminopropyl)adenine; 2-(methylthio)N6 (isopentenyl)adenine; 2-(alkyl)adenine; 2-(aminoalkyl)adenine; 2-(aminopropyl)adenine; 2-(halo)adenine; 2-(halo)adenine; 2-(propyl)adenine; 2'-Amino-2'-deoxy-ATP; 2'-Azido-2'-deoxy-ATP; 2'-Deoxy-2'-α-aminoadenosine TP; 2'-Deoxy-2'-α-azidoadenosine TP; 6-(alkyl)adenine; 6-(methyl)adenine; 6-(alkyl)adenine; 6-(methyl)adenine; 7 (deaza)adenine; 8 (alkenyl)adenine; 8 (alkynyl)adenine; 8 (amino)adenine; 8 (thioalkyl)adenine; 8-(alkenyl)adenine; 8(alkyl)adenine; 8-(alkynyl)adenine; 8-(amino)adenine; 8-(halo)adenine; 8 (hydroxyla)adenine; 8-(thioalkyl)adenine; 8-(thiol)adenine; 8-azido-adenosine; aza adenine; Deaza Adenine; N6 (methyl)adenine; N6-(isopentyl)adenine; 7-deaza-8aza-adenosine; 7-methyladenine; 1-Deazaadenosine TP; 2'-Fluoro-N6-Bzdeoxyadenosine TP; 2'-OMe-2-amino-ATP; 2'O-methyl-N6-Bz-deoxyadenosine; Petition 870250101498, dated 05 / 11 / 2025, pp. 418 / 546 29 / 109 TP; 2'-a-ethynyladenosine TP; 2-aminoadenine; 2-Aminoadenosine TP; 2-AminoATP; 2'-a-Trifluoromethyladenosine TP; 2-Azidoadenosine TP; 2'-b-ethynyladenosine TP; 2-Bromoadenosine TP; 2'-b-Trifluoromethyladenosine TP; 2-chloradenosine TP; 2'-Deoxy-2',2'-difluoroadenosine TP; 2'-Deoxy-2'-a-mercaptoadenosine TP; 2'-Deoxy-2'-a-thiomethoxyadenosine TP; 2'-Deoxy-2'-b-aminoadenosine TP; 2'Deoxy-2'-b-azidoadenosine TP; 2'-Deoxy-2'-b-bromoadenosine TP; 2'-Deoxy-2'β-chloradenosine TP; 2'-Deoxy-2'-β-fluoroadenosine TP; 2'-Deoxy-2'-biodoadenosine TP; 2'-Deoxy-2'-β-mercaptoadenosine TP; 2'-Deoxy-2'-β-thiomethoxyadenosine TP; 2-fluoroadenosine TP; 2-iodoadenosine TP; 2-mercaptoadenosine TP; 2-methoxyadenine; 2-methylthioadenosine; 2-trifluoromethyladenosine TP; 3-Deaza-3-bromoadenosine TP; 3-Deaza-3-chloradenosine TP; 3-Deaza-3-fluoroadenosine TP; 3-Deaza-3-iodoadenosine TP; 3-Deazaadenosine TP; 4'-azidoadenosine TP; 4'-Carbocyclic adenosine TP; 4'ethynyladenosine TP; 5'-Homo-adenosine TP; 8-Aza-ATP;8-bromo-adenosine TP; 8-Trifluoromethyladenosine TP; 9-Deazaadenosine TP; 2-aminopurine; 7-deaza2,6-diaminopurine; 7-deaza-8-aza-2,6-diaminopurine; 7-deaza-8-aza-2aminopurine; 2,6-diaminopurine; 7-deaza-8-aza-adenine, 7-deaza-2aminopurine; 2-thiocytes; 3-methylcytidine; 5-formylcytidine; 5hidroxymethylcytidine; 5-methylcytidine; N4-acetylcytidine; 2'-O-methylcytidine; 2'-Omethylcytidine; 5,2'-O-dimethylcytidine; 5-formyl-2'-O-methylcytidine; Lysidine; N4,2'O-dimethylcytidine; N4-acetyl-2'-O-methylcytidine; N4-methylcytidine; N4,N4-Dimethyl2'-OMe-Cytidine TP; 4-methylcytidine; 5-aza-cytidine; Pseudo-iso-cytidine; pyrrolocytidine; α-thio-cytidine; 2-(thio)cytosine; 2'-Amino-2'-desoxi-CTP; 2'-Azido-2'desoxi-CTP; 2'-Desoxi-2'-a-aminocytidine TP; 2'-Desoxi-2'-a-azidocytidine TP; 3(deaza)5(aza)cytosine; 3(methyl)cytosine; 3-(alquil)cytosine; 3-(deaza)5(aza)cytosine; 3-(methyl)cytidine; 4,2'-O-dimethylcytidine; 5 (halo)cytosine; 5 (methyl)cytosine; 5 (propynyl)cytosine; 5 (trifluoromethyl)cytosine;5-(alkyl)cytosine; Petition 870250101498, dated 05 / 11 / 2025, pp. 419 / 546 30 / 109 5-(alquinyl)cytosine; 5-(halo)cytosine; 5-(propynyl)cytosine; 5(trifluoromethyl)cytosine; 5-bromo-cytidine; 5-iodo-cytidine; 5-propynyl cytosine; 6(azo)cytosine; 6-aza-cytidine; cytosine aza; cytosine deaza; N4 (acetyl)cytosine; 1methyl-1-deaza-pseudoisocytidine; 1-methyl-pseudoisocytidin; 2-methoxy-5-methylcytidine; 2-methoxycytidine; 2-thio-5-methylcytidine; 4-methoxy-1-methylpseudoisocytidine; 4-methoxy-pseudoisocytidine; 4-thio-1-methyl-1-deazapseudoisocytidine; 4-thio-1-methyl-pseudoisocytidine; 4-Thio-pseudoisocytidine; 5aza-zebularine; 5-methyl-zebularine; pyrrolo-pseudoisocytidine; Zebularine; (E)-5(2-bromo-vinyl)cytidine TP; 2,2'-anhydrocytidine hydrochloride TP; 2'Fluor-N4-Bzcytidine TP; 2'Fluoro-N4-Acetyl-cytidine TP; 2'-O-Methyl-N4-Acetyl-cytidine TP; 2'O-Methyl-N4-Bz-cytidine TP; 2'-a-Ethynylcytidine TP; 2'-a-Trifluoromethylcytidine TP; 2'-Bethynylcytidine TP; 2'-b-Trifluoromethylcytidine TP; 2'-Desoxy-2',2'-difluorocytidine TP; 2'-Desoxi-2'-a-mercaptocytidine TP;2'-Desoxi-2'-a-thiometoxicitidine TP; 2'-Desoxi-2'-b-aminocytidine TP; 2'-Desoxi-2'-b-azidocytidine TP; 2'-Desoxi-2'-bbromocytidine TP; 2'-Desoxi-2'-b-chlorocytidine TP; 2'-Desoxi-2'-b-fluorocytidine TP; 2'-Desoxi-2'-b-iodocytidine TP; 2'-Desoxi-2'-b-mercaptocytidine TP; 2'-Desoxi2'-b-thiometoxicitidine TP; 2'-O-methyl-5-(1-propynyl)cytidine TP; 3'-ethynylcytidine TP; 4'-azidocytidine TP; 4'-carboxylic cytidine TP; 4'-ethynylcytidine TP; 5-(1propynyl)ara-cytidine TP; 5-(2-chlorophenyl)-2-thiocytes TP; 5-(4-amino-phenyl)-2thiocytesid TP; 5-Aminoalyl-CTP; 5-Cyanocytidine TP; 5-Ethynylara-cytidine TP; 5ethynylcytidine TP; 5'-Homo-cytidine TP; 5-Metoxicitidine TP; 5-TrifluoromethylCytidine TP; N4-Aminocytidine TP; N4-benzoyl-cytidine TP; Pseudoisocytidin; 7methylguanosine; N2,2'-O-dimethylguanosine; N2-methylguanosine; Wyosine; 1,2'-Odimethylguanosine; 1-methylguanosine; 2'-O-methylguanosine; 2'-O-ribosylguanosine (phosphate); 2'-O-methylguanosine; 2'-O-ribosylguanosine (phosphate);7-aminomethyl-7-deazaguanosine; 7-cyano-7-deazaguanosine; Archaeosine; Methylwyosine; N2,7-dimethylguanosine; N2,N2,2'-O-trimethylguanosine; N2,N2,7-trimethylguanosine; Petition 870250101498, dated 05 / 11 / 2025, pp. 420 / 546 31 / 109 N2,N2-dimethylguanosine; N2,7,2'-O-trimethylguanosine; 6-thio-guanosine; 7-deazaguanosine; 8-oxo-guanosine; N1-methyl-guanosine; α-thio-guanosine; 2-(propyl)guanine; 2-(alkyl)guanine; 2'-Amino-2'-deoxy-GTP; 2'-Azido-2'-deoxyGTP; 2'-Deoxy-2'-α-aminoguanosine TP; 2'-Deoxy-2'-α-azidoguanosine TP; 6-(methyl)guanine; 6-(alkyl)guanine; 6-(methyl)guanine; 6-methyl-guanosine; 7-(alkyl)guanine; 7-(deaza)guanine; 7-(methyl)guanine; 7-(alkyl)guanine; 7-deaza)guanine; 7-(methyl)guanine; 8-(alkyl)guanine; 8-(alkynyl)guanine; 8-(halo)guanine; 8-(thioalkyl)guanine; 8-(alkenyl)guanine; 8-(alkyl)guanine; 8-(alkynyl)guanine; 8-(amino)guanine; 8-(halo)guanine; 8-(hydroxyla)guanine; 8-(thioalkyl)guanine; 8-(thiol)guanine; aza guanine; guanine deaza; N-(methyl)guanine; N-(methyl)guanine; 1-methyl-6-thio-guanosine; 6-methoxy-guanosine; 6-thio7-deaza-8-aza-guanosine; 6-thio-7-deaza-guanosine; 6-thio-7-methyl-guanosine; 7-deaza-8-aza-guanosine; 7-methyl-8-oxo-guanosine; N2,N2-dimethyl-6-thioguanosine;N2-methyl-6-thio-guanosine; 1-Me-GTP; 2'-Fluoro-N2-isobutyl-guanosine TP; 2'O-methyl-N2-isobutyl-guanosine TP; 2'-α-ethinylguanosine TP; 2'-α-Trifluoromethylguanosine TP; 2'-β-ethinylguanosine TP; 2'-β-Trifluoromethylguanosine TP; 2'-Deoxy-2',2'-difluoroguanosine TP; 2'-Deoxy-2'-amercaptoguanosine TP; 2'-Deoxy-2'-α-thiomethoxyguanosine TP; 2'-Deoxy-2'-β-; aminoguanosine TP; 2'-Deoxy-2'-β-azidoguanosine TP; 2'-Deoxy-2'-β-bromoguanosine TP; 2'-Deoxy-2'-β-chloroguanosine TP; 2'-Deoxy-2'-β-fluoroguanosine TP; 2'-Deoxy-2'-β-iodoguanosine TP; 2'-Deoxy-2'-β mercaptoguanosine TP; 2'-Deoxy-2'-β-thiomethoxyguanosine TP; 4'azidoguanosine TP; 4'-carbocyclic guanosine TP; 4'-ethinylguanosine TP; 5'-Homoguanosine TP; 8-bromoguanosine TP; 9-Deazaguanosine TP; N2-isobutylguanosine TP; 1-methylinosine; Inosine; 1,2'-O-dimethylinosine; 2'-O-methylinosine; 7-methylinosine; 2'-O-methylinosine; Epoxycheuosine; galactosylcheuosine; Mannosylcheuosine; Cheuosine; allia-aminothymidine; azathymidine; deazathymidine; Petition 870250101498, dated 05 / 11 / 2025, pp. 421 / 546 32 / 109 deoxy-thymidine; 2'-O-methyluridine; 2-thiouridine; 3-methyluridine; 5carboxymethyluridine; 5-hydroxyuridine; 5-methyluridine; 5-taurinomethyl-2thiouridine; 5-taurinomethyluridine; Dihydrouridine; Pseudouridine; (3-(3-amino-3carboxypropyl)uridine; 1-methyl-3-(3-amino-5-carboxypropyl)pseudouridine; 1methylpseudouridine; 1-methyl-pseudouridine; 2'-O-methyluridine; 2'-Omethylpseudouridine; 2'-O-methyluridine; 2-thio-2'-O-methyluridine; 3-(3-amino-3carboxypropyl)uridine; 5-(carboxyhydroxymethyl)uridine; 5-carbamoylmethyl-2'-O-methyluridine; 5-carboxyhydroxymethyluridine; 5-carboxyhydroxymethyluridine; methyl ester of 5-carboxyhydroxymethyluridine; 5-carboxymethylaminomethyl-2'-O-methyluridine; 5-carboxymethylaminomethyl-2-thiouridine; 5-carboxymethylaminomethyl-2-thiouridine; 5-carboxymethylaminomethyluridine; 5-carboxymethylaminomethyluridine;5-carbamoylmethyluridine TP; 5-methoxycarbonylmethyl-2'-O-methyluridine; 5-methoxycarbonylmethyl-2-thiouridine; 5-methoxycarbonylmethyluridine; 5-methoxyuridine; 5-methyl-2-thiouridine; 5-methylaminomethyl-2-selenouridine; 5-methylaminomethyl-2-thiouridine; 5-methylaminomethyluridine; 5-methyldihydrouridine; 5-oxyacetic acid - uridine TP; 5-oxyacetic acid-methyl ester-uridine TP; N1-methyl-pseudo-uridine; uridine 5-oxyacetic acid; uridine 5-oxyacetic acid methyl ester; 3-(3-amino-3-carboxypropyl)-uridine TP; 5-(isopentenylaminomethyl)-2-thiouridine TP; 5-(iso-pentenylaminomethyl)-2'-Omethyluridine TP; 5-(iso-pentenylaminomethyl)uridine TP; 5-propynyl uracil; α-thiouridine; 1 (aminoalkylamino-carbonylethylene)-2(thio)-pseudouracil; 1 (aminoalkylaminocarbonylethylene)-2,4-(dithio)pseudouracil; 1 (aminoalkylaminocarbonylethylene)-4 (thio)pseudouracil; 1 (aminoalkylaminocarbonylethylenyl)-pseudouracil; 1 (aminocarbonylethylenel); Petition 870250101498, dated 05 / 11 / 2025, pp. 422 / 546 33 / 1092(thio)-pseudouracil; 1-(aminocarbonylethylene)-2,4-(dithio)pseudouracil; 1-(aminocarbonylethyleneyl)-4-(thio)pseudouracil; 1-(aminocarbonylethyleneyl)pseudouracil; 1-2(thio)-substituted pseudouracil; 1-2,4-(dithio)pseudouracil; 1-4-substituted (thio)pseudouracil; 1-substituted pseudouracil; 1-(aminoalkylamino-carbonylethylene)-2-(thio)-pseudouracil; 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine TP; 1-methyl-3-(3-amino-3-carboxypropyl)pseudoUTP; 1-methyl-pseudo-UTP; 2-(thio)pseudouracil; 2'-deoxyuridine; 2'-fluorouridine; 2-(thio)uracil; 2,4-(dithio)pseudouracil; 2'-methyl, 2'-amino, 2'-azido, 2'-fluoroguanosine; 2'-Amino-2'-deoxy-UTP; 2'-Azido-2'-deoxy-UTP; 2'-azidodeoxyuridine TP; 2'-O-methylpseudouridine; 2'-uridine deoxy; 2'-fluorouridine; 2'-Deoxy-2'-a-aminouridine TP; 2'-Deoxy-2'-a-azidouridine TP; 2-methylpseudouridine; 3-(3-amino-3-carboxypropyl)uracil; 4-(thio)pseudouracil; 4-(thio)pseudouracil; 4-(thio)uracil; 4-thiouracil; 5 (1,3-diazol-1-alkyl)uracil;5-(2-aminopropyl)uracil; 5-(aminoalkyl)uracil; 5-(dimethylaminoalkyl)uracil; 5-(guanidinioalkyl)uracil; 5-(methoxycarbonylmethyl)-2-(thio)uracil; 5-(methoxycarbonylmethyl)uracil; 5-(methyl)-2-(thio)uracil; 5-(methyl)-2,4-(dithio)uracil; 5-(methyl)-4-(thio)uracil; 5-(methylaminomethyl)-2-2-(thio)uracil; 5-(methylaminomethyl)-2,4-(dithio)uracil; 5-(methylaminomethyl)-4-(thio)uracil; 5-(propynyl)uracil; 5-(trifluoromethyl)uracil; 5-(2-aminopropyl)uracil; 5-(alkyl)-2-(thio)pseudouracil; 5-(alkyl)-2,4-(dithio)pseudouracil; 5-(alkyl)-4(thio)pseudouracil; 5(alkyl)pseudouracil; 5-(alkyl)uracil; 5-(alkynyl)uracil; 5-(allylamino)uracil; 5-(cyanoalkyl)uracil; 5-(dialkylaminoalkyl)uracil; 5(dimethylaminoalkyl)uracil; 5-(guanidinioalkyl)uracil; 5-(halo)uracil; 5-(L,3diazol-L-alkyl)uracil; 5-(methoxy)uracil; 5-(methoxycarbonylmethyl)-2-(thio)uracil; 5-(methoxycarbonyl-methyl)uracil; 5-(methyl)2(thio)uracil; 5-(methyl)2,4-(dithio)uracil; 5-(methyl)4-(thio)uracil; 5-(methyl)-2-(thio)pseudouracil;5-(methyl)-2,4 (dithio)pseudouracil; 5-(methyl)-4-(thio)pseudouracil; 5-(methyl)pseudouracil; 5; Petition 870250101498, dated 05 / 11 / 2025, pp. 423 / 546 34 / 109 (methylaminomethyl)-2,2-thio)uracil; 5-(methylaminomethyl)-2,4-(dithio)uracil; 5-(methylaminomethyl)-4-(thio)uracil; 5-(propynyl)uracil; 5-(trifluoromethyl)uracil; 5-aminoallyl-uridine; 5-bromo-uridine; 5-iodo-uridine; 5-uracil; 6-(azo)uracil; 6-aza-uridine; allo-uracil; uracil aza; Deaza Uracil; N3 (methyl)uracil; Pseudo-UTP-1,2-ethanoic acid; Pseudouracil; 4-thio-pseudoUTP; 1-carboxymethyl-pseudouridine; 1-methyl-1-deaza-pseudouridine; 1-propynyluridine; 1-taurinomethyl-1-methyl-uridine; 1-taurinomethyl-4-thio-uridine; 1taurinomethyl-pseudouridine; 2-methoxy-4-thio-pseudouridine; 2-thio-1-methyl-1deaza-pseudouridine; 2-thio-1-methyl-pseudouridine; 2-thio-5-aza-uridine; 2-thiodihydropseudouridine; 2-thio-di-hydrouridine; 2-thio-pseudouridine; 4-methoxy-2thio-pseudouridine; 4-methoxy-pseudouridine; 4-thio-1-methyl-pseudouridine; 4-thiopseudouridine; 5-aza-uridine; Diidropseudouridine; (±)1-(2hydroxypropyl)pseudouridine TP; (2R)-1-(2-hydroxypropyl)pseudouridine TP;(2S)1-(2-hidroxipropil)pseudouridina TP; (E)-5-(2-Bromo-vinil)ara-uridina TP; (E)-5(2-bromo-vinil)uridina TP; (Z)-5-(2-bromo-vinil)ara-uridina TP; (Z)-5-(2-Bromovinil)uridina TP; 1-(2,2,2-Trifluoroetil)-pseudo-UTP; 1-(2,2,3,3,3pentafluoropropil)pseudouridina TP; 1-(2,2-Dietoxietil)pseudouridina TP; 1(2,4,6-Trimetilbenzil)pseudouridina TP; 1-(2,4,6-Trimetilbenzil)pseudo-UTP; 1(2,4,6-Trimetil-fenil)pseudo-UTP; 1-(2-amino-2-carboxietil)pseudo-UTP; 1-(2amino-etil)pseudo-UTP; 1- (2-hidroxietil) pseudouridina TP; 1-(2metoxietil)pseudouridina TP; 1-(3,4-Bis-trifluorometoxibenzil)pseudouridina TP; 1-(3,4-dimetoxibenzil)pseudouridina TP; 1-(3-amino-3-carboxipropil)pseudoUTP; 1-(3-amino-propil)pseudo-UTP; 1-(3-ciclopropil-prop-2-inil)pseudouridina TP; 1-(4-amino-4-carboxibutil)pseudo-UTP; 1-(4-aminobenzil)pseudo-UTP; 1-(4amino-butil)pseudo-UTP; 1-(4-amino-fenil)pseudo-UTP; 1-(4azidobenzil)pseudouridina TP; 1-(4-Bromobenzil)pseudouridina TP; 1-(4clorobenzil)pseudouridina TP;1-(4-fluorobenzyl)pseudouridine TP; 1-(4; Petition 870250101498, dated 05 / 11 / 2025, pp. 424 / 546 35 / 109 iodobenzyl)pseudouridina TP; 1-(4-methanosulfonylbenzyl)pseudouridina TP; 1(4-methoxybenzyl)pseudouridina TP; 1-(4-methoxy-benzyl)pseudo-UTP; 1-(4-methoxyphenyl)pseudo-UTP; 1-(4-methylbenzyl)pseudouridina TP; 1-(4-methyl-benzyl)pseudoUTP; 1-(4-nitrobenzyl)pseudouridina TP; 1-(4-nitrobenzyl)pseudo-UTP; 1(4-nitrophenyl)pseudo-UTP; 1-(4-thiomethoxybenzyl)pseudouridina TP; 1-(4Trifluoromethoxybenzyl)pseudouridina TP; 1-(4Trifluoromethylbenzyl)pseudouridina TP; 1-(5-amino-pentyl)pseudo-UTP; 1-(6amino-hexyl)pseudo-UTP; 1,6-Dimethyl-pseudo-UTP; 1-[3-(2-{2-[2-(2-Aminoethoxy)ethoxy]-ethoxy}-ethoxy)-propionyl]pseudouridine TP; 1-{3-[2-(2-Aminoethoxy)-ethoxy]propionyl} pseudouridina TP; 1-acetylpseudouridina TP; 1-Alkyl-6-(1-propynyl)pseudo-UTP; 1-Alkyl-6-(2-propynyl)-pseudo-UTP; 1-alkyl-6-allyl-pseudo-UTP; 1Alkyl-6-ethynyl-pseudo-UTP; 1-Alkyl-6-homoallyl-pseudo-UTP; 1-Alkyl-6-vinylpseudo-UTP; 1-Allylpseudouridina TP; 1-Aminomethyl-pseudo-UTP; 1benzoylpseudouridina TP; 1-Benzyloxymethylpseudouridina TP;1-Benzil-pseudoUTP; 1-Biotinil-PEG2-pseudouridina TP; 1-Biotinilpseudouridina TP; 1-Butilpseudo-UTP; 1-cianometilpseudouridina TP; 1-Ciclobutilmetil-pseudo-UTP; 1Ciclobutil-pseudo-UTP; 1-cicloheptilmetil-pseudo-UTP; 1-Cicloheptil-pseudoUTP; 1-ciclohexilmetil-pseudo-UTP; 1-ciclohexil-pseudo-UTP; 1-ciclooctilmetilpseudo-UTP; 1-Ciclooctil-pseudo-UTP; 1-ciclopentilmetil-pseudo-UTP; 1ciclopentil-pseudo-UTP; 1-ciclopropilmetil-pseudo-UTP; 1-Ciclopropil-pseudoUTP; 1-Etil-pseudo-UTP; 1-Hexil-pseudo-UTP; 1-Homoal-pseudouridina TP; 1hidroximetilpseudouridina TP; 1-iso-propil-pseudo-UTP; 1-Me-2-tio-pseudoUTP; 1-Me-4-tio-pseudo-UTP; 1-Me-alfa-tio-pseudo-UTP; 1metanossulfonilmetilpseudouridina TP; 1-metoximetilpseudouridina TP; 1metil-6-(2,2,2-trifluoroetil)pseudo-UTP; 1-metil-6-(4-morfolino)-pseudo-UTP; 1metil-6-(4-tiomorfolino)-pseudo-UTP; 1-metil-6-(fenil)pseudo-UTP; 1-metil-6amino-pseudo-UTP; 1-metil-6-azido-pseudo-UTP; 1-metil-6-bromo-pseudo-UTP; Petition 870250101498, dated 05 / 11 / 2025, pp. 425 / 546 36 / 109 1-metil-6-butil-pseudo-UTP; 1-metil-6-cloro-pseudo-UTP; 1-metil-6-cianopseudo-UTP; 1-metil-6-dimetilamino-pseudo-UTP; 1-metil-6-etoxi-pseudo-UTP; 1-metil-6-etilcarboxilato-pseudo-UTP; 1-metil-6-etil-pseudo-UTP; 1-metil-6fluoro-pseudo-UTP; 1-metil-6-foril-pseudo-UTP; 1-metil-6-hidroxiaminopseudo-UTP; 1-metil-6-hidroxi-pseudo-UTP; 1-metil-6-iodo-pseudo-UTP; 1metil-6-iso-propil-pseudo-UTP; 1-metil-6-metoxi-pseudo-UTP; 1-metil-6metilamino-pseudo-UTP; 1-metil-6-fenil-pseudo-UTP; 1-metil-6-propil-pseudoUTP; 1-metil-6-terc-butil-pseudo-UTP; 1-metil-6-trifluorometoxi-pseudo-UTP; 1metil-6-trifluorometil-pseudo-UTP; 1-Morfolinoilpseudouridina TP; 1-Pentilpseudo-UTP; 1-fenil-pseudo-UTP; 1-Pivaloilpseudouridina TP; 1Propargilpseudouridina TP; 1-Propil-pseudo-UTP; 1-propinil-pseudouridina; 1-ptolil-pseudo-UTP; 1-terc-butil-pseudo-UTP; 1-tiometoximetilpseudouridina TP; 1-tiomorfolinometilpseudouridina TP; 1-Trifluoroacetilpseudouridina TP; 1Trifluorometil-pseudo-UTP; 1-Vinilpseudouridina TP;2,2'-anidro-uridina TP; 2'bromo-desoxiuridina TP; 2'-F-5-metil-2'-desoxi-UTP; 2'-OMe-5-Me-UTP; 2'OMe-pseudo-UTP; 2'-a-etiniluridina TP; 2'-a-Trifluorometiluridina TP; 2'-betiniluridina TP; 2'-b-Trifluorometiluridina TP; 2'-Desoxi-2',2'-difluorouridina TP; 2'-Desoxi-2'-a-mercapturidina TP; 2'-Desoxi-2'-a-tiometoxiuridina TP; 2'-Desoxi2'-b-aminouridina TP; 2'-Desoxi-2'-b-azidouridina TP; 2'-Desoxi-2'-bbromouridina TP; 2'-Desoxi-2'-b-clorouridina TP; 2'-Desoxi-2'-b-fluorouridina TP; 2'-Desoxi-2'-b-iodouridina TP; 2'-Desoxi-2'-b-mercapturidina TP; 2'-Desoxi-2'-btiometoxiuridina TP; 2-metoxi-4-tio-uridina; 2-metoxiuridina; 2'-O-metil-5-(1propinil)uridina TP; 3-Alquil-pseudo-UTP; 4'-Azidouridina TP; 4'-uridina carbocíclica TP; 4'-etiniluridina TP; 5-(1-propinil)ara-uridina TP; 5-(2furanil)uridina TP; 5-Cianouridina TP; 5-Dimetilaminouridina TP; 5'-Homouridina TP; 5-iodo-2'-fluoro-desoxiuridina TP; 5-feniletiniluridina TP; 5Trideuterometil-6-deuteroridina TP; 5-Trifluorometil-Uridina TP; 5; Petition 870250101498, dated 05 / 11 / 2025, pp. 426 / 546 37 / 109 Vinylaruridine TP; 6-(2,2,2-Trifluoroethyl)-pseudo-UTP; 6-(4-morpholino)-pseudoUTP; 6-(4-thiomorpholino)-pseudo-UTP; 6-(phenyl)-pseudo-UTP; 6-Amino-pseudoUTP; 6-Azido-pseudo-UTP; 6-Bromo-pseudo-UTP; 6-Butyl-pseudo-UTP; 6-Chloropseudo-UTP; 6-Cyan-pseudo-UTP; 6-Dimethylamino-pseudo-UTP; 6-Ethoxypseudo-UTP; 6-Ethylcarboxylate-pseudo-UTP; 6-Ethyl-pseudo-UTP; 6-Fluoropseudo-UTP; 6-Formyl pseudo-UTP; 6-Hydroxyamino-pseudo-UTP; 6-Hydroxypseudo-UTP; 6-Iodine-pseudo-UTP; 6-iso-propyl-pseudo-UTP; 6-Methoxy-pseudoUTP; 6-Methylamino-pseudo-UTP; 6-methyl-pseudo-UTP; 6-phenyl-pseudo-UTP; 6phenyl-pseudo-UTP; 6-Propyl-pseudo-UTP; 6-tert-butyl-pseudo-UTP; 6Trifluoromethoxy-pseudo-UTP; 6-Trifluoromethyl-pseudo-UTP; Alpha-thio-pseudoUTP; Pseudouridine 1-(4-methylbenzenesulfonic acid) TP; Pseudouridine 1(4-methylbenzoic acid) TP; Pseudouridine TP 1-[3-(2-ethoxy)]propionic acid; Pseudouridine 1-[3-{2-(2-[2-(2-ethoxy)-ethoxy]-ethoxy)-ethoxy}]propionic acid;Pseudouridine 1-[3-{2-(2-[2-{2(2-ethoxy)-ethoxy}-ethoxy]-ethoxy)-ethoxy}]propionic acid; Pseudouridine TP 1-[3-{2-(2-[2-ethoxy]-ethoxy)ethoxy}]propionic acid; Pseudouridine TP 1-[3-{2-(2-ethoxy)-ethoxy}]propionic acid; Pseudouridine TP 1-methylphosphonic acid; Pseudouridine TP 1-methylphosphonic diethyl ester; Pseudo-UTP-N1-3-propionic acid; Pseudo-UTP-N1-4-butanoic acid; Pseudo-UTP-N1-5-pentanoic acid; Pseudo-UTP-N1-6-hexanoic acid; Pseudo-UTP-N1-7-heptanoic acid; Pseudo-UTP-N1-methyl-pbenzoic acid; Pseudo-UTP-N1-p-benzoic acid; Wybutosin; Hydroxyvibutosin; Isowyosine; Peroxywybutosin; submodified hydroxyvibutosin; 4desmethylwyosin; 2,6-(diamino)purine; 1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl: 1,3(diaza)-2-(oxo)-phenthiazin-1-yl; 1,3-(diaza)-2-(oxo)-phenoxazin-1-yl; 1,3,5-(triaza)2,6-(dioxa)-naphthalene; 2 (amino)purine; 2,4,5-(trimethyl)phenyl; 2'methyl, 2'amino, 2'azido, 2'fluro-cytidine; 2'methyl, 2'amino, 2'azido, 2'fluro-adenine;2'methyl, 2'amino, 2'azido, 2'fluro-uridine; 2'-amino-2'-deoxyribose; 2-amino-6; Petition 870250101498, dated 05 / 11 / 2025, pp. 427 / 546 38 / 109 chloropurine; 2-aza-inosynyl; 2'-azido-2'-desoxyribose; 2'fluoro-2'-desoxyribose; bases modified as 2'-fluor; 2'-O-methyl-ribose; 2-oxo-7aminopyridopyrimidine 2-oxo-pyridopyrimidine-3-yl; 2-pyridinone; 3 nitropyrrol; 3(methyl)-7-(propynyl)isocarbostyryl; 3-(methyl)isocarbostyryl; 4-(fluoro)-6(methyl)benzimidazole; 4-(methyl)benzimidazole; 4-(methyl)indolyl; 4,6-(dimethyl)indolyl; 5 nitroidol; 5 pirimidine substitutes; 5-(methyl)isocarbostyryl; 5-nitroindol; 6(aza)pyrimidine; 6-(azo)thymine; 6-(methyl)-7-(aza)indolyl; 6-chloropurine; 6-phenylpyrrolopyrimidine-2-on-3-yl; 7-(aminoalquil-hydroxy)-1-(aza)-2-(thio)-3-(aza)phenthiazine-L-yl; 7-(aminoalquil-hydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl; 7(aminoalquil-hydroxy)-1,3-(diaza)-2-(oxo)-phenoxazin-1-yl; 7-(aminoalquil-hydroxy)L,3-(Diaza)-2-(oxo)-phenthiazine-L-yl; 7-(aminoalquil-hidroxi)-L,3-(Diaza)-2-(oxo)phenoxazine-L-yl; 7-(aza)indolyl; 7-(guanidínioalquil-hidroxi)-1-(aza)-2-(thio)-3-(aza)fenoxazinl-il;7-(guanidinioalkyl-hydroxy)-1-(aza)-2-(thio)-3-(aza)-phentiazine-l-yl; 7(guanidinioalkyl-hydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl; 7(guanidinioalkyl-hydroxy)-1,3-(diaza)-2-(oxo)-phenoxazine-1-yl; 7(guanidinioalkyl-hydroxy)-L,3-(diaza)-2-(oxo)-phenthiazine-L-yl; 7-(guanidinioalkylhydroxy)-L,3-(Diaza)-2-(oxo)-phenoxazine-L-yl; 7-(propynyl)isocarbostyryl; 7(propynyl)isocarbostyryl, propynyl-7-(aza)indolyl; 7-deaza-inosine; 1-(aza)-2-(thio)-3(aza)-phenoxazin-1-ilo 7-substituted; 1,3-(diaza)-2-(oxo)-phenoxazine-1-yl substituted with 7-pda; 9-(methyl)-imidizopyridinyl; Aminoindolyl; Anthracenyl; bisorto-(aminoalkyl-hydroxy)-6-phenyl-pyrrolo-pyrimidine-2-em-3-yl; bis-orthosubstituted-6-phenyl-pyrrole-pyrimidine-2-em-3-yl; Difluorotolyl; Hypoxanthine; Imidizopyridinyl; Inosinyl; Isocarbostyril; Isoguanisine; N2-substituted purines; N6-methyl-2-aminopurine; Purines substituted with N6; Nalkylated Derivative; Naphthalenil; Nitrobenzimidazolyl; Nitroimidazolyl; Nitroindazolyl; Nitropyrazolyl; Nubularin; Purines substituted with O6; O-alkylated derivative; ortho-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidine-2-em-3-yl; 6-phenyl-pyrrole Petition 870250101498, dated 05 / 11 / 2025, pages 428 / 546 39 / 109 pyrimidine 2-on-3-yl-ortho-substituted; Oxoformicina TP; para-(aminoalquilhidroxi)-6-phenyl-pyrrolo-pyrimidine-2-on-3-yl; 6-phenyl-pyrrolo-pyrimidine parasubstituted-2-em-3-yl; Pentacenyl; Fenanthracenyl; Phenyl; propynyl-7-(aza)indolyl; Pyrenyl; pyridopyrimidine-3-yl; pyridopyrimidine-3-yl, 2-oxo-7-aminopiridopirimidin-3-yl; pyrrolo-pyrimidine Pyrrolopyrimidinyl; Pyrrolopyrizinyl; Estylbenzyl; 1,2,4-triazóis substituídos; Tetracenyl; Tubercidine; Xanthine; Xantosine-5'-TP; 2-thio-zebularine; 5-aza-2-thio-zebularine; 7-deaza-2-aminopurine; pyridine-4-one ribonucleoside; 2-Amino-riboside-TP; Formicin A TP; Formicin B TP; pyrrolose TP; 2'-OH-ara-adenosine TP; 2'-OH-ara-cytidine TP; 2'-OH-ara-uridine TP; 2'-OH-ara-guanosine TP; 5-(2-carbomethoxyvinyl)uridine TP; and N6-(19-amino-pentaoxanonadecyl)adenosine TP.

[097] In some embodiments, the polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) include a combination of at least two (e.g., 2, 3, 4 or more) of the aforementioned modified nucleobases.

[098] In some embodiments, modified nucleobases in polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) are selected from the group consisting of pseudouridine (ψ), N1-methylpseudouridine (m1ψ), 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thiopseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine, and 2'-O-methyluridine. In some embodiments, the polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) include a combination of at least two (e.g., 2, 3, 4, or more) of the modified nucleobases mentioned above. Petition 870250101498, dated 05 / 11 / 2025, pp. 429 / 546 40 / 109

[099] In some embodiments, one or more polynucleotides of the invention are modified by replacing one or more uridine residues with one or more modified nucleobases. In certain embodiments, at least 50% of the uridine residues of the mRNA polynucleotide are replaced with N1-methylpseudouridine. In certain embodiments, between 50% and 55%, between 55% and 60%, between 60% and 65%, between 65% and 70%, between 70% and 75%, between 75% and 80%, 80% and 85%, between 85% and 90%, between 90% and 95%, and between 95% and 100% of the uridine residues of the mRNA polynucleotide are replaced with N1-methylpseudouridine. In certain embodiments, 90% of the uridine residues of the mRNA polynucleotide are replaced with N1-methylpsuedouridine. In certain embodiments, 91% of the uridine residues of the mRNA polynucleotide are replaced with N1-methylpsuedouridine. In certain embodiments, 92% of the uridine residues of the mRNA polynucleotide are replaced with N1-methylpsuedouridine.In certain embodiments, 93% of the uridine residues of the mRNA polynucleotide are replaced with N1-methylpsuedouridine. In certain embodiments, 94% of the uridine residues of the mRNA polynucleotide are replaced with N1-methylpsuedouridine. In certain embodiments, 95% of the uridine residues of the mRNA polynucleotide are replaced with N1-methylpsuedouridine. In certain embodiments, 96% of the uridine residues of the mRNA polynucleotide are replaced with N1-methylpsuedouridine. In certain embodiments, 97% of the uridine residues of the mRNA polynucleotide are replaced with N1-methylpsuedouridine. In certain embodiments, 98% of the uridine residues of the mRNA polynucleotide are replaced with N1-methylpsuedouridine. In certain embodiments, 99% of the uridine residues of the mRNA polynucleotide are replaced with N1-methylpsuedouridine. In certain embodiments, 100% of the uridine residues of the mRNA polynucleotide are replaced with N1-methylpsuedoridine. Petition 870250101498, dated 05 / 11 / 2025, pp. 430 / 546 41 / 109

[100] In some embodiments, the modified nucleobases in polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) are selected from the group consisting of 1-methyl-pseudouridine (m1ψ), 5-methoxy-uridine (mo5U), 5-methyl-cytidine (m5C), pseudouridine (ψ), α-thio-guanosine, and α-thio-adenosine. In some embodiments, the polynucleotides include a combination of at least two (e.g., 2, 3, 4, or more) of the aforementioned modified nucleobases.

[101] In some embodiments, the polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise pseudouridine (ψ) and 5-methylcytidine (m5C). In some embodiments, the polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 1-methylpseudouridine (m1ψ). In some embodiments, the polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 1-methylpseudouridine (m1ψ) and 5-methylcytidine (m5C). In some embodiments, the polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 2-thiouridine (s2U). In some embodiments, the polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 2-thiouridine and 5-methylcytidine (m5C). In some embodiments, the polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise methoxyuridine (mo5U).In some embodiments, the polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 5-methoxyuridine (mo5U) and 5-methylcytidine (m5C). In some embodiments, the polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 2'-O-methyluridine. In some embodiments, the polynucleotides (e.g., RNA polynucleotides, such as... Petition 870250101498, dated 05 / 11 / 2025, pp. 431 / 546 42 / 109 as mRNA polynucleotides) comprise 2'-O-methyluridine and 5-methylcytidine (m5C). In some embodiments, the polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise N6-methyladenosine (m6A). In some embodiments, the polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise N6-methyladenosine (m6A) and 5-methylcytidine (m5C).

[102] In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) are uniformly modified (e.g., fully modified, modified throughout the sequence) for a specific modification. For example, a polynucleotide can be uniformly modified with 5-methylcytidine (m5C), meaning that all cytosine residues in the mRNA sequence are replaced with 5-methylcytidine (m5C). Similarly, a polynucleotide can be uniformly modified for any type of nucleoside residue present in the sequence by substitution with a modified residue, such as those presented above.

[103] Exemplary nucleobases and nucleosides having a modified cytosine include N4-acetyl-cytidine (ac4C), 5-methyl-cytidine (m5C), 5-halocitidine (e.g., 5-iodo-cytidine), 5-hydroxymethyl-cytidine (hm5C), 1-methylpseudoisocytidine, 2-thio-cytidine (s2C), and 2-thio-5-methyl-cytidine.

[104] In some embodiments, a modified nucleobase is a modified uridine. Exemplary nucleobases and nucleosides that have a modified cytosine or a modified uridine include 5'cyano uridine and 4'thio uridine.

[105] In some embodiments, a modified nucleobase is a modified adenine. Exemplary nucleobases and nucleosides having a modified adenine include 7-deaza-adenine, 1-methyl-adenosine (m1A), 2-methyl Petition 870250101498, dated 05 / 11 / 2025, pp. 432 / 546 43 / 109 adenine (m2A) and N6-methyladenosine (m6A).

[106] In some embodiments, a modified nucleobase is a modified guanine. Exemplary nucleobases and nucleosides having a modified guanine include inosine (I), 1-methyl-inosine (m1I), wiosine (imG), methylwiosine (mimG), 7-deaza-guanosine, 7-cyano-7-deaza-guanosine (preQ0), 7-aminomethyl-7-deaza-guanosine (preQ1), 7-methyl-guanosine (m7G), 1-methylguanosine (m1G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine.

[107] The polynucleotides of the present disclosure may be partially or wholly modified along the entire length of the molecule. For example, one or more, or all, or a particular type of nucleotide (e.g., purine or pyrimidine, or any one or more, or all, of A, G, U, C) may be uniformly modified in a polynucleotide of the invention, or in a particular predetermined sequence region thereof (e.g., in mRNA including or excluding the poly(A) tail). In some embodiments, all nucleotides X in a polynucleotide of the present disclosure (or in a particular sequence region thereof) are modified nucleotides, wherein X may be any of the nucleotides A, G, U, C, or any of the combinations A+G, A+U, A+C, G+U, G+C, U+C, A+G+U, A+G+C, G+U+C or A+G+C.

[108] The polynucleotide may contain from about 1% to about 100% modified nucleotides (relative to the overall nucleotide content, or relative to one or more types of nucleotides, i.e., any one or more of A, G, U or C) or any intermediate percentage (for example, from 1% to 20%, from 1% to 25%, from 1% to 50%, from 1% to 60%, from 1% to 70%, from 1% to 80%, from 1% to 90%, from 1% to 95%, from 10% to 20%, from 10% to 25%, from 10% to 50%, from 10% to 60%, from 10% to 70%, from 10% to 80%, from 10% to 90%, from 10% to 95%, 10% to 100%, 20% to 25%, 20% to 50%, 20% to 60%, 20% to 70%, 20% to 80%, 20% Petition 870250101498, dated 05 / 11 / 2025, pp. 433 / 546 44 / 109 to 90%, 20% to 95%, 20% to 100%, 50% to 60%, 50% to 70%, 50% to 80%, 50% to 90%, 50% to 95%, 50% to 100%, 70% to 80%, 70% to 90%, 70% to 95%, 70% to 100%, 80% to 90%, 80% to 95%, 80% to 100%, 90% to 95%, 90% to 100%, and 95% to 100%). It is understood that any remaining percentage is explained by the presence of unmodified A, G, U, or C.

[109] Polynucleotides may contain at least 1% and at most 100% modified nucleotides, or any intermediate percentage, such as at least 5% modified nucleotides, at least 10% modified nucleotides, at least 25% modified nucleotides, at least 50% modified nucleotides, at least 80% modified nucleotides, or at least 90% modified nucleotides. For example, polynucleotides may contain a modified pyrimidine, such as a modified uracil or cytosine. In some embodiments, at least 5%, at least 10%, at least 25%, at least 50%, at least 80%, at least 90%, or 100% of the uracil in the polynucleotide is replaced with a modified uracil (for example, a uracil substituted at 5).The modified uracil can be replaced with a compound having a single singular structure, or it can be replaced with a plurality of compounds having different structures (e.g., 2, 3, 4 or more singular structures). In some embodiments, at least 5%, at least 10%, at least 25%, at least 50%, at least 80%, at least 90% or 100% of the cytosine in the polynucleotide is replaced with a modified cytosine (e.g., a cytosine substituted at 5). The modified cytosine can be replaced with a compound having a single singular structure, or it can be replaced with a plurality of compounds having different structures (e.g., 2, 3, 4 or more unique structures). In vitro transcription (IVT) of RNA (e.g., mRNA) Petition 870250101498, dated 05 / 11 / 2025, pp. 434 / 546 45 / 109

[110] “In vitro transcription (IVT)” is a method for synthesizing mRNA from a linear DNA template using an RNA polymerase, where the RNA polymerase binds to a promoter sequence and transcribes mRNA by adding complementary nucleotides in the 5' to 3' direction. The norovirus vaccines of the present disclosure comprise at least one RNA polynucleotide, such as mRNA (e.g., modified mRNA). The mRNA, for example, is transcribed in vitro from the DNA template, referred to as the “in vitro transcription template”. In some embodiments, the at least one RNA polynucleotide has at least one chemical modification. The at least one chemical modification may include, but is not expressly limited to, any modification described in the present invention.

[111] Linear DNA templates encoding mRNA sequences are prepared from purified plasmid DNA and may contain an RNA polymerase promoter sequence, encoded in the 5' UTR, a coding sequence, encoded in the 3' UTR with a poly(A) tail and a linearization cleavage site. Plasmid DNA sequences are generated using standard cloning methods on a plasmid vector structure, such as pUC19, pUC57 or pmRNAXP, and the plasmid DNA is purified from fermentation of transformed E. coli strains, typically used for plasmid production, such as Stable or DH5o, using standard methods (see, for example, U.S. Patent Application Publication NO. 2019 / 0083602, U.S. Patent Application Publication NO. 2020 / 0392518).mRNA can be produced in an IVT reaction with the addition of a cotranscriptional cap analog and a poly(A) tail encoded by a DNA template, or the cap and / or poly(A) tail can be added enzymatically after the IVT reaction. DNA plasmids may contain an adenine-guanine (AG) sequence at the beginning of the 5' UTR after a T7 promoter sequence to allow cotranscriptional capping with an analog of. Petition 870250101498, dated 05 / 11 / 2025, pages 435 / 546 46 / 109 AG of Cap 1 (m7G(5')ppp(5')(2'OMeA)pG). DNA plasmids may also contain a specific restriction enzyme cutting site after a 3' encoded poly(A) tail. Plasmids can be linearized in a digestion reaction containing purified plasmid DNA at a concentration of about 0.1 to 2 mg / mL and the appropriate restriction enzyme, such as Bbs I or BspQ I, at a concentration of about 500 to 20,000 U / mg in a digestion mixture that may contain tris hydrochloride, magnesium, potassium, acetate, albumin and / or other excipients at a solution pH of about 7 to 8. The reaction is incubated at a temperature between 34 and 40 °C, preferably 37 °C, for about 30 to 90 min, preferably 60 min.

[112] The linear DNA template can be purified by solvent extraction, alcohol precipitation, centrifugation, chromatographic and / or filtration-based methods to remove uncut plasmid DNA, restriction enzyme and digestion mixture components. Purified linear DNA templates can be prepared at a concentration of about 0.5 to 2 mg / mL, preferably 1 mg / mL, in water or in a buffer containing tris hydrochloride, ethylenediaminetetraacetic acid (EDTA) and / or other excipient at a solution pH of about 7 to 8.

[113] The IVT reaction is carried out in a temperature-controlled reaction vessel, with an incubation temperature range of about 34 to 40 °C, preferably 37 °C. The linear DNA template can be added to the IVT reaction mixture at a concentration range of about 10 to 200 pg / mL, preferably 40 to 60 pg / mL. Natural nucleoside triphosphates (NTPs), including adenosine triphosphate (ATP), guanosine triphosphate (GTP), cytidine triphosphate (CTP), uridine triphosphate (UTP), or modified NTPs such as pseudouridine (Ψ), N1-methylpseudouridine (m1Ψ), N6-methyladenosine (m6A) or N5-methylcytidine (m5C), can be used in the reaction. Petition 870250101498, dated 05 / 11 / 2025, pages 436 / 546 47 / 109 IVT, preferably ATP, GTP, CTP, and m1Ψ. NTPs can be incorporated into mRNA as a mixture of natural and modified substituted NTPs, such as a mixture of 50% UTP and 50% m1Ψ. Preferably, 100% m1Ψ is added to completely replace UTP. NTPs can be added to the IVT reaction mixture in a concentration range of about 2 to 15 mM, or preferably 8 to 14 mM for ATP, GTP, and CTP, and 4 to 7 mM for m1Ψ. An analog of AG 5' Cap 1, such as CleanCap AG (3'OMe) (m7(3OMeG)(5')ppp(5')(2'OMeA)pG) or CleanCap AG (m7(5')ppp(5')(2OMeA)pG), preferably CleanCap AG (3'OMe), can be added to the IVT reaction mixture in a concentration range of about 1 to 10 mM, preferably 3 to 5 mM. An RNA polymerase, such as RNA polymerase T7, can be added to the IVT reaction mixture in a concentration range of about 2,000 to 20,000 U / mL, preferably 8,000 to 12,000 U / mL.

[114] A pyrophosphatase, such as inorganic yeast pyrophosphatase, and an RNase inhibitor, such as murine RNase inhibitor, may be added to the IVT reaction mixture in a concentration range of 1 to 5 U / mL and 500 to 2,000 U / mL, respectively. Other components of the IVT reaction mixture may include tris hydrochloride, magnesium, spermidine, dithiothreitol (DTT), sodium, chloride, potassium, acetate, phosphate, polysorbate-20, polysorbate-80, TritonX-100, glycerol and / or other excipients at a final solution pH of about 6 to 9. The IVT reaction mixture is typically incubated with stirring for 1 to 6 hours, preferably 3 to 4 hours. Preferably, mRNA is produced in the IVT reaction with a cotranscriptional 5' Cap 1 AG analog and a 3' poly(A) tail encoded by a DNA template, without the need for additional enzymatic capping reactions or poly(A) tail addition. The IVT reaction is terminated by the addition of a DNase, such as DNase I, to Petition 870250101498, dated 05 / 11 / 2025, pp. 437 / 546 48 / 109 digest the linear DNA template into small oligonucleotides and interrupt transcription. DNase is added to the IVT reaction mixture at a concentration range of about 100 to 500 U / mL, preferably 350 U / mL, along with calcium chloride at a concentration range of about 1 to 5 mM, preferably 3.5 mM, and incubated at about 34 to 40 °C, preferably 37 °C, for 0.5 to 3 h, preferably 1 h. After digestion with DNase, a proteinase, such as Proteinase K, can be added to the IVT reaction mixture to digest the enzymes used in the IVT reaction into small peptides. Proteinase is added to the IVT reaction mixture at a concentration range of about 0.05 to 0.2 mg / mL, preferably 0.1 mg / mL, along with sodium dodecyl sulfate (SDS) and additional DTT, and incubated at about 34 to 40 °C, preferably 37 °C, for 0.5 to 3 h, preferably 1 h.Preferably, only DNase treatment is performed, and no proteinase treatment is carried out. After completion of the DNase treatments or DNase followed by proteinase, the IVT reaction mixture is adjusted to 10 to 100 mM EDTA, preferably 50 mM, to inhibit enzymatic activity.

[115] The resulting IVT reaction mixture contains the target mRNA sample and contaminants, such as digested template DNA and oligonucleotides, enzymes, including RNA polymerase, pyrophosphatase, RNase inhibitor, DNase and proteinase, small molecules, including free nucleotides, pyrophosphate, magnesium, spermidine and / or other IVT reaction matrix excipients and RNA-related contaminants, such as RNA fragments, double-stranded RNA, uncapped RNA or poly(A) tailless RNA.

[116] An initial tangential flow filtration (TFF) step can be performed after treatment with DNase and proteinase for buffer exchange and removal of small impurities. TFF is operated by pumping a Petition 870250101498, dated 05 / 11 / 2025, pp. 438 / 546 49 / 109 Feed solution through a membrane at a transmembrane pressure (TMP) of about 1 to 10 psi, wherein solution components larger than the molecular weight cutoff (MWCO) remain in the retentate, and components smaller than the MWCO can be permeated through the membrane. The membrane MWCO can range from 30 to 500 kDa in a flat sheet or hollow fiber format and can be composed of a variety of materials, including polyethersulfone (PES), polysulfone (PS), or regenerated cellulose (RC). When the IVT reaction mixture is processed through the TFF, large mRNA molecules are retained while digested impurities and other small molecules are removed from the permeate.Before starting the TFF, the IVT reaction mixture can be diluted 2 to 20 times in water or in a buffer containing tris hydrochloride, sodium phosphate, or sodium citrate at a concentration of about 1 to 100 mM, preferably 10 mM tris hydrochloride, at a pH of about 6 to 8, and EDTA at a concentration of about 1 to 10 mM, preferably 2 mM. A TFF membrane loaded with approximately 1 to 25 g of mRNA per m2 of diluted IVT reaction mixture membrane area, operated at a TMP of about 3 to 7 psi and a cross-flow shear rate of about 2000 to 12000 s-1, can be used to buffer the dilute IVT mixture exchange in 5 to 15 diafiltration volumes (DVs) in water or a buffer containing tris hydrochloride, sodium phosphate, or sodium citrate at a concentration of about 1 to 100 mM at a pH of about 6 to 8 and EDTA at a concentration of about 1 to 10 mM.Preferably, a 50 kDa hollow fiber PES membrane loaded with 5 to 10 g-mRNA / m2 operated at a TMP of about 4 psi and a cross-flow shear rate of 4000 s-1 is used for buffer exchange of the IVT mixture diluted in 10 DVs in 10 mM tris hydrochloride, 2 mM EDTA, pH 7.2.

[117] The purified solution containing mRNA in the TFF retentate can be Petition 870250101498, dated 05 / 11 / 2025, pp. 439 / 546 50 / 109 is routed to hybridization affinity chromatography using an oligo deoxythymine ligand (oligo dT) conjugated to a stationary phase to selectively bind to mRNA via complementary base pairing of the oligo dT ligand with the poly(A) tail of the mRNA. Contaminants from the IVT reaction, including RNA polymerase, pyrophosphatase, RNase inhibitor, DNase and proteinase, small molecules including free nucleotides, pyrophosphate, magnesium, spermidine, other IVT matrix excipients and RNA fragments without a poly(A) tail, are not expected to bind to the oligo dT ligand. Preferably, the DNase-treated IVT reaction mixture is routed directly to oligo dT affinity chromatography, omitting the Proteinase K and initial TFF steps.The oligo dT linker can consist of about 15 to 30 deoxythymine bases connected to a linker that couples the linker to a support surface, such as a microporous polymethacrylate monolith, a cross-linked poly(styrene-divinylbenzene) sphere, or electrospun cellulose nanofibers. The mRNA-containing solution destined for the oligo dT hybridization affinity chromatography step can be diluted approximately 2 to 50 times in an oligo dT binding matrix composed of a salt, such as sodium chloride, potassium chloride, lithium chloride, guanidine hydrochloride, or other similar salts, at a concentration of approximately 100 to 1000 mM, a buffer, such as tris hydrochloride, sodium phosphate, or sodium citrate, at a concentration of 5 to 100 mM at a pH of approximately 6 to 8, and EDTA at a concentration of approximately 1 to 10 mM.Preferably, the IVT mixture treated with DNase is diluted approximately 12 times in an oligo dT binding matrix consisting of 400 mM sodium chloride, 10 mM tris hydrochloride, 2 mM EDTA, pH 7.2. The mRNA-containing solution can be pumped through the oligo dT chromatography medium with a loading of approximately 1-8 mg / mL for a residence time of about 0.1 to 10 min, and after mRNA binding... Petition 870250101498, dated 05 / 11 / 2025, pages 440 / 546 51 / 109 with a poly(A) tail, the column is washed with 2 to 10 column volumes (CV) of a mobile phase consisting of a salt, such as sodium chloride, potassium chloride, lithium chloride, guanidine hydrochloride or other similar salts, at a concentration of about 10 to 200 mM, a buffer, such as tris hydrochloride, sodium phosphate or sodium citrate, at a concentration of 5 to 100 mM at a pH of about 6 to 8 and EDTA at a concentration of about 1 to 10 mM. Preferably, the mRNA-containing mixture is pumped through a monolithic microporous polymethacrylate medium with a loading of 2 to 3 mg / mL and a residence time of 0.5 min, and the column is washed with 5 CVs of a buffer composed of 50 mM sodium chloride, 10 mM tris hydrochloride, and 2 mM EDTA, pH 7.2.The bound mRNA is eluted from the oligo dT ligand with 2 to 10 CVs of a low ionic strength mobile phase composed of water or a buffer, such as tris hydrochloride, sodium phosphate, or sodium citrate, at a concentration of 1 to 20 mM and a pH of about 6 to 8. Preferably, the bound mRNA is eluted with 4 to 5 CVs of 10 mM tris hydrochloride, pH 7.2. The oligo dT chromatography medium can be regenerated with sodium hydroxide and reused in subsequent chromatographic purification cycles. Preferably, a polymethacrylate monolith should be regenerated with 0.5 M sodium hydroxide and reused for about 2 to 6 purification cycles of the same IVT mixture treated with DNase diluted in oligo dT binding buffer.

[118] The elution fraction from oligo dT hybridization affinity chromatography containing mRNA can be purified by chromatographic polishing methods to remove residual RNA-related impurities, such as RNA fragments, double-stranded mRNA and uncapped RNA, or residual enzymes, such as RNA polymerase. Examples of chromatographic polishing methods may include mixed-mode chromatography, hydrophobic interaction chromatography, anion exchange chromatography, phase chromatography Petition 870250101498, dated 05 / 11 / 2025, pp. 441 / 546 52 / 109 reverse chromatography, ceramic hydroxyapatite chromatography, size exclusion chromatography, or cellulose chromatography. Preferably, no additional purification method by polishing is performed after oligo dT chromatography.

[119] The elution fraction from mRNA-containing oligo dT hybridization affinity chromatography is buffer exchanged and purified by a final TFF that can be operated similarly to the initial TFF described previously. The final TFF membrane can be operated at a TMP of 1 to 10 psi, using a 30 to 500 kDa MWCO membrane in flat sheet or hollow fiber form, and can be composed of polyethersulfone (PES), polysulfone (PS), or regenerated cellulose (RC).A 50–100 kDa hollow fiber PES membrane loaded with approximately 1–20 g of mRNA per m² of membrane area, operated at a TMP of 3–7 psi and a cross-flow shear rate of about 2000–12000 s⁻¹, can be used to concentrate the oligo dT elution fraction approximately 2–20 times, followed by a buffer exchange over 4–15 days of shelf life in water or in a buffer consisting of about 1–10 mM tris hydrochloride, sodium phosphate, or sodium citrate at a pH of about 5–8. Preferably, a 50 kDa hollow fiber PES membrane loaded with 5–10 g of mRNA / m², operated at a TMP of about 4 psi and a cross-flow shear rate of 4000 s⁻¹, is used to concentrate 8 times, followed by a 6-day buffer change in 1 mM sodium citrate, pH 6.4.

[120] The final TFF mRNA-containing retentate is filtered at a flow rate of about 25-1000 L / m2-h and a loading of about 10-1000 g / m2 through a bioburden reduction filter with a nominal pore size of about 0.2 µm. The filter may be composed of a variety of materials, including hydrophilic polyvinylidene fluoride (PVDF), PES, or cellulose acetate, and may Petition 870250101498, dated 05 / 11 / 2025, pages 442 / 546 53 / 109 contain a pre-filter with a nominal pore size ranging from about 0.2 to 1 μm. Preferably, the final TFF retentate is pumped at a flow rate of 300 L / m²-h and a loading rate of 100 g / m² through a 0.2 μm PVDF filter. The mRNA concentration in the bioburden reduction filter product is calculated from an absorbance measurement of the sample at 260 nm using a spectrophotometer. The filtration product can be diluted with the final TFF diafiltration buffer until a final mRNA concentration between 0.5 and 5 mg / mL is reached. Preferably, the filtration product is diluted with 1 mM sodium citrate, pH 6.4, to an mRNA concentration of about 1 mg / mL. Purified mRNA can be stored refrigerated at approximately 2 to 8 °C or frozen at approximately -20 °C or <-60 °C. Antigenic polypeptides

[121] An “antigenic polypeptide” is a polypeptide that induces an immune response when administered to an animal, preferably a mammal. In some embodiments, an antigenic polypeptide includes gene products, naturally occurring polypeptides, synthetic polypeptides, homologs, orthologs, paralogs, fragments, and other equivalents, variants, and analogues thereof. In certain embodiments, the antigenic polypeptide is a VP1 or VP2 polypeptide from norovirus. In certain embodiments, the antigenic polypeptide is any one of SEQ ID NOs: 14 to 18. The antigenic polypeptides of the present disclosure can be prepared using any suitable method known in the art, including synthetic methods, such as, for example, solid-phase synthesis, as well as recombinant and in vitro methods, such as in vitro transcription reactions.In certain embodiments, antigenic polypeptides can be prepared by in vitro transcription of the polynucleotides disclosed in the present invention.

[122] A “variant” is a molecule that differs in its sequence of Petition 870250101498, dated 05 / 11 / 2025, pp. 443 / 546 54 / 109 amino acids or nucleic acids relative to a native sequence or reference sequence. Sequence variants may possess substitutions, deletions, insertions, or a combination of any two or three of the foregoing, at certain positions within the amino acid or nucleic acid sequence, compared to a native sequence or a reference sequence. Typically, variants possess at least 50% identity with a native sequence or a reference sequence. In some embodiments, variants share at least 80% identity or at least 90% identity with a native sequence or a reference sequence.

[123] The present disclosure provides various types of compositions based on polynucleotides or polypeptides, including variants and derivatives. These include, for example, substitutional, insertional, deletion, and covalent variants and derivatives. The term derivative is synonymous with the term “variant” and generally refers to a molecule that has been modified and / or altered in some way relative to a reference molecule or an initial molecule. Thus, polynucleotides encoding peptides or polypeptides containing substitutions, insertions and / or additions, deletions, and covalent modifications relative to the reference sequences, in particular the polypeptide sequences disclosed in the present invention, are included within the scope of this disclosure.

[124] Substitutional variants, when referring to polynucleotides, are those that have at least one nucleotide residue in a native or initial sequence removed, and a different nucleotide inserted in its place at the same position. In some embodiments, one or more uridine residues in an mRNA polynucleotide of the present disclosure are replaced with a pseudouridine. The modification of mRNA nucleosides, for example, Petition 870250101498, dated 05 / 11 / 2025, pages 444 / 546 55 / 109 with pseudouridine or a pseudouridine derivative, has been previously described. See International Patent Application Publication WO 2007 / 024708.

[125] As used in the present invention, the terms “termini” or terminal, when referring to polypeptides or polynucleotides, refer to an end of a polypeptide or polynucleotide, respectively. Such an end is not limited to the first or last site of the polypeptide or polynucleotide, but may include additional amino acids or nucleotides in the terminal regions.

[126] The polypeptide or polynucleotide molecules of the present disclosure may share a certain degree of sequence similarity or identity with reference molecules (e.g., reference polypeptides or reference polynucleotides), for example, with molecules described in the art (e.g., engineered or manipulated molecules or wild-type molecules). The term identity, as known in the art, refers to a relationship between the sequences of two or more polypeptides or polynucleotides, as determined by sequence comparison. In the art, identity also means the degree of sequence relatedness between two sequences, as determined by the number of column matches of two or more amino acid residues or nucleic acid residues.Identity measures the percentage of identical matches between the shortest of two or more sequences with gap alignments (if any) addressed by a specific mathematical model or computer program (e.g., algorithms). The identity of related peptides can be easily calculated by known methods. % identity, with respect to polypeptide or polynucleotide sequences, is defined as the percentage of residues (amino acid residues or hydroxyl acid residues). Petition 870250101498, dated 05 / 11 / 2025, pages 445 / 546 56 / 109 nucleic acid) in the candidate amino acid or nucleic acid sequence that is identical to residues in the amino acid or nucleic acid sequence of a second sequence after alignment of the sequences and the introduction of gaps, if necessary, to achieve maximum percent identity. Methods and computer programs for alignment are well known in the art. Identity depends on the percent identity calculation, but may differ in value due to gaps and penalties introduced in the calculation. Generally, variants of a specific polynucleotide or polypeptide exhibit at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, but less than 100% sequence identity with that specific reference polynucleotide or polypeptide, as determined by the sequence alignment programs and parameters described in the present invention and known to those skilled in the art.These alignment tools include those of the BLAST suite. See Stephen F. Altschul et al. (1997). “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs, Nucleic Acids Res. 25:3389 to 3402. Another popular local alignment technique is based on the Smith-Waterman algorithm. See Smith, TF & Waterman, MS (1981) “Identification of common molecular subsequences.” J. Mol. Biol. 147:195 to 197. A general global alignment technique based on dynamic programming is the Needleman-Wunsch algorithm. See Needleman, SB & Wunsch, CD (1970) “A general method applicable to the search for similarities in the amino acid sequences of two proteins.” J. Mol. Biol. 48:443 to 453.More recently, a Fast Optimal Global Sequence Alignment Algorithm (FOGSAA) has been developed that supposedly produces faster global alignment of nucleotide and protein sequences than other optimal global alignment methods, including the Needleman-Wunsch algorithm. Petition 870250101498, dated 05 / 11 / 2025, pages 446 / 546 57 / 109 Lipid nanoparticles (LNPs)

[127] As used in the present invention, “lipid nanoparticle” or “LNP” refers to any lipid composition that can be used to deliver a product, including, but not limited to, liposomes or vesicles, wherein an aqueous bulk is encapsulated by amphipathic lipid bilayers (e.g., single; unilamellar or multiple; multilamellar) or, in other embodiments, wherein the lipids coat an interior comprising a prophylactic or therapeutic product, or lipid aggregates or micelles, wherein the lipid-encapsulated prophylactic or therapeutic product is contained in a relatively disordered lipid mixture. In certain embodiments, the mRNA polynucleotides of the present invention may be encapsulated together in an LNP comprising one or more cationic or polycationic compounds.Except where indicated, LNP does not need to have an antigenic polypeptide incorporated into it and can be used to deliver a distributor (i.e., mRNA polynucleotides) to a mammal when the LNP and mRNA polynucleotides are in the same formulation.

[128] As used in the present invention, “polyamine” means compounds having two or more amino groups. Examples include putrescine, cadaverine, spermidine, and spermine.

[129] Unless otherwise specified, mol % refers to a mole percent of total lipids.

[130] Generally, the LNPs of the compositions of the invention are composed of one or more cationic lipids (including ionizable cationic lipids) and one or more poly(ethylene glycol)-lipids (PEG-lipids). In certain embodiments, the LNPs further comprise one or more non-cationic lipids. The one or more non-cationic lipids may include a phospholipid, a phospholipid derivative, a sterol, a fatty acid, or a combination thereof. Petition 870250101498, dated 05 / 11 / 2025, pp. 447 / 546 58 / 109

[131] Cationic lipids and ionizable cationic lipids suitable for LNPs are described in the present invention. Ionizable cationic lipids are characterized by the weak basicity of their lipid head groups, which affects the lipid surface charge in a pH-dependent manner, making them positively charged at acidic pH but close to neutral charge at physiological pH. Cationic lipids are characterized by monovalent or multivalent cationic charge in their head groups, which makes them positively charged at neutral pH. In certain embodiments, the cationic and ionizable lipid is capable of complexing with hydrophilic bioactive molecules to produce a hydrophobic complex that splits in the organic phase of a biphasic aqueous / organic system. It is considered that both monovalent and polyvalent cationic lipids can be used to form hydrophobic complexes with bioactive molecules.

[132] Preferred cationic and ionizable lipids for use in LNP formation include, but are not limited to, N,N-dioleylN,N-dimethylammonium chloride (DODAC); N-(2,3-dioleyloxy)propyl)- N,N,N-trimethylammonium (DOTMA); N,N-distearylN,N-dimethylammonium bromide (DDAB); N-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DODAP); 1,2-bis(oleoyloxy)-3-(trimethylammonium)propane (DOTAP); 3-(N-(N,N-dimethylaminoethane)-carbamoyl)cholesterol ('DC-Chol'); diheptadecylamidoglycylspermidine (DHGS) and N-(1,2-dimyristyloxypropyl-3-yl)-N,N-dimethyl-N-hydroxyethyl ammonium bromide (DMRIE). In addition, various commercial preparations of cationic lipids, as well as other components, are available and can be used in the present invention. These include, for example, LIPOFECTIN® (commercially available cationic lipid nanoparticles comprising DOTMA and 1,2-dioleoyl-sn-3-phosphoethanolamine (DOPE), from GIBCOBRL, Grand Island, NY, USA); and Petition 870250101498, dated 05 / 11 / 2025, pp. 448 / 546 59 / 109 LIPOFECTAMINE® (commercially available cationic lipid nanoparticles comprising N-(1-(2,3-dioleyloxy)propyl)N-(2(sperminecarboxamido)ethyl)-N,N-dimethylammonium trifluoroacetate (“DOSPA’) and (“DOPE”), from (GIBCOBRL). The following lipids are cationic and have a positive charge at pH below physiological: DODAP, DODMA, DMDMA, 1,2-Dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 4-(2,2-diocta-9,12-dienyl-[1,3]dioxolan-4-ylmethyl)-dimethylamine, DLinKDMA (WO 2009 / 132131), DLin-K-C2-DMA (WO2010 / 042877), DLin-M-C3-DMA (WO2010 / 146740 and / or WO2010 / 105209), DLin-MC3-DMA (heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate; Jayaraman et al., 2012, Angew. Chem. Int. Ed. Engl. 51:8529 to 8533), 2-{4-[(3e)-colest-5-en-3-yloxy]butoxy}-N,N-dimethyl-3-[(9Z,12Z)octadeca-9,12-dienyloxyl]propan-1-amine) (CLinDMA) and the like. Other cationic lipids suitable for use in the invention include, for example, the cationic lipids described in U.S. Patent No. 5,208,036, 5,264,618, 5,279.833 and 5,283,185, and U.S. Patent Application Publications NO. 2008 / 0085870 and 2008 / 0057080. Other cationic lipids suitable for use in the invention include, for example, lipids E0001 to E0118 or E0119 to E0180, as disclosed in Table 6 (pages 112 to 139) of International Patent Application Publication NO. WO2011 / 076807 (which also discloses methods of production and methods of use of these cationic lipids).

[133] In certain aspects of this embodiment of the invention, the LNPs comprise one or more of the following ionizable cationic lipids: DLinDMA, DlinKC2DMA, DLin-MC3-DMA, CLinDMA or S-octyl CLinDMA. See International Patent Application Publication NO WO2010 / 021865.

[134] In certain aspects of this embodiment of the invention, the LNPs comprise one or more ionizable cationic lipids described in International Patent Application Publication NO WO2011 / 022460, or any salt Petition 870250101498, dated 05 / 11 / 2025, pp. 449 / 546 60 / 109 pharmaceutically acceptable thereof, or a stereoisomer of any of the compounds or salts contained therein.

[135] When structures of the same constitution differ in relation to the spatial arrangement of certain atoms or groups, they are stereoisomers, and the considerations that are significant in the analysis of their interrelationships are topological. If the relationship between two stereoisomers is that of an object and its non-superimposable mirror image, the two structures are enantiomeric, and each structure is said to be chiral. Stereoisomers also include diastereomers, cis-trans isomers, and conformational isomers. Diastereomers can be chiral or achiral, and are not mirror images of each other. Cis-trans isomers differ only in the positions of the atoms relative to a specified plane in cases where these atoms are, or are considered as if they were, parts of a rigid structure. Conformational isomers are isomers that can be interconverted by rotations around formally simple bonds.Examples of such conformational isomers include cyclohexane conformations with chair and boat conformers, carbohydrates, linear alkane conformations with sternate, eclipsed, and gauche conformers, etc. See J. Org. Chem. 35, 2849 (1970).

[136] Many organic compounds exist in optically active forms, with the ability to rotate the plane of plane-polarized light. When describing an optically active compound, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule around its chiral center(s). The prefixes del or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, the enantiomers are identical except for the fact that Petition 870250101498, dated 05 / 11 / 2025, pages 450 / 546 61 / 109 being non-superimposable mirror images of each other. A mixture of enantiomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is called a racemic mixture. Many of the compounds described in the present invention may have one or more chiral centers and therefore may exist in different enantiomeric forms. If desired, a chiral carbon may be designated with an asterisk (*). When the bonds to the chiral carbon are represented as straight lines in the Formulas of the invention, it is understood that both (R) and (S) configurations of the chiral carbon, and therefore both enantiomers and their mixtures, are encompassed by the Formula.As used in the technique, when one wishes to specify the absolute configuration around a chiral carbon, one of the bonds to the chiral carbon can be represented as a wedge (bonding to atoms above the plane) and the other can be represented as a series or wedge of short parallel lines (bonding to atoms below the plane). The Cahn-Inglod-Prelog system can be used to assign either (R) or (S) configuration to a chiral carbon.

[137] When the compounds of the present invention contain a chiral center, the compounds exist in two enantiomeric forms and the present invention includes both enantiomers and mixtures of enantiomers, such as the specific 50:50 mixture called a racemic mixture. The enantiomers can be resolved by methods known to those skilled in the art, such as the formation of diastereomeric salts that can be separated, for example, by crystallization (see, CRC Handbook of Optical Resolutions via Diastereomeric Salt Formation, by David Kozma (CRC Press, 2001)); formation of diastereomeric derivatives or complexes that can be separated, for example, by crystallization, gas-liquid or liquid chromatography; selective reaction of an enantiomer with a specific enantiomer reagent, for example, enzymatic esterification; or gas-liquid or liquid chromatography in an ambient environment. Petition 870250101498, dated 05 / 11 / 2025, pp. 451 / 546 62 / 109 chiral, for example, on a chiral support, such as silica with a chiral ligand attached, or in the presence of a chiral solvent. It should be noted that when the desired enantiomer is converted into another chemical entity by one of the separation procedures described above, an additional step is required to release the desired enantiomeric form. Alternatively, specific enantiomers can be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts, or solvents, or by converting one enantiomer into the other by asymmetric transformation.

[138] The designation of a specific absolute configuration on a chiral carbon of the compounds of the invention is understood to mean that the designated enantiomeric form of the compounds is in enantiomeric excess (ee) or, in other words, is substantially free of the other enantiomer. For example, the R forms of the compounds are substantially free of the S forms of the compounds and are therefore in enantiomeric excess of the S forms. Conversely, the S forms of the compounds are substantially free of the R forms of the compounds and are therefore in enantiomeric excess of the R forms. Enantiomeric excess, as used in the present invention, is the presence of a particular enantiomer in more than 50%. In a particular embodiment, when a specific absolute configuration is designated, the enantiomeric excess of the compounds depicted is at least about 90%.

[139] When a compound of the present invention has two or more chiral carbons, it may have more than two optical isomers and may exist in diastereomeric forms. For example, when there are two chiral carbons, the compound may have up to 4 optical isomers and 2 pairs of enantiomers ((S,S) / (R,R) and (R,S) / (S,R)). The pairs of enantiomers (e.g., (S,S) / (R,R)) are mirror-image stereoisomers of each other. The stereoisomers that Petition 870250101498, dated 05 / 11 / 2025, pages 452 / 546 63 / 109 are not mirror images (e.g., (S,S) and (R,S)) are diastereomers. Diastereomeric pairs can be separated by methods known to those skilled in the art, for example, chromatography or crystallization, and the individual enantiomers within each pair can be separated as described above. The present invention includes each diastereomer of such compounds and mixtures thereof.

[140] LNPs may also comprise any combination of two or more of the cationic lipids described in the present invention. In certain aspects, the cationic lipid typically comprises from about 0.1 to about 99.9 mol% of the total lipid present in said particle. In certain aspects, the cationic lipid may comprise from about 80 to about 99.9 mol%. In other respects, the cationic lipid comprises from about 2% to about 70%, from about 5% to about 50%, from about 10% to about 45%, from about 20% to about 99.8%, from about 30% to about 70%, from about 34% to about 59%, from about 20% to about 40%, or from about 30% to about 40% (mol%) of the total lipid present in said particle.

[141] The LNPs described in the present invention may further comprise a non-cationic lipid, which may be any of a variety of neutral, uncharged, zwitterionic or anionic lipids capable of producing a stable complex. They are preferably neutral, although they may be negatively charged. Examples of non-cationic lipids useful in the present invention include phospholipid-related materials, such as natural phospholipids, synthetic phospholipid derivatives, fatty acids, sterols and combinations thereof. Natural phospholipids include phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylglycerol (PG), phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidic acid (phosphatidate) (PA), dipalmitoylphosphatidylcholine, monoacyl-phosphatidylcholine (lyso PC), Petition 870250101498, dated 05 / 11 / 2025, pp. 453 / 546 64 / 109 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), N-acyl-PE, phosphoinositides, and phosphosphingolipids. Phospholipid derivatives include phosphatidic acid (DMPA, DPPA, DSPA), phosphatidylcholine (DDPC, DLPC, DMPC, DPPC, DSPC, DOPC, POPC, DEPC), phosphatidylglycerol (DMPG, DPPG, DSPG, POPG), phosphatidylethanolamine (DMPE, DPPE, DSPE, DOPE), and phosphatidylserine (DOPS). The fatty acids include C14:0, palmitic acid (C16:0), stearic acid (C18:0), oleic acid (C18:1), linoleic acid (C18:2), linolenic acid (C18:3), and arachidonic acid (C20:4), C20:0, C22:0, and lecithin.

[142] In certain embodiments of the invention, the non-cationic lipid is selected from: lecithin, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, cephalin, cardiolipin, phosphatidic acid, cerebrosides, dicetylphosphate, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoylleoylphosphatidylcholine (POPC), palmitoylleoyl-phosphatidylethanolamine (POPE) and dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal). Non-cationic lipids also include sterols such as cholesterol, stigmasterol, or stigmastanol. Cholesterol is known in the art. See U.S. Patent Application Publications Nos.: US 2006 / 0240554 and US 2008 / 0020058. In certain embodiments, LNP comprises a combination of a phospholipid and a sterol.

[143] When present, the non-cationic lipid typically comprises from about 0.1% to about 65%, from about 2% to about 65%, from about 10% to about 65%, or from about 25% to about 65%, expressed as a mole percent of the total lipid present in the LNP. The LNPs described in the present invention additionally include a polyethylene glycol (PEG) lipid conjugate (“PEG-lipid”). Petition 870250101498, dated 05 / 11 / 2025, pages 454 / 546 65 / 109 which can act as a bilayer stabilizing component. The lipid component of the PEG lipid can be any non-cationic lipid described above, including natural phospholipids, synthetic phospholipid derivatives, fatty acids, sterols, and combinations thereof. In certain embodiments of the invention, PEG-lipids include PEG coupled to dialkyloxypropyl (PEG-DAA), as described, for example, in International Patent Application Publication NO WO 05 / 026372; PEG coupled to diacylglycerol (PEG-DAG), as described, for example, in U.S. Patent Publications NOS 20030077829 and 2005008689; PEG coupled to phosphatidylethanolamine (PE) (PEG-PE); or PEG conjugated to 1,2-Di-O-hexadecyl-sn-glyceride (PEG-DSG), or any mixture thereof. See, for example, U.S. Patent No. 5,885,613.

[144] In one embodiment, the PEG-DAG conjugate is a dilaurylglycerol (C12)-PEG conjugate, a dimyristylglycerol (C14) PEG conjugate, a dipalmitoylglycerol (C16) PEG conjugate, a dilaurylglycamide (C12) PEG conjugate, a dimyristylglycamide (C14) PEG conjugate, a dipalmitoylglycamide (C16) PEG conjugate, or a disterilglycamide (C18) PEG conjugate. Those skilled in the art will readily understand that other diacylglycerols may be used in PEG-DAG conjugates.

[145] In certain embodiments, PEG-lipids include, but are not limited to, PEG-dimyristolglycerol (PEG-DMG), PEG-disterilylglycerol (PEG-DSG), PEG-dipalmetoleyl, PEG-dioleyl, PEG-diestearyl, PEG-diacylglycamide (PEG-DAG), PEG-dipalmitoylphosphatidylethanolamine (PEG-DPPE) and PEG-1,2-dimyristoloxypropyl3-amine (PEG-c-DMA).

[146] In certain embodiments, PEG-lipid is PEG coupled to dimyristoylglycerol (PEG-DMG), for example, as described in Abrams et al., 2010, Molecular Therapy 18(1):171, and US Patent Application Publications Petition 870250101498, dated 05 / 11 / 2025, pp. 455 / 546 66 / 109 US 2006 / 0240554 and US 2008 / 0020058.

[147] In certain embodiments, the PEG-lipid, such as a PEG-DAG, PEG-cholesterol, PEG-DMB, comprises a polyethylene glycol with an average molecular weight ranging from about 500 daltons to about 10,000 daltons, from about 750 daltons to about 5,000 daltons, from about 1,000 daltons to about 5,000 daltons, from about 1,500 daltons to about 3,000 daltons or from about 2,000 daltons. In certain embodiments, the PEG-lipid comprises PEG400, PEG1500, PEG2000 or PEG5000.

[148] The acyl groups in any of the lipids described above are preferably acyl groups derived from fatty acids with carbon chains from about C10 to about C24. In one embodiment, the acyl group is lauroyl, myristoyl, palmitoyl, stearoyl, or oleoyl.

[149] The PEG-lipid conjugate typically comprises from about 0.1% to about 15%, from about 0.5% to about 20%, from about 1.5% to about 18%, from about 4% to about 15%, from about 5% to about 12%, from about 1% to about 4%, or about 2% expressed as a mol% of the total lipid present in said particle.

[150] In certain embodiments of the invention, the LNPs comprise one or more cationic lipids, cholesterol and 1,2-Dimyristoyl-sn-glycerol methoxypolyethylene glycol (PEG-DMG).

[151] In certain embodiments of the invention, the LNPs comprise one or more cationic lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol (PEG-DMG).

[152] In some embodiments of the invention, the LNP comprises 34 to 59 mol % of a cationic lipid, 30 to 48 mol % of a sterol, 10 to 24 mol % of a phospholipid and 1 to 2 mol % of a PEG-lipid.

[153] In some embodiments, the cationic lipid is selected from the group Petition 870250101498, dated 05 / 11 / 2025, pages 456 / 546 67 / 109 (V).

[155] In some embodiments, the phospholipid is selected from the group consisting of: Petition 870250101498, dated 05 / 11 / 2025, pages 457 / 546 68 / 109

[156] In some embodiments, the polyethylene glycol-lipid is selected from the group consisting of: Petition 870250101498, dated 05 / 11 / 2025, pages 458 / 546 69 / 109

[157] In certain embodiments of the invention, LNPs comprise lipid compounds assembled in the following molar ratios: Cationic lipid (20 to 99.8 mol%) Non-cationic lipid (0.1 to 65 mol%) and PEG-DMG (0.1 to 20 mol%).

[158] In certain embodiments of the invention, LNPs comprise lipid compounds assembled in the following molar ratios: Cationic lipid (30 to 70 mol%) Non-cationic lipid (20 to 65 mol%) and PEG-DMG (1 to 15 mol%).

[159] In certain aspects of this form, the non-cationic lipid is cholesterol. Exemplary LNPs may include cationic lipid / cholesterol / PEG-DMG in the following molar ratios: 58 / 30 / 10.

[160] In certain aspects of this embodiment, the non-cationic lipid is cholesterol and DSPC. Exemplary LNPs may include cationic lipid / cholesterol / DSPC / PEG-DMG in the following molar ratios: 59 / 30 / 10 / 1; 58 / 30 / 10 / 2; 43 / 41 / 15 / 1; 42 / 41 / 15 / 2; 40 / 48 / 10 / 2; 39 / 41 / 19 / 1; 38 / 41 / 19 / 2; 34 / 41 / 24 / 1; and 33 / 41 / 24 / 2. LNP preparation

[161] LNPs can be formed, for example, by a rapid precipitation process involving the micromixing of lipid components dissolved in ethanol with an aqueous solution, using a confined volume mixing apparatus, such as a confined volume T-mixer, a multi-inlet vortex mixer (MIVM) or a microfluidic mixing device, as described below. The lipid solution contains one or more cationic lipids, one or more non-cationic lipids (e.g., DSPC), PEG-DMG and, optionally, cholesterol, in proportions Petition 870250101498, dated 05 / 11 / 2025, pp. 459 / 546 70 / 109 specific molar concentrations in ethanol. The aqueous solution consists of a buffered saline solution of sodium citrate or sodium acetate with a pH in the range of 2 to 6, preferably 3.5 to 5.5. The two solutions are heated to a temperature in the range of 25 °C to 45 °C, preferably 30 °C to 40 °C, and then mixed in a confined volume mixer, instantly forming the LNP. When a confined volume mixer T is used, the mixer T has an internal diameter (ID) ranging from 0.25 to 1.0 mm. The alcoholic and aqueous solutions are delivered to the inlet of the mixer T using programmable syringe pumps, with a total flow rate range of 10 to 600 mL / minute. Alcoholic and aqueous solutions are combined in the confined volume mixer at a ratio in the range of 1:1 to 1:3 vol:vol, but aiming for 1:1.1 to 1:2.3.The combination of the ethanol volume fraction, reagent solution flow rates, and DI of the mixer T piping used in this mixing stage has the effect of controlling the particle size of the LNPs between 30 and 300 nm. The resulting LNP suspension is diluted twice in higher pH buffers in the range of 6 to 8 in a multi-stage sequential in-line mixing process. For the first dilution, the LNP suspension is mixed with a higher pH buffer solution (pH 6-7.5) with a mixing ratio in the range of 1:1 to 1:3 vol:vol, but aiming for 1:2 vol:vol. This buffer solution is at a temperature in the range of 15 to 40 °C, aiming for 30 to 40 °C. The resulting LNP suspension is subsequently mixed with a buffered solution at a higher pH, for example, 6 to 8, and with a mixing ratio in the range of 1:1 to 1:3 vol:vol, but aiming for 1:2 vol:vol. This subsequent buffered solution is at a temperature in the range of 15 to 40 °C, aiming for 16 to 25 °C.The mixed LNPs are kept for 30 minutes to 2 hours before an anion exchange filtration step. The temperature during the incubation period is in the range of 15 to 40 °C, aiming for 30 to 40 °C. After incubation, the LNP suspension is filtered through. Petition 870250101498, dated 05 / 11 / 2025, pages 460 / 546 71 / 109 of a 0.8 μm filter containing an anion exchange separation step. This process uses tubes with internal diameters ranging from 1 mm to 5 mm and a flow rate of 10 to 2000 mL / minute. LNPs are concentrated and diafiltered via an ultrafiltration process, in which the alcohol is removed and the buffer is exchanged for the final buffered solution, such as phosphate-buffered saline or a buffer system suitable for cryopreservation (e.g., containing sucrose, trehalose, or combinations thereof). The ultrafiltration process utilizes a tangential flow filtration (TFF) format. This process uses a nominal molecular weight membrane cutoff range of 30 to 500 kDa, targeting 100 kDa. The membrane format can be hollow fiber or flat sheet cassette. TFF processes with appropriate molecular weight cutoff retain LNP in the retentate, and the filtrate or permeate contains the alcohol and final buffer residues.The TFF process is a multi-step process with an initial lipid concentration of 20 to 30 mg / mL. After concentration, the LNP suspension is diafiltered against the final buffer (e.g., phosphate-buffered saline (PBS) with pH 7 to 8, 10 mM Tris, 140 mM NaCl with pH 7 to 8, or 10 mM Tris, 70 mM NaCl, 5 wt% sucrose with pH 7 to 8) by 5 to 20 volumes to remove alcohol and perform buffer exchange. The material is then concentrated a further 1 to 3 times by ultrafiltration. The final steps of the LNP manufacturing process consist of sterile filtering of the concentrated LNP solution into a suitable container under aseptic conditions. Sterile filtration is performed by passing the LNP solution through a pre-filter (Acropak 500 PES capsule 0.45 / 0.8 pm) and a bioload reduction filter (Acropak 500 PES capsule 0.2 / 0.8 pm).After filtration, the LNP product in the bottle is stored under appropriate conditions (2°C, -8°C or -20°C if the formulation is frozen).

[162] In some forms, the LNPs of the compositions provided in Petition 870250101498, dated 05 / 11 / 2025, pp. 461 / 546 72 / 109 of the present invention have an average geometric diameter of less than 1000 nm. In some embodiments, the LNPs have an average geometric diameter greater than 50 nm but less than 500 nm. In some embodiments, the average geometric diameter of a population of LNPs is about 60 nm, 75 nm, 100 nm, 125 nm, 150 nm, 175 nm, 200 nm, 225 nm, 250 nm, 275 nm, 300 nm, 325 nm, 350 nm, 375 nm, 400 nm, 425 nm, 450 nm, or 475 nm. In some embodiments, the average geometric diameter is between 100 and 400 nm, 100 and 300 nm, 100 and 250 nm, or 100 and 200 nm. In some modalities, the geometric mean diameter is between 60 and 400 nm, 60 and 350 nm, 60 and 300 nm, 60 and 250 nm, or 60 and 200 nm. In some modalities, the geometric mean diameter is between 75 and 250 nm. In some modalities, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the LNPs in an LNP population have a diameter of less than 500 nm.In some modalities, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the LNPs in an LNP population have a diameter greater than 50 nm but less than 500 nm. In some modalities, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the LNPs in an LNP population have a diameter of approximately 60 nm, 75 nm, 100 nm, 125 nm, 150 nm, 175 nm, 200 nm, 225 nm, 250 nm, 275 nm, 300 nm, 325 nm, 350 nm, 375 nm, 400 nm, 425 nm, 450 nm or 475 nm. In some modalities, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the LNPs in an LNP population have a diameter between 100 and 400 nm, 100 and 300 nm, 100 and 250 nm, or 100 and 200 nm. In some modalities, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the LNPs in an LNP population have a diameter between 60 and 400 nm, 60 and 350 nm, 60 and 300 nm, 60 and 250 nm, or 60 and 200 nm.

[163] In one particular embodiment, the size of the LNPs varies between about 1 and 1000 nm, preferably between about 10 and 500 nm, more preferably between about 100 and 300 nm and preferably 100 nm. Petition 870250101498, dated 05 / 11 / 2025, pp. 462 / 546 73 / 109 Therapeutic and prophylactic compositions

[164] In the present invention, vaccine compositions (e.g., pharmaceutical compositions), methods, kits, and reagents are provided for the prevention, treatment, and / or diagnosis of norovirus in humans and other mammals. Norovirus vaccines can be used as therapeutic or prophylactic agents. They can be used in medicine to prevent and / or treat infectious diseases. In some embodiments, the vaccines according to the present disclosure can be used for the treatment of norovirus.

[165] In the present invention, pharmaceutical compositions including norovirus vaccines are optionally provided in combination with one or more pharmaceutically acceptable excipients.

[166] Norovirus vaccines may be formulated or administered alone or in combination with one or more other components. For example, norovirus vaccines (vaccine compositions) may comprise other components, including, but not limited to, adjuvants.

[167] In some embodiments of the invention presented in this document, the norovirus vaccines do not include an adjuvant (i.e., they are adjuvant-free). In other embodiments, the norovirus vaccines include lipid or polymeric nanoparticles. In certain embodiments, any of the lipid nanoparticles described in this invention can act as an adjuvant when combined with norovirus vaccines.

[168] It has long been demonstrated that aluminum stimulates the immune response against co-administered antigens, primarily by stimulating a TH2 response. It is preferable that the aluminum adjuvant of the compositions provided in the present invention not be in the form of an aluminum precipitate. Aluminum-precipitated vaccines may increase the immune response. Petition 870250101498, dated 05 / 11 / 2025, pp. 463 / 546 74 / 109 to a target antigen, but have proven to be highly heterogeneous preparations and have shown inconsistent results (see Lindblad EB Immunology and Cell Biology 82: 497-505 (2004)). Aluminum-adsorbed vaccines, on the other hand, can be prepared in a standardized manner, which is an essential characteristic of vaccine preparations for administration in humans. Furthermore, the physical adsorption of a desired antigen onto the aluminum adjuvant is believed to play an important role in adjuvant function, perhaps in part by allowing slower elimination from the injection site or by enabling more efficient uptake of the antigen by antigen-presenting cells.

[169] The aluminum adjuvant of the present invention may be in the form of aluminum hydroxide (Al(OH)3), aluminum phosphate (AlPO4), aluminum hydroxyphosphate, amorphous aluminum hydroxyphosphate sulfate (AAHS) or so-called “alum” (KA1(SO4)-12H2O). See Klein et al., Analysis of aluminum hydroxyphosphate vaccine adjuvants by (27)A1 MAS NMR., J. Pharm. Sci. 89(3): 311 to 21 (2000).

[170] In some embodiments of the invention presented herein, the aluminum adjuvant is aluminum hydroxyphosphate or AAHS. The phosphate-to-aluminum ratio in the aluminum adjuvant can vary from 0 to 1.3. In some embodiments of this aspect of the invention, the phosphate-to-aluminum ratio is in the range of 0.1 to 0.70. In certain embodiments, the phosphate-to-aluminum ratio is in the range of 0.2 to 0.50. APA is an aqueous suspension of aluminum hydroxyphosphate. APA is manufactured by mixing aluminum chloride and sodium phosphate in a 1:1 volumetric ratio to precipitate the aluminum hydroxyphosphate. After the mixing process, the material is reduced in size with a high-shear mixer to achieve a target aggregate particle size in the range of 2 to 8 µm. The product is then Petition 870250101498, dated 05 / 11 / 2025, pp. 464 / 546 75 / 109 diafiltrated in physiological saline solution and steam sterilized. See, for example, International Patent Application Publication NO WO2013 / 078102.

[171] In some embodiments of the present invention, the aluminum adjuvant is in the form of AAHS (referred to in the present invention interchangeably as Merck aluminum adjuvant (MAA)). MAA has a zero charge at neutral pH, while AIOH has a net positive charge and AIPO4 typically has a net negative charge at neutral pH.

[172] A person skilled in the art will be able to determine an ideal dosage of aluminum adjuvant that is safe and effective in enhancing the immune response to the target antigenic polypeptides. For a discussion of the safety profile of aluminum, as well as the amounts of aluminum included in FDA-licensed vaccines, see Baylor et al., Vaccine 20: S18 to S23 (2002). Generally, an effective and safe dose of aluminum adjuvant ranges from 150 to 600 μg / dose (concentration of 300 to 1200 μg / mL). In specific embodiments of the formulations and compositions of the present invention, there are between 200 and 300 μg of aluminum adjuvant per vaccine dose. In alternative embodiments of the formulations and compositions of the present invention, there are between 300 and 500 μg of aluminum adjuvant per vaccine dose. Formulations and methods of use of the norovirus vaccine

[173] The norovirus vaccines of the present disclosure may be formulated or administered in combination with one or more pharmaceutically acceptable excipients. In some embodiments, the vaccine compositions comprise at least one additional active substance, such as, for example, a therapeutically active substance, a prophylactic substance, or a combination of both. The vaccine compositions may be sterile, pyrogen-free, or both sterile and pyrogen-free. General considerations regarding the formulation and / or manufacture of pharmaceutical agents, such as Petition 870250101498, dated 05 / 11 / 2025, pp. 465 / 546 76 / 109 vaccine compositions can be found, for example, in Remington: The Science and Practice of Pharmacy, 21st ed., Lippincott Williams & Wilkins, 2005.

[174] The formulations of the norovirus vaccine compositions described in the present invention may be prepared by any method known or subsequently developed in the field of pharmacology. In general, such preparatory methods include the step of combining the active ingredient (e.g., one or more polynucleotides) with an excipient and / or one or more other accessory ingredients and then, if necessary and / or desirable, dividing, shaping and / or packaging the product into a desired single or multiple dose unit.

[175] The relative amounts of the active ingredient, the pharmaceutically acceptable excipient and / or any additional ingredients in a pharmaceutical composition, according to this disclosure, will vary depending on the identity, size and / or condition of the individual treated and also on the route of administration of the composition. By way of example, the composition may comprise between 0.1% and 100%, for example, between 0.5% and 50%, between 1% and 30%, between 5% and 80%, or at least 80% (w / w) of the active ingredient.

[176] Some aspects of the present disclosure provide formulations of the norovirus vaccine, wherein the vaccine is formulated in an amount effective to produce a specific immune response to the antigen in an individual (e.g., production of antibodies specific to an antigenic polypeptide of the norovirus). An “effective amount” of a norovirus RNA vaccine is provided based, at least in part, on the target tissue, target cell type, means of administration, physical characteristics of the polynucleotide (e.g., size and extent of modified nucleosides) and other components of the norovirus RNA vaccine, and other determinants. In Petition 870250101498, dated 05 / 11 / 2025, pp. 466 / 546 77 / 109 In general, an effective amount of the RNA vaccine composition against norovirus provides an induced or enhanced immune response based on antigen production in the cell, preferably more efficient than a composition containing a corresponding unmodified polynucleotide encoding the same antigen or a peptide antigen. Increased antigen production can be demonstrated by increased cell transfection (the percentage of cells transfected with the RNA vaccine), increased translation of polynucleotide proteins, decreased nucleic acid degradation (as demonstrated, for example, by increased translation time of proteins from a modified polynucleotide), or altered host cell antigen-specific immune response.

[177] In some embodiments, the antigen-specific immune response is characterized by measuring an anti-antigenic polypeptide antibody titer produced in an individual who has been administered a norovirus vaccine, as provided in the present invention. An antibody titer is a measure of the amount of antibodies in an individual, for example, antibodies that are specific to a particular antigen (e.g., a norovirus antigenic polypeptide, such as a VP1 or VP2 polypeptide) or epitope of an antigen. The antibody titer is typically expressed as the inverse of the highest dilution that gives a positive result. Enzyme-linked immunosorbent assay (ELISA) is a common assay for determining antibody titers, for example.

[178] In some modalities, an antibody titer is used to assess whether an individual has had an infection or to determine whether immunizations are necessary. In some modalities, an antibody titer is used to determine the intensity of an autoimmune response, to determine whether a booster immunization is needed, to determine whether a previous vaccine was Petition 870250101498, dated 05 / 11 / 2025, pp. 467 / 546 78 / 109 effective and to identify any recent or previous infections. According to the present disclosure, an antibody titer can be used to determine the intensity of an immune response induced in an individual by the norovirus vaccine. Vaccine administration methods

[179] Norovirus vaccines can be administered prophylactically or therapeutically as part of an active immunization schedule to healthy individuals or at the onset of infection, during the incubation phase, or during active infection after symptom onset. A prophylactically effective dose is a therapeutically effective dose that prevents infection by the virus at a clinically acceptable level. In some embodiments, the therapeutically effective dose is a dose listed in the vaccine label. In some embodiments, the amount of vaccine of the present disclosure delivered to a cell, tissue, or individual may be an effective amount for immunoprophylaxis.

[180] Norovirus vaccines can be formulated for administration by any route that results in a therapeutically effective outcome. These routes include, but are not limited to, intradermal, intramuscular, intranasal, intratracheal, and / or subcutaneous administration. In some embodiments, norovirus vaccines are administered intramuscularly.

[181] The present disclosure provides methods comprising administering vaccines to an individual who needs them. The exact amount required will vary from individual to individual, depending on the species, age and general condition of the individual, the severity of the disease, the particular composition, the mode of administration, the mode of activity and the like.

[182] Norovirus vaccine compositions are typically formulated in unit dose form to facilitate administration and Petition 870250101498, dated 05 / 11 / 2025, pp. 468 / 546 79 / 109 uniformity of dosage. It should be understood, however, that the total daily use of the vaccine compositions may be decided by the attending physician within the scope of good medical judgment. The specific therapeutically effective, prophylactically effective, or imaging-appropriate dose level for any particular patient will depend on a variety of factors, including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the patient's age, body weight, general health, sex, and diet; the timing of administration, the route of administration, and the excretion rate of the specific compound employed; the duration of treatment; medications used in combination or concomitantly with the specific compound employed; and similar factors well known in medical techniques.

[183] ​​Norovirus vaccines may be administered with other prophylactic or therapeutic compounds. As a non-limiting example, a prophylactic or therapeutic compound may be an adjuvant or a booster. As used in the present invention, when referring to a prophylactic composition, such as a vaccine, the term “booster” refers to an extra administration of the prophylactic composition (vaccine). A booster (or booster vaccine) may be administered after a previous administration of the prophylactic composition.The time between the initial administration of the prophylactic composition and the booster may be, but is not limited to, 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 15 minutes, 20 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 1 day, 36 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week. Petition 870250101498, dated 05 / 11 / 2025, pp. 469 / 546 80 / 109 days, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 18 months, 2 years, years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years, 11 years, 12 years, years, 14 years, 15 years, 16 years, 17 years, 18 years, 19 years, 20 years, 25 years, years, 35 years, 40 years, 45 years, 50 years, 55 years, 60 years, 65 years, 70 years, years, 80 years, 85 years, 90 years, 95 years or more than 99 years. In some formulations, the time between the initial administration of the prophylactic composition and the booster may be, but is not limited to, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months, or 1 year.

[184] Norovirus vaccines can be used in a variety of contexts, depending on the prevalence of infection or the degree or level of unmet medical need. As a non-limiting example, norovirus vaccines can be used to treat and / or prevent a variety of noroviruses. Vaccines exhibit superior properties as they produce much higher antibody titers and produce earlier responses than commercially available antiviral agents and compositions. Treatment methods

[185] The present invention provides compositions (e.g., pharmaceutical compositions), methods, kits, and reagents for the prevention and / or treatment of norovirus in humans and other mammals. Norovirus vaccines can be used as therapeutic or prophylactic agents. They can be used in medicine to prevent and / or treat infectious diseases. In exemplary aspects, the norovirus vaccines of the present disclosure are used to provide prophylactic protection against norovirus. Prophylactic protection against norovirus can be achieved after administration of a norovirus vaccine of the present disclosure. The vaccines can be administered one, two, three, four, or more times. It is possible, although less Petition 870250101498, dated 05 / 11 / 2025, pages 470 / 546 81 / 109 desirable, administer the vaccine to an infected individual to obtain a therapeutic response. The dosage may need to be adjusted accordingly.

[186] In some embodiments, the norovirus vaccines of the present disclosure can be used as a method to prevent a norovirus infection in an individual, the method comprising administering to said individual at least one norovirus vaccine as described in the present invention. In some embodiments, the norovirus vaccines of the present disclosure can be used as a method to inhibit a primary norovirus infection in an individual, the method comprising administering to said individual at least one norovirus vaccine as described in the present invention. In some embodiments, the norovirus vaccines of the present disclosure can be used as a method to treat a norovirus infection in an individual, the method comprising administering to said individual at least one norovirus vaccine as described in the present invention.In some embodiments, the norovirus vaccines of the present disclosure can be used as a method to reduce the incidence of norovirus infection in an individual, the method comprising administering to said individual at least one norovirus vaccine, as described in the present invention. In some embodiments, the norovirus vaccines of the present disclosure can be used as a method to inhibit the spread of norovirus from a first norovirus-infected individual to a second norovirus-uninfected individual, the method comprising administering to at least one of said first individual and second individual at least one norovirus vaccine, as provided in the present invention.

[187] A method for inducing an immune response in an individual Petition 870250101498, dated 05 / 11 / 2025, pp. 471 / 546 82 / 109 against a norovirus is provided in some aspects of the invention. The method involves administering to the individual a norovirus vaccine described in the present invention, thereby inducing in the individual a specific immune response to the antigenic polypeptide of the norovirus or to an immunogenic fragment thereof. EXAMPLES

[188] The following examples are merely illustrative and should not be construed as limiting. The content of the figures and all published references, patents and patent applications cited throughout this application are expressly incorporated by reference into the present invention. Example 1: Preparation of mRNAs

[189] DNA sequences encoding antigenic VP1 proteins from noroviruses were prepared and used for subsequent in vitro RNA transcription reactions. VP1 protein sequences were retrieved from public databases (GenBank, INSDC), and a single consensus sequence was selected for each genotype (i.e., GenBank ID QBW96040 for GII.4, GenBank ID NP_056821 for GI.1, GenBank ID AWT08315 for GII.6, GenBank ID for YP_009518839 GII.2, and GenBank ID QJF54133 GII.3) based on the most common recent sequence. The selected DNA sequences were modified by introducing a codon-modified sequence or a GC-optimized sequence for stabilization. The DNA sequences were altered from the native sequence as follows. Silent mutations were introduced to maximize the codon adaptation index (CAI). See Sharp PM, Li WH.The codon adaptation index—a measure of directional synonymous codon usage bias, and its potential applications. Nucleic Acids Res. 1987, February 11; 15(3):1281-95. Sequences of five or more of the same nucleotide were broken using the second most frequent codon. Furthermore, DNA 30. Petition 870250101498, dated 05 / 11 / 2025, pp. 472 / 546 83 / 109 mers with G / C content above 80% were mutated to reduce the G / C content to 80% or less, using the second most frequent codon for Pro (CCC->CCA), Gly (GGC->GGA), and / or Ala (GCC->GCA). For example, using the short amino acid sequence Proline-Proline, as found, for example, in DNA GII. 3: (1) the native sequence CCC-CCT was first mutated to CCC-CCC to optimize CAI; and then (2) subsequently modified to the second most frequent codon for Proline (i.e., CCA) to avoid homopolymer sequences. The codon-optimized DNA sequences are shown as SEQ ID NOs: 9 to 13 in Table 1 below. Table 1: Sequences SEQ ID NO: Description Sequence 1 GII.4 Organism: Synthetic construct Molecule type: Other RNA AUGAAGAUGGCCAGCAGCGACGCCAACCCAAGCGACGGCAGCGC AGCCAACCUGGUGCCCGAGGUGAACAACGAGGUGAUGGCCCUGG AGCCAGUGGUGGGAGCAGCCAUCGCAGCCCCAGUGGCAGGCCAG CAGAACGUGAUCGACCCAUGGAUCCGGAACAACUUCGUGCAGGC CCCAGGAGGCGAGUUCACCGUGAGCCCACGGAACGCCCCAGGCG AGAUCCUGUGGAGCGCACCACUGGGCCCAGACCUGAACCCAUAC CUGAGCCACCUGGCCCGGAUGUACAACGGCUACGCCGGCGGCUU CGAGGUGCAGGUGAUCCUGGCCGGCAACGCCUUCACCGCAGGCA AGAUCAUCUUCGCCGCCGUGCCACCCAACUUCCCAACCGAGGGCC UGAGCCCAAGCCAGGUGACCAUGUUCCCACACAUCAUCGUGGAC GUGAGGCAGCUGGAGCCCGUGCUGAUCCCACUGCCCGACGUGCG GAACAACUUCUACCACUACAACCAGAGCAACGACAGCACCAUCAA GCUGAUCGCCAUGCUGUACACCCCACUGCGGGCCAACAACGCCG GCGACGACGUGUUCACCGUGAGCUGCAGGGUGCUGACCAGGCCC AGCCCAGACUUCGACUUCAUCUUCCUGGUGCCACCCACCGUGGA GAGCCGGACCAAGCCCUUCAGCGUGCCCGUGCUGACCGUGGAGG AGAUGACCAACAGCCGGUUCCCAAUCCCACUGGAGAAGCUGUUC ACCGGACCAAGCAGCGCCUUCGUGGUGCAGCCACAGAACGGCCG GUGCACCACCGACGGAGUGCUGCUGGGCACCACCCAGCUGAGCC CAGUGAACAUCUGCACCUUCCGGGGCGACGUGACCCACAUCACCGGCAGCCGGAACUACACCAUGAACCUGGCCAGCCAGAACUGGAA CAACUACGACCCAACCGAGGAGAUCCCAGCCCCACUGGGCACCCC AGACUUCGUGGGCAAGAUCCAGGGCAUGCUGACCCAGACCACCA GAACCGACGGCAGCACCAGAGGCCACAAGGCCACCGUGUACACCG GCAGCGCCGACUUCGCCCCAAAGCUGGGCCGGGUGCAGUUCGAG ACCGACACCGACCACGACUUCGAGGCCAACCAGAACACCAAGUUC ACCCCAGUGGGCGUGAUCCAGGACGGCAGCACCACCCACCGGAAC GAGCCACAGCAGUGGGUGCUGCCCAGCUACAGCGGCAGGAACAC Petition 870250101498, dated 05 / 11 / 2025, pp. 473 / 546 84 / 109 SEQ ID NO: Description Sequence CCACAACGUGCACCUGGCACCAGCCGUGGCACCAACCUUCCCAGG CGAGCAGCUGCUGUUCUUCCGGAGCACCAUGCCAGGCUGCAGCG GCUACCCAAACAUGGACCUGGACUGCCUGCUGCCACAGGAGUGG GUGCAGUACUUCUACCAGGAGGCAGCCCCAGCACAGAGCGACGU GGCCCUGCUGCGGUUCGUGAACCCAGACACCGGACGGGUGCUG UUCGAGUGCAAGCUGCACAAGAGCGGCUACGUGACCGUGGCCCA CACCGGACAGCACGACCUGGUGAUCCCACCCAACGGCUACUUCCG GUUCGACAGCUGGGUGAACCAGUUCUACACCCUGGCCCCAAUGG GCAACGGAACCGGACGGAGGAGGGUGGUG 2 GI.1 Organism: Synthetic construct Molecule type: Other RNA AUGAUGAUGGCCAGCAAGGACGCCACCAGCAGCGUGGACGGAGC CAGCGGCGCAGGACAGCUGGUGCCCGAGGUGAACGCCAGCGACC CACUGGCCAUGGACCCAGUGGCCGGAAGCAGCACCGCAGUGGCC ACCGCAGGCCAGGUGAACCCAAUCGACCCAUGGAUCAUCAACAAC UUCGUGCAGGCCCCACAGGGCGAGUUCACCAUCACGCCCAAACAA CACCCCAGGCGACGUGCUGUUCGACCUGAGCCUGGGCCCACACC UGAACCCAUUCCUGCUGCACCUGAGCCAGAUGUACAACGGCUGG GUGGGCAACAUGCGGGUGCGGAUCAUGCUGGCCGGCAACGCCU UCACCGCCGGCAAGAUCAUCGUGAGCUGCAUCCCACCCGGCUUC GGCAGCCACAACCUGACCAUCGCCCAGGCCACCCUGUUCCCACAC GUGAUCGCCGACGUGCGGACCCUGGACCCAAUCGAGGUGCCACUGGAGGACGUGCGGAACGUGCUGUCACAACCACGACCGGAACC AGCAGACCAUGCGGCUGGUGCUCACCCCACUGCGG ACCGGAGGCCGGAACCGGACAAGCUUCGUGGCCGGCCGGG CCACCCACCGUGGAGCAAGACCCGGCCCUUCCACCCUGCCCAAC CUGCCACUGAGCAGCCUGACACAGCCGGGCCCCACUGCCCAUC AGCAGCAUGGCAUCAGCCCAACACGU CCCCAGUGAGCCUGAGCCACGUGGCCAAUCCGGGGCACCAGC AACGGCACCGUGAUCAACCUGACCGAGCUGGACGGCACCAUU CCACCCAUUCGAGGCCCAGCCCCAAUCGGCUUCCCAGACCUGGG CGGCUGCGACUGGCACAUCAGAUCGACCCAUCCAGU GCCAGACCCAGUACGACGUGCACCACCCCAGACACCUUCGUGC CACACCUGGCAGCAUCCAGGCCAACAGG CAUCGGCAGCGGCACAG UACGUGGCGUGCUGAUCAGCCCACCCAGCCACCAG CGU GUACCCACCCG GCUUCGGCGAGGUGCUGGUUUCAUGAGCAAGAAUGCCCGG CCCAGGCCCCUACAACCUGCCCUGCCUGCUGCCACAGGAGUACAU CAGCCACCUGGCCAGCGAGCAGCCCAACCGUGGGCGAACGUGCCAG GAGUUCAAGGCCUACCCAGACGGCUUCACCUGCGUGCCCAACGGAGCCAGCAG CGGCCCACAGCAGCUG CCCAUCAACGGCGUGU UCGUGUUCGUGAGCUGGGUGAGCCGGUUCUACCAGCUGAAGCC CGUGGGAACCGCCAGCAGCGCCAGAGGACGGCUGGGACUGAGGC Petition 870250101498, dated 05 / 11 / 2025, pp. 474 / 546 85 / 109 SEQ ID NO: Description Sequence GG 3 GII.6 Organism: Synthetic construct Molecule type: Other RNA AUGAAGAUGGCCAGCAACGACGCCGCCCCAAGCAACGACGGAGCC GCCAACCUGGUGCCCGAGGCCACCAACGAGGUGAUGGCCCUGGA GCCCGUGGUGGGAGCCAGCAUCGCAGCCCCAGUGGUGGGGGCCAGC AGAACAUCAUCGACCCAUGGAUCCGGGAGAACUUCGUGCAGGCC CCACAGGGCGAGUUCACCGUGAGCCCACGGAACAGCCCAGGCGA GAUGCUGCUGAACCUGGAGCUGGGCCCAGAGCUGAACCCAUACC UGGGCCACCUGAGCCGGAUGUACAACGGCUACGCCGGCGGCAUG CAGGUGCAGGUGGUGCUGGCCGGCAACGCCUUCACCGCCGGCAA GAUCAUCUUCGCCGCCGUGCCACACACUUCCCAGUGGAACA UCAGCGCCGCCCAGAUCACCAUGUGCCCACACGUGAUCGUGGAC GUGCGGCAGCUGGAGCCCGUGCUGCUGCCACUGCCCGACAUCCG GAACCGGUUCUUCCACUACAACCAGGAGAACACCCCACGGAUGC GGCUGGUGGCCAUGCUGUACACCCCACUGCGGGCCAACAGCGGC GAGGACGUGUUCACCGUGAGCUGCCGGGUGCUGACCAGGCCAG CCCCAGACUUCGAGUUCACCUUCCUGGUGCCACCCACCGUGGAG AGCAAGACCAAGCCCUUCACCCUGCCCAUCCUGACCCUGGGCGAG CUGAGCAACAGCCGGUUCCCAGCCCCAAUCGACAUGCUGUACACC GACCCAAACGAGGCCAUCGUGGUGCAGCCACAGAACGGCCGGUG CACCCUGGACGGCACCCUGCAGGGCACCACCCAGCUGGUGCCCACCCAGAUCUGCAGCUUCCGGGGCACCCUGAUCAGCCAGACCAGCC GGAGCGCAGACAGCACCGACAGCGCCCCACGGGUGCGGAACCACC CACUGCACGUGCAGCUGAAGAACCUGGACGGCACCCCAUACGAC CCAACCGACGAGGUGCCCGCAGUGCUGGGCGCCAUCGACUUCAA GGGCACCGUGUUCGGCAUCGCCAGCCAGCGGAACACCACCGGCA GCAGCAUCGGAGCCACCCGGGCACACGAGGUGCACAUCGACACCA CCAACCCACGGUACACCCCAAAGCUGGGCAGCGUGCUGAUGUAC AGCGAGAGCAACGACUUCGACGACGGCCAGCCCACCCGGUUCACC CCAAUCGGCAUGGGCGCCGACGACUGGCGGCAGUGGGAGCUGCC CGAGUACAGCGGCCACCUGACCCUGAACAUGAACCUGGCCCCAGC CGUGGCACCAGCCUUCCCAGGCGAGCGGAUCCUGUUCUUCCGGA GCGUGGUGCCCAGCGCAGGAGGCUACGGCAGCGGCCACAUCGAC UGCCUGAUCCCACAGGAGUGGGUGCAGCACUUCUACCAGGAGGC CGCACCAAGCCAGAGCGCCGUGGCCCUGAUCCGGUACGUGAACC CAGACACCGGCCGGAACAUCUUCGAGGCCAAGCUGCACCGGGAG GGCUUCAUCACCGUGGCCAACAGCGGCAACAACCCAAUCGUGGU GCCACCCAACGGCUACUUCCGGUUCGAGGCCUGGGUGAACCAGU UCUACACCCUGACCCCAAUGGGCACCGGACAGGGACGGAGGCGG GUGCAG 4 GII.2 Organism: Synthetic construction Molecule type: AUGAAGAUGGCCAGCAACGACGCCGCACCAAGCACCGACGGAGCC GCAGGACUGGUGCCCGAGAGCAACAACGAGGUGAUGGCCCCUGGAGCCCGUGGCAGGAGCCGCACUGGCAGCACCAGUGACCGGCCAG ACCAACAUCAUCGACCCAUGGAUCCGGGCCAACUUCGUGCAGGC CCCAAACGGCGAGUUCACCGUGAGCCCACGGAACGCCCCAGGCGA GGUGCUGCUGAACCUGGAGCUGGGCCCAGAGCUGAACCCAUACC Petition 870250101498, dated 05 / 11 / 2025, pages 475 / 546 86 / 109 SEQ ID NO: Description Sequence Other RNA UGGCCCACCUGGCCCGGAUGUACAACGGCUACGCCGGCGGCAUG GAGGUGCAGGUGAUGCUGGCCGGCAACGCCUUCACCGCCGGCAA GCUGGUGUUCGCCGCCGUGCCACACACUUCCCAGUGGAACC UGAGCCCACAGCAGAUCACCAUGUUCCCACACGUGAUCAUCGAC GUGCGGACCCUGGAGCCCGUGCUGCUGCCACUGCCCGACGUGCG GAACAACUUCUUCCACUACAACCAGAAGGACGACCCAAAGAUGC GGAUCGUGGCCAUGCUGUACACCCCACUGCGGAGCAACGGCAGC GGCGACGACGUGUUCACCGUGAGCUGCCGGGUGCUGACCAGGC CCAGCCCAGACUUCGACUUCACCUACCUGGUGGCCACCCACCGUGG AGAGCAAGACCAAGCCCUUCACCCUGCCCAUCCUGACCCUGGGCG AGCUGAGCAACAGCCGGUUCCCAGUGAGCAUCGACCAGAUGUAC ACCAGCCCAAACGAGAUCAUCAGCGUGCAGUGCCAGAACGGCCG GUGCACCCUGGACGGCGAGCUGCAGGGCACCACCCAGCUGCAGG UGAGCGGCAUCUGCGCCUUCAAGGGCGAGGUGACCGCCCACCUG CACGACAACGACCACCUGUACAACGUGACCAUCACCAACCUGAAC GGCAGCCCAUUCGACCCAAGCGAGGACAUCCCAGCCCCACUGGGC GUGCCCGACUUCCAGGCCGGGUGUUCGGCAUCAUCAGCCAGCG GGACAAGCACAACAGCCCAGGCCACAACGAG CCCGCCAACCGGGG ACACGACGCCGUGGUGCCCACCUACACCGCCCAGUACACCCCAAA GCUGGGCCAGAUCCAGAUCGGCACCUGGCAGACCGACGACCUGA CCGUGAACCAGCCCGUGAAGUUCACCCCAGUGGGCCUGAACGACACCGAGCACUUCAACCAGUGGGUGGUGCCACGGUACGCCGGCGC CC UGAACCUGAACACCAACCUG GCCCCAAGCGUGGCCCCAGUGU UCCCAGGCGAGCGGCUGCUGUUCUUCCGGAGCUACAUCCCACUG AAGGGCGGCUACGGCAACCCAGCCAUCGACUGCCUGCUGCCACA GGAGUGGGUGCAGCACUUCUACCAGGAGGCCGCCCCAAGCAUGA GCGAGGUGGCCCUGGUGCGGUACAUCAACCCAGACACCGGCCGG GCCCUGUUCGAGGCCAAGCUGCACCGGGCCGGCUUCAUGACCGU GAGCAGCAACACCAGCGCCCCAGUGGUGGUGCCCGCCAACGGCU ACUUCCGGUUCGACAGCUGGGUGAACCAGUUCUACAGCCUGGCC CCAAUGGGCACCGGCAACGGACGGAGGCGGGUGCAG 5 GII.3 Organism: Synthetic construction Type of molecule: Outro RNA AUGAAGAUGGCCAGCAACGACGCCACCCCAAGCAACGACGGAGCC GCAGGCCUGGUGCCCGAGAUCAACAACGAGGCCAUGGCCCUGGA GCCCGUGGCAGGAGCAGCCAUCGCCGCACCACUGACCGGCCAGCA GAACAUCAUCGACCCAUGGAUCAUGAACAACUUCGUGCAGGCCC CAGGCGGCGAGUUCACCGUGAGCCCACGGAACAGCCCAGGCGAG GUGCUGCUGAACCUGGAGCUGGGCCCAGAGAUCAACCCAUACCU GGCCCACCUGGCCCGGAUGUACAACGGCUACGCCGGCGGCUUCG AGGUGCAGGUGGUGCUGGCCGGCAACGCCUUCACCGCCGGCAAG AUCAUCUUCGCCGCCAUCCCACCCAACUUCCCAAUCGACAACCUG AGCGCCGCCCAGAUCACCAUGUGCCCACACGUGAUCGUGGACGUGCGGCAGCUGGAGCCCGUGAACCUGCCCAUGCCCGACGUGCGGA ACAACUUCUUCCACUACAACCAGGGAAGCGACAGCCGGCUGCGG CUGGUGGCCAUGCUGUACACCCCACUGCGGGCCAACAACAGCGG CGACGACGUGUUCACCGUGAGCUGCCGGGUGCUGACCAGGCCCA Petition 870250101498, dated 05 / 11 / 2025, pages 476 / 546 87 / 109 SEQ ID NO: Description Sequence GCCCAGAGUUCAGCUUCAACUUCCUGGUGCCACCCACCGUGGAG AGCAAGACCAAGCCCUUCACCCUGCCCAUCCUGACCAUCAGCGAG AUGAGCAACAGCCGGUUCCCAGUGCCCAUCGACAGCCUGCACACC AGCCCAACCGAGAACAUCGUGGUGCAGUGCCAGAACGGCCGGGU GACCCUGGACGGCGAGCUGAUGGGCACCACCCAGCUGCUGCCCA GCCAGAUCUGCGCGCCUUCCGGGGAGUGCUGACCCGGAGCACCAGC CGGGCAAGCGACCAGGCAGACACCGCCACCCCACG GCUGUU CAAC UACUACUGGCACAUCCAGCUGGACAACCUGAACGGCACCCCAUAC GACCCAGCCGAGGACAUCCCAGGCCCACUGGGCACCCCAGACUUC CGGGGCAAGGUGUUCGGCGUGGCCAGCCAGCGGAACCCAGACAG CACCACCCGGGCCCACGAGGCCAAGGUGGACACCACCGCCGGCCG GUUCACCCCAAAGCUGGGCAGCCUGGAGAUCAGCACCGAGAGCG ACGACUUCGACCAGAACCAGCCCACCCGGUUCACCCCAGUGGGCA UCGGCGUGGACAACGAGGCCGACUUCCAGCAGUGGAGCCUGCCC GACUACAGCGGCCAGUUCACCCACAACAUGAACCUGGCCCCAGCC GUGGCCCCAAACUUCCCAGGCGAGCAGCUGCUGUUCUUCCGGAG CCAGCUGCCCAGCAGCGGAGGACGGAGCAACGGCAUCCUGGACU GCCUGGUGCCACAGGAGUGGGUGCAGCACUUCUACCAGGAGAG CGCACCAGCCCAGACCCAGGUGGCCCUGGUGCGGUACGUGAACC CAGACACCGGCCGGGUGCUGUUCGAGGCCAAGCUGCACAAGCUG GGCUUCAUGACCAUCGCCAAGAACGGCGACAGCCCAAUCACCGUGCCACCCAACGGCUACUUCCGGUUCGAGAGCUGGGUGAACCCAU UCUACACCCUGGCCCCAAUGGGCACCGGCAACGGACGGAGGCGG GUGCAG 6 UTR 5' Organism: Synthetic construct Molecule type: Other RNA A(2'OMe)GGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUA AGAGCCACC 7 UTR 3' Organism: Synthetic construct Molecule type: Other RNA GCGGCCGCUUAAUUAAGCUGCCUUCUGCGGGGCUUGCCUUCUG GCCAUGCCCUUCUUCUCUCUCCCUUGCACCUGUACCUCUUGGUCUU UGAAUAAAGCCUGAGUAGGAAGUCUAGAAAAAAAAAAAAAAAAA aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaaaa 8 UTR 3' Organism: Synthetic construct Molecule type: Other RNA GCUGCCUUCUGCGGGGCUUGCCUUCUGGCCAUGCCCUUCUUCU CUCCCUUGCACCUGUACCUCUUGGUCUUUGAAUAAAGCCUGAG UAGGAAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA Petition 870250101498, dated 05 / 11 / 2025, pp. 477 / 546 88 / 109 SEQ ID NO: Descrição Sequência 9 GII.4 Organismo: Construção sintética Tipo de molécula: Outro DNA ATGAAGATGGCCAGCAGCGACGCCAACCCAAGCGACGGCAGCGCA GCCAACCTGGTGCCCGAGGTGAACAACGAGGTGATGGCCCTGGAG CCAGTGGTGGGAGCAGCCATCGCAGCCCCAGTGGCAGGCCAGCAG AACGTGATCGACCCATGGATCCGGAACAACTTCGTGCAGGCCCCAG GAGGCGAGTTCACCGTGAGCCCACGGAACGCCCCAGGCGAGATCC TGTGGAGCGCACCACTG GGCCCAGACCTGAACCCATACCTGAGCCA CCTGGCCCGGATGTACAACGGCTACGCCGGCGG CTTCGAGGTGCA GGTGATCCTGGCCGGCAACGCCTTCACCG CAGGCAAGATCATCTTC GCCGCCGTGCCACCCAACTTCCCAACCGAGGGCCTGAGCCCAAGCC AGGTGACCATGTTCCCACACATCATCGTGGACGTGAGGCAGCTGGA GCCCGTGCTGATCCCACTGCCCGACGTG CGGAACAACTTCTACCACT ACAACCAGAGCAACGACAGCACCATCAAGCTGATCGCCATGCTGTA CACCCCACTGCGGGCCAACAACGCCGGCGACGACGTGTTCACCGTG AGCTGCAGGGTGCTGACCAGGCCCAG CCCAGACTTCGACTTCATCT TCCTGGTGCCACCCACCGTGGAGAGCCGGACCAAGCCCTTCAGCGT GCCCGTGCTGACCGTGGAGGAGATGACCAACAGCCGGTTCCCAATC CCACTGGAGAAGCTGTTCACCGGACCAAGCAGCGCCTTCGTGGTGC AGCCACAGAACGGCCGGTGCACCACCGACGGAGTGCTGCTGGGCA CCACCCAGCTGAGCCCAGTGAACATCTGCACCTTCCGGGGCGACGTGACCCACATCACCGGCAGCCGGAACTACACCATGAACCTGGCCAGC CAGAACTGGAACAACTACGACCCAACCGAGGAGATCCCAGCCCCAC TGGGCACCCCAGACTTCGTGGGCAAGATCCAGGGCATGCTGACCCA GACCACCAGAACCGACGGCAGCACCAGAGGCCACAAGGCCACCGT GTACACCGGCAGCGCCGACTTCGCCCCAAAGCTGGGCCGGGTGCA GTTCGAGACCGACACCGACCACGACTTCGAGGCCAACCAGAACACC AAGTTCACCCCAGTGGGCGTGATCCAGGACGGCAGCACCACCCACC GGAACGAGCCACAGCAGTGGGTGCTGCCCAGCTACAGCGGCAGGA ACACCCACAACGTG CACCTGGCACCAGCCGTGG CACCAACCTTCCC AGGCGAGCAGCTGCTGTTCTTCCGGAGCACCATGCCAGGCTGCAGC GGCTACCCAAACATGGACCTGGACTGCCTGCTGCCACAGGAGTGGG TGCAGTACTTCTACCAGGAGGCAGCCCCAGCACAGAGCGACGTGGC CCTGCTGCGGTTCGTGAACCCAGACACCGGACGGGTGCTGTTCGAG TGCAAGCTGCACAAGAGCGGCTACGTGACCGTGGCCCACACCGGA CAGCACGACCTGGTGATCCCACCCAACGGCTACTTCCGGTTCGACA GCTGGGTGAACCAGTTCTACACCCTGGCCCCAATGG GCAACGGAAC CGGACGGAGGAGGGTGGTG 10 GI.1 Organismo: Construção sintética Tipo de molécula: Outro DNA ATGATGATGGCCAGCAAGGACGCCACCAGCAGCGTGGACGGAGCC AGCGGCGCAGGACAGCTGGTGCCCGAGGTGAACGCCAGCGACCCA CTGGCCATGGACCCAGTGGCCGGAAGCAGCACCGCAGTGGCCACCGCAGGCCAGGTGAACCCAATCGACCCATGGATCATCAACAACTTCG TGCAGGCCCCACAGGGCGAGTTCACCATCAGCCCAAACAACACCCC AGGCGACGTGCTGTTCGACCTGAGCCTGGGCCCACACCTGAACCCA TTCCTGCTGCACCTGAGCCAGATGTACAACGG CTGGGTGGGCAACA TGCGGGTGCGGATCATGCTGGCCGGCAACGCCTTCACCGCCGG CAA GATCATCGTGAGCTGCATCCCACCCGGCTTCGG CAG CCACAACCTG Petição 870250101498, de 05 / 11 / 2025, pág. 478 / 546 89 / 109 SEQ ID NO: Descrição Sequência ACCATCGCCCAGGCCACCCTGTTCCCACACGTGATCGCCGACGTGC GGACCCTGGACCCAATCGAGGTGCCACTGGAGGACGTGCGGAACG TGCTGTTCCACAACAACGACCGGAACCAGCAGACCATGCGGCTGGT GTGCATGCTGTACACCCCACTGCGGACCGGAGGCGGAACCGGAGA CAGCTTCGTGGTGGCCGGCCGGGTGATGACCTGCCCAAGCCCAGAC TTCAACTTCCTGTTCCTGGTGCCACCCACCGTGGAGCAGAAGACCCG GCCCTTCACCCTGCCCAACCTGCCACTGAGCAGCCTGAGCAACAGCC GGGCCCCACTGCCCATCAGCAGCATGGGCATCAGCCCAGACAACGT GCAGAGCGTGCAGTTCCAGAACGGCCGGTGCACCCTGGACGGACG GCTGGTGGGCACCACCCCAGTGAGCCTGAGCCACGTGGCCAAGATC CGGGGCACCAGCAACGGCACCGTGATCAACCTGACCGAGCTGGAC GGCACCCCATTCCACCCATTCGAGGG CCCAGCCCCAATCGGCTTCCC AGACCTGGGCGGCTGCGACTGGCACATCAACATGACCCAGTTCGGC CACAGCAGCCAGACCCAGTACGACGTGGACACCACCCCAGACACCT TCGTGCCACACCTGGG CAGCATCCAGGCCAACGGCATCGGCAGCG GCAACTACGTGGGCGTG CTGAGCTGGATCAGCCCACCCAGCCACCC AAGCGGCAGCCAGGTGGACCTGTGGAAGATCCCAAACTACGGCAG CAGCATCACCGAGGCCACCCACCTGGCCCCAAGCGTGTACCCACCC GGCTTCGGCGAGGTGCTGGTGTTCTTCATGAGCAAGATGCCCGGCC CAGGCGCCTACAACCTGCCCTGCCTGCTGCCACAGGAGTACATCAGCCACCTGGCCAGCGAGCAGGCCCCAACCGTGGGCGAGGCAGCCCT GCTGCACTACGTGGACCCAGACACCGGCCGGAACCTGGGCGAGTTC AAGGCCTACCCAGACGGCTTCCTGACCTGCGTGCCCAACGGAGCCA GCAGCGGCCCACAGCAG CTGCCCATCAACGG CGTGTTCGTGTTCGT GAGCTGGGTGAGCCGGTTCTACCAGCTGAAGCCCGTGGGAACCGC CAGCAGCGCCAGAGGACGGCTGGGACTGAGGCGG 11 GII.6 Organismo: Construção sintética Tipo de molécula: Outro DNA ATGAAGATGGCCAGCAACGACGCCGCCCCAAGCAACGACGGAGCC GCCAACCTGGTGCCCGAGGCCACCAACGAGGTGATGGCCCTGGAG CCCGTGGTGGGAGCCAGCATCGCAGCCCCAGTGGTGGGCCAGCAG AACATCATCGACCCATGGATCCGGGAGAACTTCGTGCAGGCCCCAC AGGGCGAGTTCACCGTGAGCCCACGGAACAGCCCAGGCGAGATGC TGCTGAACCTGGAGCTGGGCCCAGAGCTGAACCCATACCTGGGCCA CCTGAGCCGGATGTACAACGGCTACGCCGGCGG CATGCAGGTGCA GGTGGTGCTGGCCGGCAACGCCTTCACCGCCGGCAAGATCATCTTC GCCGCCGTGCCACCACACTTCCCAGTGGAGAACATCAGCGCCGCCC AGATCACCATGTGCCCACACGTGATCGTGGACGTGCGGCAGCTGGA GCCCGTGCTGCTG CCACTGCCCGACATCCGGAACCG GTTCTTCCACT ACAACCAGGAGAACACCCCACGGATGCGGCTGGTGGCCATGCTGT ACACCCCACTGCGGGCCAACAGCGGCGAGGACGTGTTCACCGTGA GCTGCCGGGTGCTGACCAGGCCAGCCCCAGACTTCGAGTTCACCTTCCTGGTGCCACCCACCGTGGAGAGCAAGACCAAGCCCTTCACCCTG CCCATCCTGACCCTGGGCGAGCTGAGCAACAGCCGGTTCCCAGCCC CAATCGACATGCTGTACACCGACCCAAACGAGGCCATCGTGGTGCA GCCAGAACGGCCGGTGCACCCTGGACGGCACCCTGCAGGGCAC CACCCAGCTGGTG CCCACCCAGATCTGCAGCTTCCG GGGCACCCTG Petition 870250101498, dated 05 / 11 / 2025, pp. 479 / 546 90 / 109 SEQ ID NO: Description Sequence ATCAGCCAGACCAGCCGGAGCGCAGACAGCACCGACAGCGCCCCA CGGGTGCGGAACCACCCACTGCACGTGCAGCTGAAGAACCTGGAC GGCACCCCATACGACCCAACCGACGAGGTGCCCGCAGTGCTGGGC GCCATCGACTTCAAGGGCACCGTGTTCGGCATCGCCAGCCAGCGGA ACACCACCGGCAGCAGCATCGGAGCCACCCGGGCACACGAGGTGC ACATCGACACCACCAACCCACGGTACACCCCAAAGCTGGGCAGCGT GCTGATGTACAGCGAGAGCAACGACTTCGACGACGGCCAGCCCACC CGGTTCACCCCAATCGG CATGGGCGCCGACGACTG GCGGCAGTGG GAGCTGCCCGAGTACAGCGGCCACCTGACCCTGAACATGAACCTGG CCCCAG CCGTGGCACCAG CCTTCCCAGGCGAGCGGATCCTGTTCTTC CGGAGCGTGGTGCCCAGCGCAGGAGGCTACGGCAGCGGCCACATC GACTGCCTGATCCCACAGGAGTGGTGCAGCACTTCTACCAGGAGG CCGCACCAAGCCAGAGCGCCGTGGCCCTGATCCGGTACGTGAACCC AGACACCGGCCGGAACATCTTCGAGGCCAAGCTGCACCGGGAGGG CTTCATCACCGTGGCCAACAGCGGCAACAACCCAATCGTGGTGCCA CCCAACGG CTACTTCCGGTTCGAGGCCTGGGGTGAACCAGTTCTACA CCCTGACCCCCAATGGGCACCGGACAGGGACGGAGGCGGGTGCAG 12 GII.2 Organism: Synthetic construct Molecule type: Other DNA ATGAAGATGGCCAGCAACGACGCCGCACCAAGCACCGACGGAGCC GCAGGACTGGTGCCCGAGAGCAACAACGAGGTGATGGCCCTGGAGCCCGTGGCAGGAGCCGCACTGGCAGCACCAGTGACCGGCCAGACC AACATCATCGACCCATGGATCCGGGCCAACTTCGTG CAGGCCCCAA ACGGCGAGTTCACCGTGAGCCCACGGAACGCCCCAGGCGAGGTGC TGCTGAACCTGGAGCTGGGCCCAGAGCTGAACCCATACCTGGCCCA CCTGGCCCGGATGTACAACGGCTACGCCGGCGG CATGGAGGTGCA GGTGATGCTGGCCGGCAACGCCTTCACCG CCGGCAAGCTGGTGTTC GCCGCCGTGCCACCACACTTCCCAGTGGAGAACCTGAGCCCACAGC AGATCACCATGTTCCCACACGTGATCATCGACGTGCGGACCCTGGA GCCCGTGCTGCTG CCACTGCCCGACGTG CGGAACAACTTCTTCCACT ACAACCAGAAGGACGACCCAAAGATGCGGATCGTGGCCATGCTGT ACACCCCACTGCGGAGCAACGGCAGCGGCGACGACGTGTTCACCGT GAGCTGCCGGGTGCTGACCAGGCCCAGCCCAGACTTCGACTTCACC TACCTGGTGCCACCCACCGTGGAGAGCAAGACCAAGCCCTTCACCC TGCCCATCCTGACCCTGGGCGAGCTGAGCAACAGCCGGTTCCCAGT GAGCATCGACCAGATGTACACCAGCCCAAACGAGATCATCAGCGTG CAGTGCCAGAACGGCCGGTGCACCCTGGACGGCGAGCTGCAGGGC ACCACCCAG CTGCAGGTGAGCGGCATCTGCGCCTTCAAGGGCGAG GTGACCGCCCACCTGCACGACAACGACCACCTGTACAACGTGACCA TCACCAACCTGAACGGCAGCCCATTCGACCCAAGCGAGGACATCCC AGCCCCACTGGGCGTGCCCGACTTCCAGGGCCGGGTGTTCGGCATC ATCAGCCAGCGGGACAAGCACAACAGCCCAGGCCACAACGAGCCCGCCAACCGGGGACACGACGCCGTGGTGCCCACCTACACCGCCCAGT ACACCCCAAAGCTGGGCCAGATCCAGATCGGCACCTGGCAGACCGA CGACCTGACCGTGAACCAGCCCGTGAAGTTCACCCCAGTGGGCCTG AACGACACCGAGCACTTCAACCAGTGGGTGGTGCCACGGTACGCCG GCGCCCTGAACCTGAACACCAACCTGGCCCCAAGCGTGGCCCCAGT Petition 870250101498, dated 05 / 11 / 2025, pages 480 / 546 91 / 109 SEQ ID NO: Descrição Sequência GTTCCCAGGCGAGCGGCTGCTGTTCTTCCGGAGCTACATCCCACTG AAGGGCGGCTACGGCAACCCAGCCATCGACTGCCTGCTGCCACAGG AGTGGGTGCAGCACTTCTACCAGGAGGCCG CCCCAAGCATGAGCG AGGTGGCCCTGGTGCGGTACATCAACCCAGACACCGGCCGGGCCCT GTTCGAGGCCAAGCTGCACCGGGCCGGCTTCATGACCGTGAGCAGC AACACCAGCGCCCCAGTGGTGGTGCCCGCCAACGGCTACTTCCGGT TCGACAGCTGGGTGAACCAGTTCTACAGCCTGGCCCCAATGGGCAC CGGCAACGGACGGAGGCGGGTGCAG 13 GII.3 Organismo: Construção sintética Tipo de molécula: Outro DNA ATGAAGATGGCCAGCAACGACGCCACCCCAAGCAACGACGGAGCC GCAGGCCTGGTGCCCGAGATCAACAACGAGGCCATGGCCCTGGAG CCCGTGGCAGGAGCAGCCATCGCCGCACCACTGACCGGCCAGCAG AACATCATCGACCCATGGATCATGAACAACTTCGTGCAGGCCCCAG GCGGCGAGTTCACCGTGAGCCCACGGAACAGCCCAGGCGAGGTGC TGCTGAACCTGGAGCTGGGCCCAGAGATCAACCCATACCTGGCCCA CCTGGCCCGGATGTACAACGGCTACGCCGGCGGCTTCGAGGTGCA GGTGGTGCTGGCCGGCAACGCCTTCACCGCCGGCAAGATCATCTTC GCCGCCATCCCACCCAACTTCCCAATCGACAACCTGAGCGCCGCCCA GATCACCATGTGCCCACACGTGATCGTGGACGTGCGGCAGCTGGAG CCCGTGAACCTGCCCATGCCCGACGTGCGGAACAACTTCTTCCACTA CAACCAGGGAAGCGACAGCCGGCTGCGGCTGGTG GCCATGCTGTA CACCCCACTGCGGGCCAACAACAGCGGCGACGACGTGTTCACCGTG AGCTGCCGGGTGCTGACCAGGCCCAGCCCAGAGTTCAGCTTCAACT TCCTGGTGCCACCCACCGTGGAGAGCAAGACCAAGCCCTTCACCCT GCCCATCCTGACCATCAG CGAGATGAGCAACAGCCGGTTCCCAGTG CCCATCGACAGCCTGCACACCAGCCCAACCGAGAACATCGTGGTGC AGTGCCAGAACGGCCGGGTGACCCTGGACGGCGAGCTGATGGGCA CCACCCAG CTGCTGCCCAGCCAGATCTGCGCCTTCCGGGGAGTGCT GACCCGGAGCACCAGCCGGGCAAGCGACCAGGCAGACACCGCCAC CCCACGG CTGTTCAACTACTACTGGCACATCCAGCTGGACAACCTGA ACGGCACCCCATACGACCCAGCCGAGGACATCCCAGGCCCACTGGG CACCCCAGACTTCCGGGGCAAGGTGTTCGGCGTGGCCAGCCAGCG GAACCCAGACAGCACCACCCGGGCCCACGAGGCCAAGGTGGACAC CACCGCCGGCCGGTTCACCCCAAAGCTGGGCAGCCTGGAGATCAGC ACCGAGAGCGACGACTTCGACCAGAACCAGCCCACCCGGTTCACCC CAGTGGGCATCGGCGTGGACAACGAGGCCGACTTCCAGCAGTGGA GCCTGCCCGACTACAGCG GCCAGTTCACCCACAACATGAACCTGGC CCCAGCCGTGGCCCCAAACTTCCCAGGCGAG CAGCTGCTGTTCTTCC GGAGCCAGCTGCCCAGCAGCGGAGGACGGAGCAACGGCATCCTGG ACTGCCTGGTGCCACAGGAGTGGGTGCAGCACTTCTACCAGGAGA GCGCACCAGCCCAGACCCAGGTGGCCCTGGTGCGGTACGTGAACCCAGACACCGGCCGGGTGCTGTTCGAGGCCAAGCTGCACAAGCTGGG CTTCATGACCATCGCCAAGAACGGCGACAGCCCAATCACCGTGCCA CCCAACGG CTACTTCCGGTTCGAGAGCTGGGTGAACCCATTCTACAC CCTGGCCCCAATGGGCACCGGCAACGGAGGCCAAGGGGCGAG4GGGCGAG44. MKMASSDANPSDGSAANLVPEVNNEVMALEPVVGAAAAPVAGQQ Petition 870250101498, of 05 / 11 / 2025, p. 481 / 546 92 / 109 SEQ ID NO: Description Sequence Organism: Synthetic construct Molecule type: Other protein NVIDPWIRNNFVQAPGGEFTVSPRNAPGEILWSAPLGPDLNPYLSHLA RMYNGYAGGFEVQVILAGNAFTAGKIIFAAVPPNFPTEGLSPSQVTMF PHIIVDVRQLEPVLIPLPDVRNNFYHYNQSNDSTIKLIAMLYTPLRANNA GDDVFTVSCRVLTRPSPDFDFIFLVPPTVESRTKPFSVPVLTVEEMTNSR FPIPLEKLFTGPSSAFVVQPQNGRCTTDGVLLGTTQLSPVNICTFRGDVT HITGSRNYTMNLASQNWNNYDPTEEIPAPLGTPDFVGKIQGMLTQTT RTDGSTRGHKATVYTGSADFAPKLGRVQFETDTDHDFEANQNTKFTP 15 GI.1 Organism: Synthetic construction Molecule type: Other protein MMMASKDATSSVDGASGAGQLVPEVNASDPLAMDPVAGSSTAVAT AGQVNPIDPWIINNFVQAPQGEFTISPNNTPGDVLFDLSLGPHLNPFLL HLSQMYNGWVGNMRVRIMLAGNAFTAGKIIVSCIPPGFGSHNLTIAQ ATLFPHVIADVRTLDPIEVPLEDVRNVLFHNNDRNQQTMRLVCMLYTP LRTGGGTGDSFVVAGRVMTCPSPDFNFLFLVPPTVEQKTRPFTLPNLPL SSLSNSRAPLPISSMGISPDNVQSVQFQNGRCTLDGRLVGTTPVSLSHV AKIRGTSNGTVINLTELDGTPFHPFEGPAPIGFPDLGGCDWHINMTQF GHSSQTQYDVDTTPDTFVPHLGSIQANGIGSGNYVGVLSWISPPSHPS GSQVDLWKIPNYGSSITEATHLAPSVYPPGFGEVLVFFMSKMPGPGAY NLPCLLPQEYISHLASEQAPTVGEAALLHYVDPDTGRNLGEFKAYPDGF LTCVPNGASSGPQQLPINGVFVFVSWVSRFYQLKPVGTASSARGRLGL RR 16 GII.6 Organism: Synthetic construction Molecule type: Other protein MKMASNDAAPSNDGAAN LVPEATN EVMALEPVVGASIAAPVVGQQ NIIDPWIRENFVQAPQGEFTVSPRNSPGEMLLNLELGPELNPYLGHLSR MYNGYAGGMQVQVVLAGNAFTAGKIIFAAVPPHFPVENISAAQITMC PHVIVDVRQLEPVLLPLPDIRNRFFHYNQENTPRMRLVAMLYTPLRAN SGEDVFTVSCRVLTRPAPDFEFTFLVPPTVESKTKPFTLPILTLGELSNSRF PAPIDMLYTDPNEAIVVQPQNGRCTLDGTLQGTTQLVPTQICSFRGTLI SQTSRSADSTDSAPRVRNHPLHVQLKNLDGTPYDPTDEVPAVLGAIDF KGTVFGIASQRNTTGSSIGATRAHEVHIDTTNPRYTPKLGSVLMYSESN DFDDGQPTRFTPIGMGADDWRQWELPEYSGHLTLNMNLAPAVAPA FPGERILFFRSVVPSAGGYGSGHIDCLIPQEWVQH FYQEAAPSQSAVAL IRYVNPDTGRNIFEAKLHREGFITVANSGNNPIVVPPNGYFRFEAWVN QFYTLTPMGTGQGRRRVQ 17 GII.2 Organism: Synthetic construction Molecule type: Other protein MKMASNDAAPSTDGAAG LVPESNN EVMALEPVAGAALAAPVTGQT NIIDPWIRANFVQAPNGEFTVSPRNAPGEVLLNLELGPELNPYLAHLAR MYNGYAGGMEVQVMLAGNAFTAGKLVFAAVPPHFPVENLSPQQIT MFPHVIIDVRTLEPVLLPLPDVRNNFFHYNQKDDPKMRIVAMLYTPLR SNGSGDDVFTVSCRVLTRPSPDFDFTYLVPPTVESKTKPFTLPILTLGELS NSRFPVSIDQMYTSPNEIISVQCQNGRCTLDGELQGTTQLQVSGICAFK GEVTAHLHDNDHLYNVTITNLNGSPFDPSEDIPAPLGVPDFQGRVFGII SQRDKHNSPGHNEPANRGHDAVVPTYTAQYTPKLGQIQIGTWQTDD LTVNQPVKFTPVGLNDTEHFNQWVVPRYAGALNLNTNLAPSVAPVFP GERLLFFRSYIPLKGGYGNPAIDCLLPQEWVQHFYQEAAPSMSEVALVR. Petition 870250101498, dated 05 / 11 / 2025, pp. 482 / 546 93 / 109 SEQ ID NO: Description Sequence YINPDTGRALFEAKLHRAGFMTVSSNTSAPVVVPANGYFRFDSWVNQ FYSLAPMGTGNGRRRVQ 18 GII.3 Organism: Synthetic construct Molecule type: Other protein MKMASNDATPSNDGAAGLVPEINNEAMALEPVAGAAIAAPLTGQQN IIDPWIMNNFVQAPGGEFTVSPRNSPGEVLLNLELGPEINPYLAHLAR MYNGYAGGFEVQVVLAGNAFTAGKIIFAAIPPNFPIDNLSAAQITMCP HVIVDVRQLEPVNLPMPDVRNNFFHYNQGSDSRLRLVAMLYTPLRAN NSGDDVFTVSCRVLTRPSPEFSFNFLVPPTVESKTKPFTLPILTISEMSNS RFPVPIDSLHTSPTENIVVQCQNGRVTLDGELMGTTQLLPSQICAFRGV LTRSTSRASDQADTATPRLFNYYWHIQLDNLNGTPYDPAEDIPGPLGTP DFRGKVFGVASQRNPDSTTRAHEAKVDTTAGRFTPKLGSLEISTESDDF DQNQPTRFTPVGIGVDNEADFQQWSLPDYSGQFTHNMNLAPAVAP NFPGEQLLFFRSQLPSSGGRSNGILDCLVPQEWVQHFYQESAPAQTQV ALVRYVNPDTGRVLFEAKLHKLGFMTIAKNGDSPITVPPNGYFRFESW VNPFYTLAPMGGTGNGRRRVQ Example 2: Preparation of purified mRNA for five sequences encoded by norovirus VP1.

[190] Five purified DNA plasmids were generated by GenScript Probio Biotech and were constructed on a pUC57 main strand with a T7 promoter sequence, an encoded 5' UTR sequence (SEQ ID NO: 6), norovirus VP1 DNA sequences GII.4, GI.1, GII.6, GII.2 or GII.3 (SEQ ID NO: 9 to 13), encoding VP1 mRNA CDSs from norovirus GII.4, GI.1, GII.6, GII.2 or GII.3 (SEQ ID NO: 1 to 5) and an encoded 3' UTR sequence (SEQ ID NO: 7) with an encoded poly(A) tail. DNA plasmids were linearized using the restriction enzyme BbsI-HF (New England Biolabs) for plasmids encoding GII.4, GII.6, GII.2, or GII.3 (SEQ ID NO: 9, 11 to 13) and the restriction enzyme BspQI (New England Biolabs) for the plasmid encoding GI.I (SEQ ID NO: 10).Approximately 1 mg of plasmid was added to a linearization reaction mixture at a concentration of about 0.2 to 0.4 mg / mL with 1 to 2 U / mL of the appropriate restriction enzyme in a digestion buffer (New England Biolabs) and incubated for about 1 ha at 37 °C. The linearization reactions were purified by precipitation steps with isopropanol and ethanol to generate a purified linear DNA template with a concentration of about 0.8 to 1.2. Petition 870250101498, dated 05 / 11 / 2025, pp. 483 / 546 94 / 109 mg / mL. Five IVT reactions were performed on a 10 mL scale in a 60 mL high-density polyethylene (HDPE) flask (Nalgene) mixed in a shaker incubator (Benchmark Scientific) set to a temperature of approximately 37 °C. Purified linear DNA template was added to the IVT reaction mixtures at a concentration of approximately 40 to 60 pg / mL. ATP, GTP, and CTP (New England Biolabs) were added to the IVT reaction mixture in a concentration range of approximately 8 to 14 mM, m1Ψ (BOC Sciences) was fully replaced with UTP and added at approximately 4 to 6 mM, and CleanCap AG (3'OMe) (TriLink Biotechnologies) was added at approximately 3 to 5 mM. RNA polymerase T7 (New England Biolabs) was added to the IVT reaction mixtures at a concentration of approximately 10,000 to 12,000 U / mL, yeast inorganic pyrophosphatase (New England Biolabs) at approximately 2 U / mL, and murine RNase inhibitor (New England Biolabs) at 1 U / mL.IVT reaction mixtures were prepared in a transcription buffer matrix similar to 1X T7 Transcription Buffer (New England Biolabs), containing tris hydrochloride, magnesium, spermidine, DTT, and other excipients, to a final solution pH of approximately 6 to 9. The IVT reaction mixtures were incubated for 3 to 4 hours, and the reaction was stopped by the addition of DNase I (New England Biolabs) at a concentration range of approximately 350 U / mL along with calcium chloride (Sigma Aldrich) at a concentration of 3.5 mM and incubated at 37°C for 1 hour.

[191] The five IVT reaction mixtures were tempered with approximately 50 mM EDTA (Thermo Fisher Scientific) and diluted to approximately 300 mL in an oligo dT binding matrix consisting of 400 mM sodium chloride (Thermo Fisher Scientific), 10 mM tris hydrochloride (Thermo Fisher Scientific), 2 mM EDTA, pH 7.2. The five diluted IVT reaction mixtures were purified using 40 mL CIMmultus oligo dT monolithic columns (Sartorius AG) with a residence time of approximately 0.5 min. After mRNA hybridization Petition 870250101498, dated 05 / 11 / 2025, pp. 484 / 546 95 / 109 loaded with a poly(A) tail to the oligo dT ligand, the column was washed with 5 CVs of a buffer consisting of 50 mM sodium chloride, 10 mM tris hydrochloride, 2 mM EDTA, pH 7.2, and the bound mRNA was eluted with 5 CVs of 10 mM tris hydrochloride, pH 7.2. The five oligo dT elution fractions were loaded onto 235 cm2e 50 kDa hollow fiber PES membranes (Repligen) and operated at a TMP of approximately 4 psi and a cross-flow shear rate of 4000 s-1 to concentrate approximately 8 times and exchange the buffer 6 DVs in 1 mM sodium citrate (Thermo Fisher Scientific), pH 6.4. The final TFF retentates were pumped at a flow rate of 300 L / m2-h through an 18 cm2, 0.2 µm PVDF bioburden reduction filter (Millipore).The mRNA concentrations of the bioburden reduction filter product were calculated from an absorbance measurement of the sample at 260 nm using a spectrophotometer, and the product was diluted with 1 mM sodium citrate, pH 6.4, to approximately 1 mg / mL, packaged in conical tube containers, and stored at <-60 °C. The final yields of purified mRNA from 10 mL IVT reactions were 85 mg, 78 mg, 89 mg, 75 mg, and 78 mg for mRNAs GII.4, GI.I, GII.6, GII.2, and GII.3, respectively. The purified mRNAs were analyzed by agarose gel electrophoresis using a 2% agarose E-Gel electrophoresis system and Power Snap (Thermo Fisher Scientific), and the expected size and purity were observed. Figure 1 shows an image of a 2% agarose E-gel purified for five norovirus VP1-encoded sequences with a loading of 50 ng of mRNA per strip.Lanes 1 to 2 and 10 to 12 are blank, lanes 3 and 9 contain an ssRNA ladder (New England Biolabs), lane 4 contains GI.I, lane 5 contains GII.2, lane 6 contains GII.3, lane 7 contains GII.4 and lane 8 contains GII.6. Example 3: Encapsulation of mRNAs in LNPs mRNA / LNP preparation Petition 870250101498, dated 05 / 11 / 2025, pages 485 / 546 96 / 109

[192] LNPs encapsulating one or up to five different norovirus mRNA constructs (e.g., GI.1, GII.2, GII.3, GII.4, and / or GII.6) can be formed by rapid precipitation using a microfluidic mixer, a multi-inlet vortex mixer, or a T-mixer to micromix two fluid streams. One fluid stream contains lipids dissolved in ethanol, and the other fluid stream is an aqueous solution containing mRNA. The lipid solution prepared in ethanol contains cationic lipid, cholesterol, PEG-DMG, and phospholipid (DSPC) in specified molar proportions and is heated to a temperature in the range of 25 to 45 °C. The mRNA solution, prepared to achieve a target wt% mRNA, consists of a sodium citrate-buffered saline solution with a pH in the range of 4 to 6 and is maintained at a temperature in the range of 16 to 25 °C.The molar proportions of lipids and the weight percentage of mRNA are selected to achieve a nitrogen-to-phosphate (N / P) ratio in the range of 2 to 9, with the goal of reaching 5 to 7. The lipid and mRNA solutions are micromixed to instantly form mRNA-encapsulating LNPs (mRNA / LNPs).

[193] For mixed microfluidic mRNA / LNPs, mRNA- and lipid-containing solution streams are combined at 8 to 15 mL / min in a 1:1 to 5:1 ratio to produce 16 to 50% vol:vol alcohol in the mixed solution and to achieve an N / P ratio in the range of 2 to 9, aiming for 5 to 7. The resulting mRNA / LNP suspension then undergoes buffer exchange and alcohol removal via dialysis. The mRNA / LNP suspension is dialyzed 2 to 4 times against the final buffered solution in a pH range of 7 to 8. The final buffered solution may contain a cryoprotectant (e.g., containing sucrose, trehalose, or a combination). The dialysis step may utilize a nominal membrane molecular weight cutoff range of 30 to 500 kDa. Before terminal sterile filtration, the mRNA / LNP suspension may be combined with suspensions Petition 870250101498, dated 05 / 11 / 2025, pages 486 / 546 97 / 109 additional norovirus mRNA / LNPs encoding VP1 proteins from different norovirus genotypes (e.g., GI.1, GII.2, GII.3, GII.4, and / or GII.6) are used to form a co-formulated bivalent, trivalent, quadrivalent, or pentavalent product. The monovalent or co-formulated mRNA / LNP suspensions are then filtered through 0.2 µm polyethersulfone (PES) or polyvinylidene fluoride (PVDF) sterilizing filters into sterile, sealed glass vials. The resulting mRNA / LNP formulation can then be stored under refrigerated (2 to 8 °C) or frozen (-20 ± 10 °C or < -60 °C) conditions. If monovalent mRNA / LNP formulations are prepared in sterile vials, these formulations can be equilibrated at a temperature in the range of 16 to 25 °C and combined with additional norovirus mRNA / LNP formulations encoding VP1 proteins from different norovirus genotypes (e.g., GI.1, GII.2, GII.3, GII.4 and / or GII.6) to form a final co-formulated bivalent, trivalent, quadrivalent or pentavalent vaccine before administration.

[194] In micromixing using a confined volume T-mixer, the T-mixer has an internal diameter (ID) of 0.25 to 1.0 mm. Lipid and mRNA solutions are supplied to the T-mixer inlet via programmable pumps. The total flow rate at the T-mixer inlet ranges from 100 to 600 mL / min. The lipid and mRNA solutions are distributed to the T-mixer at a ratio in the range of 0.9:1 to 1:3 vol:vol, with a target range of 1:1.1 to 1:2 to produce a 16 to 53% vol:vol alcohol in the mixed solution and to achieve an N / P ratio in the range of 2 to 9, targeting 5 to 7. The resulting mRNA / LNP suspension is diluted twice in higher pH buffers in the pH range of 6 to 8, using a multi-stage sequential in-line mixing process. The mRNA / LNP suspension is first diluted with a buffered solution at a higher pH (6 to 8) using a mixing ratio in the range Petition 870250101498, dated 05 / 11 / 2025, pp. 487 / 546 The first dilution involves mixing the mRNA / LNP suspension with a buffered solution at a higher pH (pH 6 to 8) using a mixing ratio in the range of 1:1 to 1:3 vol:vol, aiming for 1:2 vol:vol. This buffered solution is at a temperature in the range of 15 to 40°C, but aiming for 30 to 40°C. The second dilution involves mixing the mRNA / LNP suspension with a buffered solution at a higher pH (pH 6 to 8) using a mixing ratio in the range of 1:1 to 1:3 vol:vol, aiming for 1:2 vol:vol. The buffered solution for the second dilution is at a temperature in the range of 15 to 40°C, but aiming for 16 to 25°C. The fully diluted mRNA / LNP suspension is held for 30 minutes to 4 hours at a temperature in the range of 15 to 40°C, but aiming for 16 to 25°C, before undergoing anion exchange filtration. After the incubation step is complete, the mRNA / LNP suspension is filtered through a 0.8 µm anion exchange filter, using tubes with internal diameters (ID) ranging from 1 to 10 mm and a flow rate in the range of 10 to 2,000 mL / min.The mRNA / LNPs are concentrated and diafiltered by ultrafiltration in a tangential flow filtration (TFF) format to remove alcohol. The mRNA / LNP suspension is then buffered in the final buffered solution, with a pH between 7 and 8. The final buffered solution may be suitable for cryopreservation (e.g., containing sucrose, trehalose, or a combination). TFF processes may utilize a hollow fiber or flat sheet membrane with a nominal molecular weight cutoff range of 30 to 500 kDa, targeting 500 kDa, to retain the mRNA / LNPs in the retentate. The multi-step TFF process begins with a concentration step to achieve an mRNA concentration of 0.4 to 0.7 mg / mL followed by diafiltration against the final buffer (e.g., modified Dulbecco's phosphate buffered saline (mDPBS) with pH 7 to 8 or 10 mM Tris, 10% w / v Sucrose, pH 7 to 8) for 5 to 20 volumes to remove alcohol and perform buffer exchange.The resulting mRNA / LNP suspension is then concentrated 1 to 5 times further using ultrafiltration. Once concentrated, the mRNA / LNP suspension undergoes bioburden reduction filtration using sequential 0.45 µm and 0.2 µm PES filters. Petition 870250101498, dated 05 / 11 / 2025, pp. 488 / 546 99 / 109 cellulose acetate (CA) and / or PVDF. The mRNA / LNP suspension with reduced bioburden is then stored under refrigerated (2 to 8 °C) or frozen (<-60 °C) conditions until later use. Before terminal sterile filtration, the mRNA / LNP suspension is thawed in a water bath at a temperature in the range of 20 to 30 °C and can be combined with additional norovirus mRNA / LNP suspensions encoding VP1 proteins specific to different norovirus genotypes (e.g., GI.1, GII.2, GII.3, GII.4 and / or GII.6) to form a co-formulated bivalent, trivalent, quadrivalent or pentavalent product. The resulting mRNA / LNP suspension can then be diluted to a target mRNA concentration before undergoing terminal sterile filtration using sequential 0.45 µm and 0.2 µm PES and / or PVDF filters and packaged in vials. The terminally sterile filtered mRNA / LNP suspension can also be lyophilized.The final mRNA / LNP vials (liquid or lyophilized) are then stored under refrigerated (2 to 8 °C) or frozen (-20 ± 10 °C or < -60 °C) conditions. Terminally sterilized monovalent norovirus mRNA / LNP formulations (GI.1, GII.2, GII.3, GII.4, or GII.6) in sterile vials can be thawed or reconstituted with diluent (e.g., saline solution) and combined with additional norovirus mRNA / LNP formulations encoding VP1 proteins from different norovirus genotypes (e.g., GI.1, GII.2, GII.3, GII.4, and / or GII.6) to form a final co-formulated bivalent, trivalent, quadrivalent, or pentavalent vaccine for administration. Preparation of mRNA / LNP formulations

[195] LNPs encapsulating a norovirus mRNA construct were formed by rapid precipitation using microfluidics or T-mixers to micromix two fluid streams. One fluid stream contained lipids dissolved in ethanol and the other fluid stream was a solution Petition 870250101498, dated 05 / 11 / 2025, pages 489 / 546 100 / 109 aqueous solution containing mRNA. The lipid solution prepared in ethanol contained cationic lipid, cholesterol, PEG-DMG, and phospholipid (DSPC) in a specified molar ratio. The aqueous solution consisted of a 10 mM sodium citrate buffer, pH 4.5 to 5.5, and contained mRNA.

[196] For mixed microfluidic LNPs, mRNA and lipid solution streams were combined at 12 mL / min in a 3:1 ratio to produce a 25% vol:vol alcohol in the mixed solution. The resulting LNP suspension had an N / P ratio in the range of 5 to 8. The mRNA / LNP suspension underwent buffer exchange and ethanol removal by dialysis. The mRNA / LNP suspensions were dialyzed 3x against 20 mM Tris, 10% sucrose (w / v), pH 7.5 in volumes 100 to 200x the product using SpectraPor® Float-A-Lyzers® (Repligen) with a molecular weight limit of 100 kDa. The dialyzed mRNA / LNP suspension was then filtered through sterile 0.2 µm polyethersulfone (PES; Pall) or polyvinylidene fluoride (PVDF; Millipore) filters into sterile, sealed glass vials. The mRNA / LNP formulation was then stored under refrigeration (2-8 °C) or freezing (20 °C or < -60 °C).Prior to use, mRNA / LNP vials were equilibrated at room temperature and used as a monovalent vaccine or co-formulated with additional monovalent norovirus mRNA / LNP formulations encoding VP1 proteins from different norovirus genotypes (e.g., GI.1, GII.2, GII.3, GII.4, and / or GII.6) to form a bivalent, trivalent, quadrivalent, or pentavalent co-formulated vaccine.

[197] For mRNA / LNPs prepared in a T-mixer, the lipid-containing solution stream was heated to a temperature in the range of 35 to 40 °C and then mixed with the mRNA-containing solution stream in a confined volume mixer (ID 0.5 mm) using programmable pumps. The total flow rate at the T-mixer inlet ranged from 100 to 150 mL / min. Petition 870250101498, dated 05 / 11 / 2025, pages 490 / 546 101 / 109 and distributed the streams in a ratio of 0.90:1 to 1.3:1 to produce 43 to 53 vol to vol% alcohol in the mixed solution. The resulting mRNA / LNP suspension had an N / P ratio in the range of 5 to 8 and was 2x diluted in higher pH buffers (pH range 6 to 8) using a multi-stage sequential in-line mixing process. For the first dilution, the mRNA / LNP formulation was mixed with 20 mM sodium citrate, 300 mM sodium chloride, pH 6, in a 1:1 vol:vol ratio. The buffered solution was maintained at a temperature in the range of 35 to 40 °C. The mRNA / LNP formulation was then mixed with mDPBS, pH 7.5, in a 1:1 vol:vol ratio. The mDPBS solution, pH 7.5, was at a temperature in the range of 16 to 25 °C. The resulting mRNA / LNP suspension was maintained for 30 min at a temperature range of 16 to 25 °C before undergoing anion exchange filtration.Following filtration, the mRNA / LNP suspension was then concentrated and diafiltered using an ultrafiltration process to remove alcohol and perform a buffer exchange in the final buffered solution. TFF was used for the ultrafiltration process. A PES membrane using a hollow fiber format with a nominal molecular weight cutoff of 500 kDa was used for ultrafiltration. Ultrafiltration was first used to concentrate the mRNA / LNP suspension 6 to 8 times by volume, targeting an mRNA concentration of 0.4 to 0.7 mg / mL. Alcohol was removed by subsequent diafiltration (10 diavolumes) using 20 mM Tris, 10% sucrose (w / v), pH 7.5. The mRNA / LNP suspension was then concentrated 3 times by volume, targeting an mRNA concentration of 1.0 to 1.5 mg / mL. Once concentrated, the monovalent mRNA / LNP formulation underwent bioburden reduction filtration using sequential 0.45 pm and 0.2 pm PES, CA, and / or PVDF filters.The monovalent mRNA / LNP suspension with reduced bioburden is then stored under frozen conditions (< -60 °C) until later use. Before terminal sterile filtration, the mRNA / LNP suspension was thawed in... Petition 870250101498, dated 05 / 11 / 2025, pp. 491 / 546 102 / 109 water bath at a temperature between 20 and 30 °C. The thawed mRNA / LNP suspension was then sterilely filtered using sequential 0.45 µm and 0.2 µm PES and / or PVDF filters. After filtration and under aseptic conditions, the mRNA / LNP suspension was diluted to the final target mRNA concentration using sterile 20 mM Tris, 10% (w / v) sucrose, pH 7.5, and placed in sterile, sealed vials. The sealed vials containing mRNA / LNP were then stored under freezing conditions (< -60 °C). Prior to administration, mRNA / LNP vials were equilibrated at room temperature and used as a monovalent vaccine or co-formulated with additional monovalent norovirus mRNA / LNP formulations encoding VP1 proteins from different norovirus genotypes (e.g., GI.1, GII.2, GII.3, GII.4, and / or GII.6) to form a bivalent, trivalent, quadrivalent, or pentavalent co-formulated vaccine. Example 4: In vivo immunization with mRNAs encapsulated in LNPs Studies with mice

[198] This study was designed to test the immunogenicity in mice of candidate vaccines against norovirus. The animals tested were 6-8 week old BALB / c mice obtained from Charles River Laboratories. The test vaccines included mRNA sequences encoding the VP1 proteins of 5 norovirus genotypes GI.1, GII.2, GII.3, GII.4 and GII.6, formulated in LNPs. Control animals were vaccinated with empty LNPs.

[199] In week 0 and week 4, animals were immunized intramuscularly with a total volume of 100 pL of each test vaccine, which was administered in a 50 pL immunization in each quadriceps. The candidate vaccines evaluated in this study were described above and are described in Table 2 below. Sera were collected from all animals. Route of Petition 870250101498, dated 05 / 11 / 2025, pp. 492 / 546 103 / 109 administration (ROA). Table 2: Dosage in mice Animal Group NO Treatment Dose Level (pg) ROA Volume (mL) Dosing Schedule 1 8 LNP 34 IM 0.1 Weeks 0.4 2 8 GI.1 1 IM 0.1 Weeks 0.4 3 8 GII.4 1 IM 0.1 Weeks 0.4 4 8 GII.2 1 IM 0.1 Weeks 0.4 5 8 GII.3 1 IM 0.1 Weeks 0.4 6 8 GII.6 1 IM 0.1 Weeks 0.4 7 8 GII.4 + GI.1 + GII.2 + GII.3 + GII.6 (5-valent) 1 + 1 + 1 + 1 + 1 IM 0.1 Weeks 0.4

[200] To test for the presence of antibodies capable of binding to norovirus VLPs, 384-well ELISA plates were coated with 50 ng / well of one of the following VLPs representing norovirus genotypes: GI.1, GII.2, GII.3, GII.4, and GII.6. During coating, a liquid handler made 10-point, 4-times serial dilutions of the sera in blocking buffer. After coating, the ELISA plates were washed, incubated with blocking buffer, evacuated, and then incubated with samples from the serum dilution plate. After 2 hours of incubation, the ELISA plates were washed and the goat mouse anti-IgG (Fc)-HRP conjugate was added to each well. The plates were incubated for 1 hour, washed, and incubated with chemiluminescent substrate for 15 minutes before luminescence reading (ultrasensitive, 0.1 seconds / well) in a plate reader.Interpolated endpoint titers were calculated as the highest dilution at which the relative luminescence signal (RLU) is above the 50,000 RLU threshold. Samples where no dilution exceeded the threshold were given a titer of “25”. For samples above the threshold at the highest dilution tested – 1:13,107,200 – the value… Petition 870250101498, dated 05 / 11 / 2025, pp. 493 / 546 104 / 109 13,107,200 was used for the titer. Samples in which the well value was exactly equal to 50,000 RLU received the interpolated titer value at that exact dilution. Serum antibody titers were plotted as geometric mean titers with 95% confidence intervals using GraphPad Prism software.

[201] FIGURES 2A to 2E represent the final interpolated titers of serum samples from animals vaccinated with the test vaccines. The vaccine groups tested are shown on the x-axis and the VLP binding of each of the different norovirus genotypes is plotted. The dashed line at 50 indicates the limit of detection. A value of 25 indicates no binding, even at the lowest dilution tested. Compared to the candidate monovalent vaccine, administration of the pentavalent vaccine induced comparable serum IgG titers specific for the five norovirus genotypes GI.1, GII.2, GII.3, GII.4 and GII. The second dose of all monovalent and pentavalent vaccines increased antibody titers at week 6.

[202] To probe the functional antibody response, the ability of serum at week 6 (after dose 2) to block VLP binding to HBGA was evaluated. 384-well HBGA plates were coated with 250 ng / well of porcine gastric mucin (PGM) or 1:1000 diluted human saliva, depending on the assay genotype. During coating, a liquid handler made 10-point, 2-times serial dilutions of the sera in blocking buffer. After dilution, 30 µL / well of VLP GI.1, GII.2, GII.3, GII.4, or GII.6 were added to each sample. After coating, the HBGA plates were washed, incubated with blocking buffer, evacuated, and incubated with the serum + VLP dilution plate mixture. After 2 hours of incubation, the plates were washed and serum from rabbit hyperimmunized with the corresponding VLP was added to each well. After 1 hour of incubation, the plates were washed and... Petition 870250101498, dated 05 / 11 / 2025, pp. 494 / 546 105 / 109 added HRP anti-rabbit goat IgG (specific Fc fragment). Plates were incubated for 1 hour, washed, and incubated with chemiluminescent substrate for 15 minutes before luminescence reading (ultrasensitive, 0.1 seconds / well) on a plate reader. For the HBGA blocking assay, fifty percent blocking titers (BT50), defined as the titer at which luminescence readings were 50% of the positive control, were determined for each sample. A value of 10 was assigned to samples with BT50 less than 20. BT50 values ​​were plotted as the geometric mean with a 95% confidence interval using GraphPad Prism software.

[203] FIGURES 3A to 3E represent the HBGA blocking titers of serum samples from animals vaccinated with the test vaccines. The vaccine groups tested are shown on the x-axis and BT50 against each of the five different norovirus genotypes is plotted. The dashed line at 20 indicates the limit of detection. A value of 10 indicates absence of blocking, even at the lowest dilution tested. Compared to the monovalent candidate vaccine, administration of the pentavalent vaccine induced comparable HBGA blocking titers, specific for the five norovirus genotypes GI.1, GII.2, GII.3, GII.4 and GII.6. Studies on non-human primates (NHP)

[204] This study was designed to test the immunogenicity of candidate norovirus vaccines in non-human primates. The animals tested were rhesus monkeys located at the NIRC, New Iberia, Louisiana, USA. The test vaccines included mRNA sequences encoding the VP1 proteins of five norovirus genotypes GI.1, GII.2, GII.3, GII.4, and GII.6 formulated in LNPs. Control animals were vaccinated with empty LNPs.

[205] In week 0 and week 4, the animals were immunized via Petition 870250101498, dated 05 / 11 / 2025, pages 495 / 546 106 / 109 intramuscular injections with a total volume of 500 pL of each test vaccine were administered into the posterior aspect of the right thigh. The candidate vaccines evaluated in this study were described above and are detailed in Table 3 below. Sera were collected from all animals. Table 3: NHP Dosage Group NO of animals Treatment Dose level ROA Volume (mL) Dosage schedule 1 4 LNP control NA IM 0.5 Weeks 0.4 2 4 GII.4 monovalent 40 pg IM 0.5 Weeks 0.4 3 4 GI.1, GII.2, GII.3, GII.4, and GII.6 (Low dose, 10 pg / genotype) 50 pg IM 0.5 Weeks 0.4 4 4 GI.1, GII.2, GII.3, GII.4, and GII.6 (High dose, 40 pg / genotype) 200 pg IM 0.5 Weeks 0.4

[206] To test for the presence of antibodies capable of binding to norovirus VLPs, 384-well ELISA plates were coated with 50 ng / well of one of the VLPs GI.1, GII.2, GII.3, GII.4, or GII.6, representing the norovirus genotypes: GI.1, GII.2, GII.3, GII.4, and GII.6. During coating, a liquid handler performed 10-point, 4-times serial dilutions of the sera in blocking buffer. After coating, the ELISA plates were washed, incubated with blocking buffer, evacuated, and then incubated with samples from the serum dilution plate. After 2 hours of incubation, the ELISA plates were washed and the goat anti-human IgG (Fc-specific fragment)-HRP conjugate was added to each well. The plates were incubated for 1 hour, washed, and incubated with chemiluminescent substrate for 15 minutes before luminescence reading (ultrasensitive, 0.1 seconds / well) in a plate reader. Interpolated endpoint titers Petition 870250101498, dated 05 / 11 / 2025, pages 496 / 546 107 / 109 were calculated as the highest dilution at which the relative luminescence signal (RLU) is above a cutoff of 50,000 RLU. Samples where no dilution crossed the threshold received a titer of “25”, for samples above the threshold at the highest dilution tested – 1:13,107,200 – the value 13,107,200 was used for the titer. Samples where a well value was exactly the same as 50,000 RLU received the interpolated titer value at that exact dilution. Serum antibody titers were plotted as geometric mean titers with 95% confidence intervals using GraphPad Prism software.

[207] FIGURES 4A to 4E represent interpolated endpoint titers of serum samples from animals vaccinated with the test vaccines. The vaccine groups tested are shown on the x-axis and VLP binding of each of the five different norovirus genotypes is plotted. The dashed line at 50 indicates the limit of detection. A value of 25 indicates no binding, even at the lowest dilution tested. Inoculations at two dose levels of 50 pg or 200 pg of the pentavalent candidate vaccine produced comparable and robust serum IgG binding antibody titers specific for the five norovirus genotypes G1.1, G11.2, G11.3, G11.4 and G11.6. The pentavalent candidate vaccines and the monovalent G11.4 vaccine produced comparable serum IgG ELISA titers against G11. 4. The second dose of the pentavalent vaccine at both dose levels increased antibody titers, which remained stable until week 8.

[208] To probe the functional antibody response, the ability of serum to block VLP binding to HBGA was evaluated. 384-well HBGA plates were coated with 250 ng / well of porcine gastric mucin (PGM) or 1:1000 diluted human saliva, depending on the assay genotype. During coating, a liquid handler made serial 10-point, 2-fold dilutions of the sera in blocking buffer. After dilution, 30 pL / well of one of the Petition 870250101498, dated 05 / 11 / 2025, pages 497 / 546 108 / 109 VLPs GI.1, GII.2, GII.3, GII.4, or GII.6 were added to each sample. After coating, the HBGA plates were washed, incubated with blocking buffer, evacuated, and incubated with the serum dilution plate mixture + VLP. After 2 hours of incubation, the plates were washed, and rabbit serum hyperimmunized with the corresponding VLP was added to each well. After 1 hour of incubation, the plates were washed, and HRP anti-rabbit goat IgG (Fc-specific fragment) was added. The plates were incubated for 1 hour, washed, and incubated with chemiluminescent substrate for 15 minutes before luminescence reading (ultrasensitive, 0.1 seconds / well) on a plate reader. For the HBGA blocking assay, fifty percent blocking titers (BT50) were determined, defined as the titer at which luminescence readings were 50% of the positive control, for each sample. A value of 10 was assigned to samples with a BT50 less than 20.BT50 values ​​were plotted as the geometric mean with a 95% confidence interval using GraphPad Prism software.

[209] FIGURES 5A to 5E represent the HBGA blocking titers of serum samples from animals vaccinated with the test vaccines. The vaccine groups tested are shown on the x-axis and BT50 against each of the five different norovirus genotypes is plotted. The dashed line at 20 indicates the limit of detection. A value of 10 indicates absence of blocking, even at the lowest dilution tested. Inoculations at two dose levels of 50 pg or 200 pg of the pentavalent candidate vaccine produced comparable and robust HBGA blocking antibody titers specific to the five norovirus genotypes GI.1, GII.2, GII.3, GII.4 and GII.6. The pentavalent candidate vaccines and the monovalent GII.4 vaccine produced comparable HBGA blocking antibody titers against GII.4. The second dose at both dose levels increased the antibody titers. Petition 870250101498, dated 05 / 11 / 2025, pages 498 / 546 109 / 109

[210] The disclosed object should not be limited in scope by the specific embodiments and examples described in the present invention. In fact, various modifications of the disclosure, in addition to those described, will become apparent to those skilled in the art from the preceding description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

[211] All references (e.g., publications, patents, or patent applications) cited in this document are incorporated into the present invention by reference in their entirety and for all purposes, to the same extent as if each individual reference (e.g., publication, patent, or patent application) were specifically and individually indicated to be incorporated by reference in its entirety for all purposes. Other embodiments are included in the following claims. Petition 870250101498, dated 05 / 11 / 2025, pages 499 / 546

Claims

1 / 14 CLAIMS 1. Messenger ribonucleic acid (mRNA) polynucleotide encoding a norovirus VP1 polypeptide, characterized in that the mRNA polynucleotide is selected from the group consisting of SEQ ID NOs: 1 to 5 and sequences having at least 70% identity with them, and in which at least one uridine residue in the mRNA polynucleotide is replaced with N1-methylpseudouridine.

2. mRNA polynucleotide, according to claim 1, characterized in that the mRNA polynucleotide is derived from a norovirus selected from the group consisting of: a norovirus GII.4, GI.1, GII.2, GII.3 and GII.

6.

3. mRNA polynucleotide, according to claim 1 or 2, characterized in that the mRNA polynucleotide additionally comprises a heterologous 5' untranslated region (UTR) and a heterologous 3' UTR.

4. mRNA polynucleotide, according to claim 3, characterized in that the 5' UTR comprises the polynucleotide sequence of SEQ ID NO:

6.

5. mRNA polynucleotide, according to claim 4, characterized in that the 5' UTR additionally comprises the 5' N7-Methyl-G(3'OMe)ppp cap structure.

6. mRNA polynucleotide, according to any one of claims 3 to 5, characterized in that the 3' UTR comprises a poly(A) sequence and / or a poly(C) sequence.

7. mRNA polynucleotide, according to claim 6, characterized in that the poly(A) sequence comprises from 10 to 200 adenosine nucleotides and / or the poly(C) sequence comprises from 10 to 200 cytosine nucleotides.

8. mRNA polynucleotide, according to claim 6, characterized in that the poly(A) sequence comprises from 10 to 100 adenosine nucleotides.

9. mRNA polynucleotide, according to claim 6, characterized in that the poly(A) sequence comprises from 10 to 80 adenosine nucleotides.

10. mRNA polynucleotide, according to claim 6, characterized in that the poly(A) sequence comprises 50 to 70 adenosine nucleotides.

11. mRNA polynucleotide, according to claim 6, characterized in that the poly(C) sequence comprises from 10 to 100 cytosine nucleotides.

12. mRNA polynucleotide, according to claim 6, characterized in that the poly(C) sequence comprises from 20 to 70 cytosine nucleotides.

13. mRNA polynucleotide, according to claim 6, characterized in that the poly(C) sequence comprises from 20 to 60 cytosine nucleotides.

14. mRNA polynucleotide, according to claim 6, characterized in that the poly(C) sequence comprises from 10 to 40 cytosine nucleotides.

15. mRNA polynucleotide, according to claim 7, characterized in that the poly(A) sequence comprises 80 adenine nucleotides.

16. mRNA polynucleotide, according to any one of claims 3 to 9, characterized in that the UTR 3' comprises the polynucleotide sequence of SEQ ID NO: 7 or SEQ ID NO:

8.

17. mRNA polynucleotide, according to claim 10, characterized in that the 3' UTR comprises the polynucleotide sequence of SEQ ID NO:

7.

18. mRNA polynucleotide, according to claim 10, characterized in that the 3' UTR comprises the polynucleotide sequence of SEQ ID NO:

8.

19. mRNA polynucleotide, according to any one of claims 1 to 10, characterized in that the mRNA polynucleotide comprises, from the 5' to the 3' direction: a 5' UTR comprising the polynucleotide sequence of SEQ ID NO: 6; a polynucleotide encoding a norovirus VP1 polypeptide, wherein the polynucleotide is selected from the group consisting of SEQ ID NOs: 1 to 5 and sequences having at least 70% identity therewith; and a 3' UTR comprising the polynucleotide sequence of SEQ ID NO: 7; and wherein the 5' UTR further comprises the 5' cap structure N7-MethylG(3'OMe) ppp, and all uridine residues in the polynucleotide encoding the norovirus VP1 polypeptide are substituted with N1-methylpseudouridine.

20. mRNA polynucleotide, according to any one of claims 1 to 10, characterized in that the mRNA polynucleotide comprises, from the 5' to the 3' direction: a 5' UTR comprising the polynucleotide sequence of SEQ ID NO: 6; a polynucleotide encoding a norovirus VP1 polypeptide, wherein the polynucleotide is selected from the group consisting of SEQ ID NOs: 1 to 5 and sequences having at least 70% identity therewith; and a 3' UTR comprising the polynucleotide sequence of SEQ ID NO: 8; and wherein the 5' UTR additionally comprises the 5' N7-MethylG(3'OMe) ppp cap structure, and all uridine residues in the polynucleotide encoding the norovirus VP1 polypeptide are substituted with N1-methylpseudouridine.

21. mRNA polynucleotide, according to any one of claims 1 to 20, characterized in that the mRNA polynucleotide comprises at least one histone stem loop structure.

22. mRNA polynucleotide, according to any one of claims 1 to 21, characterized in that at least 50% of the uridine residues in the mRNA polynucleotide are replaced with N1-methylpseudouridine.

23. mRNA polynucleotide, according to any one of claims 1 to 21, characterized in that at least 75% of the uridine residues in the mRNA polynucleotide are substituted with N1-methylpseudouridine.

24. mRNA polynucleotide, according to any one of claims 1 to 21, characterized in that at least 85% of the uridine residues in the mRNA polynucleotide are substituted with N1-methylpseudouridine.

25. mRNA polynucleotide, according to any one of claims 1 to 21, characterized in that at least 95% of the uridine residues in the mRNA polynucleotide are substituted with N1-methylpseudouridine.

26. mRNA polynucleotide, according to any one of claims 1 to 21, characterized in that 100% of the uridine residues in the mRNA polynucleotide are replaced with N1-methylpseudouridine.

27. Combination, characterized in that it comprises one or more mRNA polynucleotides defined in any of claims 1 to 26.

28. Composition, characterized in that it comprises at least one mRNA polynucleotide encoding a norovirus VP1 polypeptide defined in any one of claims 1 to 26, and a pharmaceutically acceptable carrier.

29. Composition, characterized in that it comprises at least two mRNA polynucleotides encoding norovirus VP1 polypeptides defined in any one of claims 1 to 26, and a pharmaceutically acceptable carrier.

30. Composition, characterized in that it comprises at least three mRNA polynucleotides encoding norovirus VP1 polypeptides defined in any one of claims 1 to 26, and a pharmaceutically acceptable carrier.

31. Composition, characterized in that it comprises at least four mRNA polynucleotides encoding norovirus VP1 polypeptides defined in any one of claims 1 to 26, and a pharmaceutically acceptable carrier.

32. Composition, characterized in that it comprises at least five mRNA polynucleotides encoding norovirus VP1 polypeptides defined in any one of claims 1 to 26, and a pharmaceutically acceptable carrier.

33. Composition, characterized by the fact that it comprises five mRNA polynucleotides encoding norovirus VP1 polypeptides and a pharmaceutically acceptable carrier, wherein each of the five Petition 870250101498, dated 05 / 11 / 2025, page.The 536 / 546 6 / 14 mRNA polynucleotides comprise, from the 5' to the 3' direction: a 5' UTR comprising the polynucleotide sequence of SEQ ID NO: 6; a polynucleotide encoding a norovirus VP1 polypeptide, wherein the polynucleotide is selected from the group consisting of SEQ ID NOs: 1 to 5 and sequences having at least 70% identity with them; and a 3' UTR comprising the polynucleotide sequence of SEQ ID NO: 7; and wherein the 5' UTR additionally comprises the 5' cap structure N7-MethylG(3'OMe) ppp, and wherein the composition comprises each of the SEQ ID NOs: 1 to 5 and sequences having at least 70% identity therewith, wherein in each of the SEQ ID NOs: 1 to 5 and sequences having at least 70% identity therewith, all uridine residues in the five mRNA polynucleotides are substituted with N1-methylpseudouridine.

34. Composition, characterized in that it comprises five mRNA polynucleotides encoding norovirus VP1 polypeptides and a pharmaceutically acceptable carrier, wherein each of the five mRNA polynucleotides comprises, from the 5' to the 3' direction: a 5' UTR comprising the polynucleotide sequence of SEQ ID NO: 6; a polynucleotide encoding a norovirus VP1 polypeptide, wherein the polynucleotide is selected from the group consisting of SEQ ID NOs: 1 to 5 and sequences having at least 70% identity therewith; and a 3' UTR comprising the polynucleotide sequence of SEQ ID NO: 8; and wherein UTR 5' additionally comprises the structure cap 5' N7-MethylG(3'OMe) ppp, and wherein the composition comprises each of the SEQ ID NOs: Petition 870250101498, dated 05 / 11 / 2025, page.537 / 546 7 / 14 1 to 5 and sequences having at least 70% identity with them, wherein in each of the SEQ ID NOs: 1 to 5 and sequences having at least 70% identity with them, all uridine residues in the five mRNA polynucleotides are replaced with N1-methylpseudouridine.

35. Composition, according to any one of claims 28 to 34, characterized in that the composition further comprises one or more additional mRNA polynucleotides derived from a norovirus selected from the group consisting of a norovirus of genogroup I, a norovirus of genogroup II, a norovirus of genogroup III, a norovirus of genogroup IV and a norovirus of genogroup V.

36. Composition, characterized in that it comprises at least one mRNA polynucleotide encoding a norovirus VP1 polypeptide and a pharmaceutically acceptable carrier.

37. Composition according to claim 36, characterized in that it further comprises at least one, at least two, at least three, at least four or at least five mRNA polynucleotides encoding a VP1 polypeptide from norovirus.

38. Composition according to claim 36 or 37, characterized in that the VP1 polypeptide of norovirus is derived from norovirus of genogroup I or norovirus of genogroup II.

39. Composition according to claim 38, characterized in that the VP1 polypeptide of norovirus is derived from a genogroup selected from the group consisting of: a norovirus GII.4, GI.1, GII.2, GII.3 and GII.

6.

40. Composition, according to any one of claims 36 to 39, characterized in that the norovirus VP1 polypeptide is selected from the group consisting of SEQ ID NOs: 14 to 18 and sequences having at least 70% identity with them.

41. Composition, according to any one of claims 28 to 40, characterized in that each mRNA polynucleotide is separately encapsulated in a lipid nanoparticle (LNP), comprising one or more cationic or polycationic compounds.

42. Composition, according to any one of claims 28 to 40, characterized in that each mRNA polynucleotide is encapsulated together in an LNP comprising one or more cationic or polycationic compounds.

43. Composition, according to claim 41 or 42, characterized in that each mRNA polynucleotide encapsulated in the LNP is present in an equal amount.

44. Composition, according to claim 41 or 42, characterized in that each mRNA polynucleotide encapsulated in the LNP is not present in an equal amount.

45. Composition, according to any one of claims 41 to 44, characterized in that the LNP comprises one or more of a cationic lipid, a sterol, a phospholipid and a polyethylene glycol-lipid.

46. ​​Composition, according to any one of claims 41 to 45, characterized in that the LNP comprises a cationic lipid, a sterol, a phospholipid and a polyethylene glycol-lipid.

47. Composition, according to any one of claims 41 to 46, characterized in that the LNP comprises 34 to 59 mol% of a cationic lipid, 30 to 48 mol% of a sterol, 10 to 24 mol% of a phospholipid and 1 to 2 mol% of a polyethylene glycol-lipid.

48. Composition, according to any one of claims 41 to 47, characterized in that the cationic lipid is selected from the group Petition 870250101498, dated 05 / 11 / 2025, page 539 / 546 9 / 14 49. Composition according to any one of claims 41 to 48, characterized in that the sterol is: (V).

50. Composition, according to any one of claims 41 to 49, characterized in that the phospholipid is selected from the group consisting of: Petition 870250101498, dated 05 / 11 / 2025, pp. 540 / 546 10 / 14 51. Composition, according to any one of claims 41 to 50, characterized in that the polyethylene glycol lipid is selected from Petition 870250101498, dated 05 / 11 / 2025, page 541 / 546 11 / 14 0. ______________________________________________(XII)______________________________________________ 52. Composition, according to any one of claims 45 to 47, characterized in that the cationic lipid is (13Z, 16Z)-N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine.

53. Composition, according to any one of claims 45 to 47, characterized in that the sterol is cholesterol.

54. Composition according to any one of claims 45 to 47, characterized in that the phospholipid is distearolphosphatidylcholine (DSPC).

55. Composition, according to any one of claims 45 to 47, characterized in that the polyethylene glycol lipid is dimyristoyl glycerol polyethylene glycol (DMG-PEG).

56. Composition, according to any one of claims 45 to 55, characterized in that the LNP comprises 49 to 59 mol% of (13Z, 16Z)N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine.

57. Composition, according to any one of claims 45 to 56, characterized in that the LNP comprises about 58 mol% of (13Z,16Z)-N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine.

58. Composition, according to any one of claims 45 to 57, characterized in that the LNP comprises about 49 mol % of (13Z, 16Z)-N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine.

59. Vaccine, characterized in that it comprises the mRNA polynucleotide defined in any one of claims 1 to 26, the combination defined in claim 27, or the composition defined in any one of claims 28 to 58.

60. Vaccine, according to claim 59, characterized in that the vaccine additionally comprises a pharmaceutically acceptable carrier. Petition 870250101498, dated 05 / 11 / 2025, pp. 542 / 546 12 / 14 61. Vaccine, according to claim 59 or 60, characterized in that the vaccine additionally comprises an adjuvant.

62. Vaccine, according to any one of claims 59 to 61, characterized in that the vaccine is monovalent, bivalent, trivalent, quadrivalent or pentavalent.

63. mRNA polynucleotide, according to any one of claims 1 to 26, combination, according to claim 27, composition, according to any one of claims 28 to 58, or vaccine, according to any one of claims 59 to 62, characterized in that the mRNA polynucleotide, the combination, the composition and / or the vaccine are immunogenic in a mammalian species.

64. Kit or kit of parts comprising mRNA polynucleotide, according to any one of claims 1 to 26, combination, according to claim 27, composition, according to any one of claims 28 to 58, or vaccine, according to any one of claims 59 to 62, characterized in that the kit or kit of parts optionally further comprises a liquid vehicle for solubilization and / or technical instructions providing information on administration and dosage of the components.

65. mRNA polynucleotide, according to any one of claims 1 to 26, combination, according to claim 27, composition, according to any one of claims 28 to 58, or vaccine, according to any one of claims 59 to 62, or kit or kit of parts, according to claim 64, characterized in that they are for use as a medicament.

66. mRNA polynucleotide, according to any of the claims 1 to 26, combination, according to claim 27, composition, according to any of the claims 28 to 58, or vaccine, according to any of the claims 59 to 62, or kit or kit of parts, according to claim 64, characterized in that they are for use in the manufacture of a medicament for the treatment or prophylaxis of a norovirus infection or a disorder related to a norovirus infection.

67. mRNA polynucleotide, according to any one of claims 1 to 26, combination, according to claim 27, composition, according to any one of claims 28 to 58, or vaccine, according to any one of claims 59 to 62, or kit or kit of parts, according to claim 64, characterized in that they are for use in the treatment or prophylaxis of a norovirus infection or a disorder related to a norovirus infection.

68. mRNA polynucleotide, according to any one of claims 1 to 26, combination, according to claim 27, composition, according to any one of claims 28 to 58, or vaccine, according to any one of claims 59 to 62, or kit or kit of parts, according to claim 64, characterized in that an effective quantity of the nucleic acid, combination, composition, vaccine or active component of the kit or kit of parts is administered by injection.

69. Use of an mRNA polynucleotide defined in any one of claims 1 to 26, of the combination defined in claim 27, of a composition defined in any one of claims 28 to 58, of a vaccine defined in any one of claims 59 to 62, or of the kit or kit of parts defined in claim 64, characterized in that it is for the manufacture of a medicament to treat or prevent a disorder. Petition 870250101498, dated 05 / 11 / 2025, pp. 544 / 546 14 / 14 70. Use according to claim 69, characterized in that the disorder is a norovirus infection or a disorder related to a norovirus infection.

71. Vector, characterized in that it comprises one or more nucleic acids encoding the mRNA polynucleotide defined in any one of claims 1 to 26.

72. Host cell, characterized in that it comprises the mRNA polynucleotide defined in any one of claims 1 to 26, the combination defined in claim 27, or the vector defined in claim 71.

73. Polypeptide, characterized in that it is encoded by the mRNA polynucleotide defined in any one of claims 1 to 26.

74. Method for producing a virus-like particle (VLP) comprising one or more norovirus VP1 polypeptides, characterized in that the method comprises transcribing the mRNA polynucleotide defined in any one of claims 1 to 26, the combination defined in claim 27, or the vector defined in claim 71, in a recombinant nucleic acid expression system under conditions suitable for assembling one or more norovirus VP1 polypeptides expressed in a VLP.

75. VLP, characterized in that it comprises one or more norovirus VP1 polypeptides produced according to the method defined in claim 74.

76. Product, process, system, kit, means or use, characterized in that it comprises one or more elements described in the descriptive report, claims, drawings, sequence listing, or summary of this application, when applicable. Petition 870250101498, dated 05 / 11 / 2025, pp. 545 / 546